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Abstract 
HYDROZIRCONATION/ZR-ZN TRANSMETALATION/ALDIMINE ADDITION: 
ONE-POT SYNTHESIS OF ALLYLIC, C-CYCLOPROPYLALKYL, 
AND HOMOALLYLIC AMINES FROM ALKYNES. 
 
Christopher Kendall, PhD 
 
University of Pittsburgh, 2004 
 
 The Zr-Zn transmetalation, aldehyde addition methodology developed in the Wipf group 
was extended to the synthesis of allylic amines.  The use of toluene as a reaction solvent was 
required to obtain high yields and low reaction times.  N-Phosphinoyl-, N-sulfonoyl-, and N-
carbamoylimines were excellent substrates for this transformation.  Many chiral ligands were 
tested for asymmetric catalysis, but minimal ee was achieved.  Addition to chiral phosphinimines 
was also attempted, but the diastereoselectivities were low. 
 A novel three-component C-cyclopropylalkylamine synthesis was discovered while 
attempting to perform the allylic amine synthesis in CH2Cl2.  The mechanism of this trans-
formation is not fully understood; however, this is the first reported example of a high-yielding 
Simmons-Smith cyclopropanation with CH2Cl2 as the carbene precursor.  This reaction was 
optimized by adding CH2I2 to the reaction mixture once all imine was consumed.  Addition of 
CH2I2 prior to imine substrate resulted in homoallylic amine formation. 
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 1. Introduction 
1.1. Hydrozirconation1 
 Hydrozirconation with Cp2ZrHCl (Schwartz reagent) is one of the few general methods 
available for the direct conversion of readily available alkenes and alkynes into organometallic 
reagents (Figure 1).2  Another advantage zirconocenes have over other organometallics are 
reaction conditions that are compatible with the presence of many functional groups.  The 
majority of synthetic applications utilize alkenylzirconocenes (4), since the reaction of Cp2ZrHCl 
with alkynes is very fast and highly regioselective, whereas alkenes are not as reactive, and 
furthermore internal alkylzirconocenes are rapidly isomerized into terminal alkylzirconocenes.3  
If this isomerization can be avoided, the hydrozirconation of an internal alkene generates a 
stereocenter, but very little effort has been made towards asymmetric hydrozirconation.4
 
R1
Cp2ZrHCl ClCp2Zr R1
R2
Cp2ZrHCl ClCp2Zr R2
1 2
43  
Figure 1. Hydrozirconation to form alkyl- and alkenylzirconium reagents. 
 
 While hydrozirconation is the most common method for forming organozirconocenes, 
Cp2ZrEt2 and Cp2ZrBu2 (easily prepared by reacting Cp2ZrCl2 with the appropriate alkyllithium 
reagent) can be used to form zirconacyclopentanes, -cyclopentenes, and -cyclopentadienes,5 
which then react very similarly to acyclic organozirconocenes.  Cp2ZrR2 reagents can also be 
inserted into vinyl halides,6 methoxy enol ethers,7 enolsilanes,8 and vinyl sulfides, sulfoxides, 
and sulfones9 to form alkenylzirconocenes. 
 Cp2ZrHCl was first prepared in 197010 and used to hydrozirconate alkenes11 and 
alkynes12 by Wailes and co-workers.  Subsequently, Schwartz and co-workers treated the 
resulting alkyl-13 and alkenylzirconocenes14 with inorganic electrophiles, and used trans-
metalation (from Zr to Al) to increase their reactivity towards organic electrophiles.15  Schwartz 
reagent is a moderately air-, moisture-, and light-sensitive colorless solid that can be handled and 
1 
 weighed on a balance.  The hydrozirconation of terminal alkynes proceeds rapidly (5-15 min) at 
room temperature in CH2Cl2 or THF, and is very easily monitored visually since Cp2ZrHCl is 
insoluble in most organic solvents whereas the colored organozirconocenes 4 are highly soluble. 
 In general, amides, ketones, aldehydes and nitriles are not compatible with hydro-
zirconation conditions, but alkynes can be selectively hydrozirconated in the presence of certain 
esters.  Functional groups that are recovered unchanged after exposure to Schwartz reagent 
include carbamates, acetals, epoxides, ethers, halides, and sulfides.  Alcohols undergo an acid-
base reaction with one equivalent of Cp2ZrHCl and thereafter do not significantly interfere with 
alkene or alkyne hydrozirconation.  Schwartz reagent has been used as a reducing agent by 
Ganem and co-workers for the deoxygenation of β-ketoesters to α,β-unsaturated esters,16 and for 
the reduction of amides to imines.17  Cp2ZrHCl also reduces N,N-disubstituted amides to 
aldehydes,18 and phosphine oxides to phosphines.19
 Though the ionic character of the C-Zr bond is almost equivalent to that of the C-Mg 
bond, organozirconocenes are much weaker nucleophiles than Grignard reagents due to steric 
shielding at the metal center by the two cyclopentadienyl ligands.  Small electrophiles such as 
halogens, protons, dioxygen, CO,20 and isocyanides,21 can be directly added to the C-Zr bond.  
One of the most widely used applications of organozirconocenes is for the preparation of (E)-
vinyl halides by alkyne hydrozirconation followed by halogenation.  (Z)-Vinyl halides can also 
be prepared by hydrozirconating stannylacetylenes.22  Regiospecific deuterium labeling can be 
achieved by quenching organozirconocenes with D2O or by using Cp2ZrDCl for hydro-
zirconation.23  Hanzawa, Taguchi and co-workers have developed the synthetic utility of acyl-
zirconocenes (formed by CO insertion into the C-Zr bond) and demonstrated their reactivity in 
aldehyde additions,24 imine additions,25 Pd-catalyzed cross-coupling,26 and Pd-catalyzed 1,2- or 
1,4-additions to α,β-unsaturated ketones.27
 Suzuki and co-workers have prepared allylzirconocenes by hydrozirconation of allenes.  
These reagents readily converted aldehydes into homoallylic alcohols in high diastereo-
selectivities.28  Along with acylzirconocenes, however, allylzirconocenes are the only classes of 
organozirconium reagents that will react directly with organic electrophiles such as aldehydes. 
 One way to increase alkenylzirconocene reactivity towards organic electrophiles is to 
reduce the steric congestion about zirconium by chloride abstraction.  Suzuki and co-workers 
reported that cationic zirconocenes prepared in situ reacted rapidly with aldehydes to generate 
2 
 allylic alcohols (Scheme 1).29  For example, when 6, the product of hydrozirconation of 1-
hexyne, was treated with aldehyde 5 in the presence of 5 mol% of AgClO4, alcohol 7 was 
isolated in 90% yield after only a 10 min reaction time.  In the absence of the Ag(I) salt, only 
17% conversion was observed after 2 h.  Wipf and Xu have shown that cationic alkenyl-
zirconocenes promote an epoxide rearrangement/[1,2]-hydrogen shift of terminal epoxides, 
followed by vinylation of the resulting aldehyde, affording secondary allylic alcohols.30
 
ClCp2Zr C4H9
5 mol% AgClO4, CH2Cl2
(90%)
O
HPh
OH
Ph C4H9
5 7
6
 
Scheme 1. Alkenylzirconocene addition to aldehydes catalyzed by AgClO4.  
 
 A second general solution to the lack of reactivity of alkenylzirconocenes is trans-
metalation.  Many metals can be used for transmetalation from alkyl- and alkenylzirconocenes;b 
however, the most synthetically useful are Pd and Ni, Cu, and Zn.  Negishi and co-workers 
discovered that alkenylzirconocenes could be coupled to aryl or alkenyl halides under Ni-31 or 
Pd-catalysis.32  A recent total synthesis of lissoclinolide demonstrates a typical application of this 
methodology (Scheme 2).33  Protected propargyl alcohol 9 was hydrozirconated with an in situ 
generated reagent34 and the resulting alkenylzirconocene 10 was iodinated to form (E)-vinyl 
iodide 11.  Pd-catalyzed coupling with propargyl alcohol 8, Swern oxidation and then a Corey-
Fuchs reaction converted 11 into 1,1-dibromide 12.  Pd-catalyzed Negishi coupling of vinyl 
bromide 12 with zirconocene 10 occurred exclusively at the trans-position.  Carboxylic acid 13 
was then formed by lithium-halogen exchange of the remaining vinyl bromide with a CO2 
quench.  Finally, the natural product was formed by Ag+-catalyzed lactonization of 13, and 
deprotection.  The Zr-Pd coupling methodology has aslo been used in a total synthesis of 
papulacandin.35
 Fu and co-workers have extended the Pd-catalyzed coupling of alkenylzirconocenes to 
alkyl halides,36 and Lipshutz and Frieman have recently reported that the heterogeneous Ni-
catalyzed coupling of alkenylzirconocenes and aryl halides can be significantly accelerated by 
using microwaves.37
 
3 
 HO
TBS-Cl
imidazole
(95%)
TBSO
i-BuZrCp2Cl
benzene
TBSO ZrCp2Cl
I2
THF
(89%)
TBSO I
1. 8, 5 mol% Pd(PPh3)4,
    pyrrolidine
2. DMSO, (COCl)2
3. CBr4, PPh3, K2CO3
(63%)
TBSO
Br
Br
1. 10, 5 mol% Pd(PPh3)4,
    pyrrolidine
2. t-BuLi; CO2
(71%)
TBSO
CO2H
OTBS 1. 5 mol% AgNO3, MeOH
2. HF, MeCN
(85%)
OH
HO
O
O
8 9 10
11
12
13 lissoclinolide  
Scheme 2. Pd-catalyzed alkenylzirconocene and vinyl bromide coupling in Negishi’s total 
synthesis of lissoclinolide. 
 
 Transmetalation from Zr to Cu combines the ease of preparation of organozirconocenes 
with the wide scope of reactions of organocopper reagents.38  Wipf and co-workers showed that 
Cu(I)-catalyzed addition of alkenylzirconocenes to acid chlorides afforded α,β-unsaturated 
ketones,39 and that Cu catalyzes the conjugate addition of alkylzirconocenes to enones.40,41  
Lipshutz and co-workers have worked extensively on the preparation of cyanocuprates using a 
hydrozirconation, transmetalation sequence.42  These cuprate reagents can be alkylated with 
epoxides or activated (benzylic or allylic) halides,43 and used in conjugate additions to α,β-
unsaturated ketones.44  Lipshutz and Wood reported a three-component coupling of cyano-
cuprates, cyclopentenones and aldehydes (or propargylic triflates) for the synthesis of 
prostaglandin-like compounds (Scheme 3).45  For example, disubstituted cyclopentenone 18 was 
prepared in one pot and 74% yield as a 12:1 mixture of stereoisomers using alkyne 14, 2-
cyclopentene-1-one and aldehyde 17.  The same sequence has also been performed on a solid 
support.46
 
1.2. The Zr-Zn Transmetalation Methodology47 
 Negishi and co-workers discovered a significant acceleration in the Pd(0)-catalyzed cross 
coupling of alkenylzirconocenes with alkenyl, aryl, and alkynyl halides upon addition of ZnCl2 
4 
 to the reaction mixture (Scheme 4).48  For example, the Pd(0)-catalyzed coupling of zirconocene 
20 with vinyl bromide 19 yielded no trace of product after 6 h, whereas a 72% isolated yield of 
the desired diene 21 was obtained after 1 h when the reaction was performed in the presence of a 
stoichiometric amount of ZnCl2.  This acceleration is likely due to a transmetalation of the 
alkenyl organometallic from the large zirconocene to the much smaller zinc, followed by another 
transmetalation, to palladium, and continuing in the standard Pd(0)-coupling catalytic cycle.49
 
OTIPS
1. Cp2ZrHCl, THF
2. MeLi
MeCp2Zr OTIPS
1. 10 mol% Me2Cu(CN)Li,
    1 equiv Me3ZnLi
2. 2-cyclopentenone
OZnMe2Li
OTIPS
O
H CO2Me
(74%)
O
OTIPS
OH
CO2Me
H
H
18
14
15
16
17
 
Scheme 3. One-pot synthesis of prostaglandins by conjugate addition, enolate trapping. 
ClCp2Zr Et
Et
Br
MeO2C
5 mol% Pd(PPh3)4, 1 equiv ZnCl2,
THF, rt, 1 h
(72%)
MeO2C
Et
Et
19 21
20
 
Scheme 4. ZnCl2-accelerated coupling of alkenyl zirconocenes.  
 
 Panek and Hu optimized50 this process for their synthesis of the unnatural amino acid 
Adda.51  The recent total synthesis of callystatin A by Langille and Panek used a ZnCl2-assisted 
sp2-sp2 coupling of an alkenylzirconocene, and a second hydrozirconation to prepare a (Z)-vinyl 
halide (Scheme 5).52  Trimethylsilylalkyne 22 was hydrozirconated at 50 °C and the resulting 
terminal zirconocene 23 was quenched selectively at Zr with iodine, affording (E)-vinyl iodide 
25.  Negishi coupling replaced the iodine with an ethyl group and, after several steps, iodo-
desilylation and another Negishi coupling (selectively at the vinyl bromide) formed (Z)-vinyl 
iodide 27.  A second hydrozirconation was used to prepare alkenylzirconocene 28, which was 
coupled to 27 to form the carbon skeleton of the natural product.  Completion of the total 
5 
 synthesis required only two deprotections and an oxidation.  The Zr-Zn-Pd transmetalation 
sequence has also been used in the total syntheses of reveromycin B,53 motuporin,54 FR 
901464,55 eunicenone A,56 β-carotene,57 pitiamide A,58 and xerulin.59
 
TMS
OBn
Cp2ZrHCl
THF, 50 °C OBnClCp2Zr
TMS I2
OBnI
TMS
EtMgBr, ZnCl2
5 mol% Pd(PPh3)4, THF
(96%)
(89%)
OBn
TMS
TMS Br
O OTIPS
1. NIS, EtCN
2. Me2Zn,  5 mol%
    Pd[P(t-Bu)3]4, THF, 0 °C
I
O OTIPS
O
i-PrO
ZrCp2Cl
ZnCl2, 5 mol% Pd(PPh3)4,
THF
(51%)
O OTIPS
O
Oi-Pr
O OH
O
O
22 23 24
25 26
27
28
29 callystatin A
(78%)
 
Scheme 5. Two applications of alkenylzirconocenes in Panek’s total synthesis of callystatin A.  
 
 Wipf and Xu reported in 1993 a high yielding preparation of allylic alcohols from 
alkenylzirconocenes and aldehydes mediated by dialkylzinc reagents (Scheme 6).60  For 
example, hexenyl zirconocene 6 was added to benzaldehyde in the presence of Me2Zn to afford 
allylic alcohol 33 in 93% isolated yield (based on benzaldehyde).  The reaction mechanism is 
thought to involve a Zr-Zn transmetalation, forming alkenyl zinc species 31, followed by a Zr-
accelerated61 1,2-addition of exclusively the alkenyl group of 31 to aldehyde 32.62  When the 
reaction solvent is CH2Cl2, this one-pot reaction is completed within 10 h on an 18 mmol scale.63  
Substituted benzaldehydes and aliphatic aldehydes were also effective electrophiles, and 
6 
 functional groups tolerated on the alkynes included silyl ethers and benzyl esters.  The allylic 
alcohols were isolated in 54-94% yield.  Me2Zn can be used in catalytic quantities,64 and this 
same net transformation has been shown to be mediated by both ZnBr265 66 and MeLi.
 
C4H9
Cp2ZrHCl
CH2Cl2, rt
ClCp2Zr C4H9
Me2Zn
-65 °C
MeZn
C4H9
O
HPh
0 °C
OH
Ph C4H9
33 (93%)
31
30 6
32
 
Scheme 6. Zr-Zn transmetalation and in situ addition to aldehydes.  
 
 Wipf and Xu used the Zr-Zn transmetalation/aldehyde addition strategy to rapidly 
prepare triene 36, an early intermediate in their total synthesis of curacin A (Scheme 7).67  
Hydrozirconation of alkyne 34 and transmetalation with Et2Zn was followed by addition of tiglic 
aldehyde to the reaction mixture, and then the expected allylic alcohol was immediately oxidized 
to the corresponding ketone 35, isolated in 85% overall yield.  Pd(0)-catalyzed Bu3SnH 
reduction of the triflate formed by trapping of the kinetic enolate afforded the all-trans-triene 36 
in 71% yield.  A similar sequence was used to prepare the all-(E)-polyene fragments of 
asukamycin68 and nisamycin.69
 Williams and co-workers have used the Zr-Zn exchange methodology in their total 
synthesis of ratjadone (Scheme 8).70  Construction of the 5,6-dihydropyran-2-one was initiated 
by addition to aldehyde 38 of the alkenylzirconocene prepared from alkyne 37.  Allylic alcohol 
39 was isolated as a 1:1 mixture of diastereomers in very high yield.  To set the stereochemistry 
of the newly formed stereocenter, the alcohol was oxidized and the resulting enone immediately 
subjected to an assymetric reduction, which gave a 5:1 mixture of diastereomers. 
 
7 
 OBDPS
1. Cp2ZrHCl, CH2Cl2, rt
2. Et2Zn, -60 °C
3. tiglic aldehyde, 0 °C
4. MnO2, hexanes, rt
OBDPS
O
1. KHMDS, THF, -78 °C
2. Tf2NPh, 0 °C
3. Bu3SnH, Pd2(dba)3,
    LiCl, PPh3, THF, reflux
OBDPS
OMe
S
N
curacin A
(85%) (71%)
34 35
36
H H
 
Scheme 7. Zr-Zn transmetalation/aldehyde addition in Wipf’s total synthesis of curacin A. 
O
OH
OH
O O
ratjadone
BDPSO
1. Cp2ZrHCl, CH2Cl2
2. Me2Zn, -65 °C
3. OHC
SPh
(92%)
-65 °C → rt
BDPSO
OH
SPh
1. DMP, NaHCO3
2. LiAlH4, PhNHEt,
    40, Et2O
(98%)
BDPSO
OH
SPh
37
39
41, dr = 5:1
HO
Ph
NMe2
40
(38)
 
Scheme 8. Zr-Zn transmetalation/aldehyde addition in Williams’ total synthesis of ratjadone.  
 
 Williams and co-workers again used this methodology in their total synthesis of 
laulimalide (Scheme 9).71  To set the desired C20 stereocenter, a chelation-controlled addition to 
aldehyde 43 of the alkenylzinc reagent, derived from hydrozirconation of alkyne 42 and trans-
metalation with Me2Zn, was used.  The desired allylic alcohol 44 was obtained as a 4:1 mixture 
of diastereomers.  The next step in their sequence involved another popular organometalic 
reaction of alkenes, namely a ring-closing metathesis.  The one-pot Zr-Zn transmetalation 
protocol was preferable in this case to addition of an alkenylzincate reagent, which required 
preparation and isolation of the corresponding vinyl iodide, then lithium-halogen exchange with 
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 t-BuLi, and finally transmetalation with Me2Zn.  Though the addition of this zincate gave a 
higher diastereoselectivity, the Zr-Zn transmetalation/aldehyde addition protocol was considered 
more practical.  The same zincate strategy was earlier used to form the same C20 stereocenter, 
using very similar substrates, by Messenger and Davidson.72  Through the diastereoselectivity of 
the addition was very high (only one stereoisomer was obtained), the yield was low (45%) and 
the reaction mixture was contaminated with 15% of a difficult to separate by-product resulting 
from methyl addition to the aldehyde. 
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Scheme 9. Zr-Zn transmetalation/aldehyde addition in Williams’ synthesis of laulimalide. 
 
 Murakami and Furusawa used the Zr-Zn methodology to prepare both erythro- and threo-
sphingosine, using a highly diastereoselective addition of alkenylzirconocene 47 to Garner’s 
aldehyde (46) in the presence of Et2Zn (Scheme 10).73  Interestingly, the choice of solvent used 
for the reaction dictated the relative stereochemistry of the allylic alcohol product.  In CH2Cl2, 
the syn-alcohol 48 was formed in high diastereoselectivity and high yield.  However, keeping all 
other conditions identical but performing the entire one-pot reaction in THF, anti-alcohol 49 was 
favored with a diastereoselectivity of 12:1 and an isolated yield of 67%.  An improved yield of 
70% and a selectivity of 20:1 was achieved by using half an equivalent of ZnBr2 instead of one 
equivalent of Et2Zn. 
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Scheme 10. Zr-Zn transmetalation/aldehyde addition in the diastereoselective synthesis of 
sphingosines. 
 
 Chavez and Jacobsen extended the Zr-Zn methodology to the addition to ketones, 
specifically epoxyketone 51.74  Their total synthesis of fostriecin required a diastereoselective, 
chelation-controlled vinylation of enantiomerically pure 51 (Scheme 11).  The most successful 
model study was hydrozirconation of 1-octyne, transmetalation with Me2Zn and addition to 51, 
which afforded the expected tertiary allylic alcohol with a diastereoselectivity of >30:1 and in 
75% isolated yield.  Using alkyne 50 in place of 1-octyne also afforded the desired allylic 
alcohol (isolated as TES-ether 52 in 45% combined overall yield) with >30:1 diastereo-
selectivity.  The Zr-Zn methodology has also been extended to α-ketoesters by Wipf and 
Stephenson.75
 Unsuccessful use of this methodology has been reported in stereocontrolled additions to 
in situ formed oxacarbenium ions (due to competitive alkyl group transfer)76 and in studies 
towards the nautral products halicholactone,77 constanolactone A,78 and macrolactin A.79  In the 
latter synthesis, a late-stage hydrozirconation of enyne 54, transmetalation to Me2Zn, and 
addition to aldehyde 53 was planned (Figure 2).  Though a test addition to benzaldehyde did 
afford the desired 1,2-addition product in 50% yield, no addition to aldehyde 53 was observed 
and the approach was abandoned. 
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Scheme 11. Zr-Zn transmetalation/ketone addition in Jacobsen’s total synthesis of fostriecin.  
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Figure 2. Unsuccessful Zr-Zn transmetalation/aldehyde addition in an attempted total synthesis 
of macrolactin A. 
 
 In their initial communication on the Zr-Zn transmetalation/aldehyde addition 
methodology, Wipf and Xu reported that performing the reaction detailed in Scheme 6 in the 
presence of 8 mol% of proline-derived ligand 55 and at -20 °C afforded enantiomerically 
enriched allylic alcohol (S)-33, though with a low ee of 38%.  Wipf and Ribe improved the ee to 
95% by performing the reaction at -30 °C in toluene, in the presence of 10 mol% of amino thiol 
56 (Scheme 12).80  Critically, the process also required a 60 min incubation, at -30 °C, of the 
zirconocene/Me2Zn/chiral ligand mixture prior to addition to the electrophile.  Without this 
added step, which was believed to allow for complete solvation of the chiral ligand, the ee’s of 
the reaction product were not reproducible.81  The amino thiol ligand 56 gave generally moderate 
to high ee’s for all substrates tested, including electron-rich aromatic aldehydes and aliphatic 
aldehydes (63-74% ee), and benzaldehyde and more electron-deficient aromatic aldehydes (83-
11 
 99% ee).  When performed in the presence of amino thiol 56, the reaction ee displayed a strong, 
positive non-linear effect.82
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Scheme 12. Catalytic asymmetric Zr-Zn transmetalation/aldehyde addition. ,  
 
 The catalytic asymmetric Zr-Zn transmetalation/aldehyde addition has been used in 
several natural product total syntheses.  Danishefsky and Trauner used this reaction at a very late 
stage of their total synthesis of halichlorine (Scheme 13).83  Since Horner-Wadsworth-Emmons 
homologation of the aldehyde prepared by oxidation of alcohol 57 was unsuccessful, alkyne 58 
was instead prepared and used in an asymmetric vinylation of aldehyde 59, catalyzed by amino 
alcohol 55.  The desired bis-allylic alcohol 60 was isolated in 67% yield as a 4:1 mixture of 
diastereomers.  In the absence of ligand 55, the ratio of diastereomers was 1:1.  Completion of 
the total synthesis required only protection of the newly formed allylic alcohol, deprotection of 
the primary alcohol and ester and their subsequent coupling under Keck macrolactonization 
conditions, and a final deprotection. 
 Wipf and Reeves used this asymmetric methodology in their formal synthesis of leucas-
candrolide A (Scheme 14).84  The zirconocene 62 was added to aldehyde 61 in the presence of 
Me2Zn and 25 mol% of amino thiol 56.  Allylic alcohol 63 was isolated in 62% yield as a 5:1 
mixture of diastereomers, though the major diastereomer had a configuration at the new alcohol 
stereocenter that was opposite to that predicted.  This forced a change in strategy for completion 
of the macrocyclic core.  In the absence of an external chiral ligand, the Me2Zn-mediated 
alkenylzirconocene addition to aldehyde 61 afforded a 1.8:1 mixture of diastereomers.85  
12 
 Williams and co-workers also used the Zr-Zn methodology to construct the same C-C bond in 
their approach to leucascandrolide A, though as with their approach to ratjadone (Scheme 8), no 
chiral ligand was employed and the newly formed allylic alcohol was immediately oxidized and 
then stereoselectively reduced.86
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Scheme 13. Catalytic asymmetric Zr-Zn transmetalation/aldehyde addition in Danishefsky’s 
total synthesis of halichlorine. 
 
 Porco and co-workers used the asymmetric Zr-Zn transmetalation/aldehyde addition in 
their total synthesis of lobatamide C (Scheme 15).87  Again, amino thiol 56 was used in catalytic 
quantities (10 mol%), here to affect the Et2Zn-mediated addition of alkenylzirconocene 66 to 
aldehyde 65.  The desired allylic alcohol was isolated in 68% yield but only as a 2:1 mixture of 
diastereomers, however, other methods evaluated for setting this stereocenter, including lipase 
reduction, asymmetric reduction of the corresponding dienone, and catalytic asymmetric alkynyl-
ation of the aldehyde, were no more effective.  In the absence of 56, the alcohol 67 was isolated 
in 87% yield as a 1:1 mixture of diastereomers. 
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Scheme 14. Catalytic asymmetric Zr-Zn transmetalation/aldehyde addition in Wipf’s total 
synthesis of leucascandrolide A.  
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Scheme 15. Catalytic asymmetric Zr-Zn transmetalation/aldehyde addition in Porco’s total 
synthesis of lobatamide C.  
 
 Li and Walsh have recently reported the catalytic asymmetric vinylation of ketones using 
the Zr-Zn transmetalation strategy (Scheme 16).88  Though Walsh and co-workers had previously 
reported a catalytic asymmetric vinylation of aldehydes using a B-Zn transmetalation/aldehyde 
14 
 addition,89 in the presence of the chiral amino alcohol (-)-MIB,90 a different approach was 
required for ketones.  High levels of enantiocontrol were achieved using Zr-Zn transmetalation 
and catalytic quantities of the chiral Ti complex prepared from Ti(Oi-Pr)4 and diol 70.91  Under 
these conditions, tertiary alcohols were formed in high yield (84-98%) and with good ee (79-
97%).  For example, vinylation of acetophenone (68) with alkenylzirconocene 6 in the presence 
of stoichiometric Me2Zn and Ti(Oi-Pr)4, and catalytic diol 70, afforded tertiary allylic alcohol 71 
in 85% isolated yield with an ee of 93% (the absolute stereochemistry was not determined).  The 
analogous vinylation of propiophenone (69) afforded alcohol 72 in 90% yield and 94% ee.  Other 
ketones succesfully tested included various arene-substituted acetophenones, 4-methyl-2-
pentanone, and a few α,β-unsaturated ketones. 
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Scheme 16. Catalytic asymmetric Zr-Zn transmetalation/ketone addition. 
 
 The goal of the research presented here was to develop an asymmetric synthesis of allylic 
amines by extending the Zr-Zn transmetalation methodology to imines.  Though an obvious 
disconnection, the 1,2-addition of functionalized organometallic reagents to imines has not been 
widely exploited for the synthesis of allylic amines.  An asymmetric synthesis of α-chiral 
benzylamines (by addition to benzaldimines) would produce valuable building blocks which 
could be used to prepare analogues of ligand 56 and improve the asymmetric allylic alcohol 
synthesis detailed in Scheme 12. 
 
1.3. Allylic Amines 
 Allylic amines are important chiral intermediates in organic synthesis, for example in the 
preparation of unnatural amino acids.92  This moiety is found in such natural products as 
15 
 motuporin,93 hemiasterlin,94 cyclotheonamide B,95 and curacin A,96 and is also used as a peptide 
isostere.97  As such, the preparation of allylic amines has long received considerable attention 
from the synthetic community.98
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 Though chiral allylic amines have been traditionally prepared by olefination of amino 
aldehydes,- ,99 this approach suffers from the low stability and ease of epimerization of the 
aldehydes.  The most used modern method for the preparation of allylic amines is the Overman 
rearrangement. ,100  This process is a [3,3]-sigmatropic rearrangement, without loss of stereo-
chemical integrity, of allylic imidates into allylic trichloroacetamides.  A recent demonstration of 
the methodology was reported in the asymmetric total synthesis of antofine by Kim and co-
workers (Scheme 17).101  Chiral allylic alcohol 73 was converted into allylic amide 74 under 
standard Overman rearrangement conditions.  Due in part to the relatively harsh conditions 
needed to deprotect the trichloroacetamide formed, alternate [3,3]-processes continue to be 
explored, including rearrangements of allyl cyanates,102 phosphorimidates103 and phospho-
lidines.104  Significantly, the metal-catalyzed preparation of enantiomerically enriched allylic 
amines from racemic imidates has been achieved105 and continues to be improved.106
 The most developed catalytic asymmetric preparation of allylic amines are allylic 
aminations of π-allyl complexes, pioneered by Trost.107  A recent demonstration of this 
methodology was reported by Nakanishi and Mori as the first key step in their asymmetric total 
synthesis of strychnine (Scheme 18).108  Allylic carbonate 76 was aminated by sulfonamide 77 
16 
 via its chiral π-allyl Pd-complex, affording allylic sulfonamide 78 in 75% yield with an ee of 
84%.  Though this transformation has not been as extensively used by the synthetic community 
as the Overman rearrangement, the methodology continues to be developed.109
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Scheme 17. An Overman rearrangement in the total synthesis of antofine by Kim et al.  
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Scheme 18. Asymmetric allylic amination in Mori’s total synthesis of strychnine.  
 
 Two other catalytic asymmetric preparations of allylic amines that have recently been 
described are Ni(II)-catalyzed hydroamination of dienes,110 and the aza-Baylis-Hilman reaction, 
using the modified cinchona alkaloid β-isocepeidine.111  Several methods have been reported for 
the preparation of chiral allylic amines from non-racemic precursors, including nucleophilic 
displacement of allylic bromides;112 tellurium-mediated reductive opening of aziridine methanol 
derivatives113 and the closely related indium-mediated opening of 2-iodo-methyl aziridines;114 
deoxygenation of 3-amino-1,2-diols;115 and dehydration of β-hydroxy-γ-amino sulfones.116  The 
17 
 lipase117 or chiral acid118 mediated resolution of racemic primary allylic amines has also been 
used to prepare enantiomerically pure allylic amines. 
 The 1,2-addition of alkenylorganometallic reagents to imines has not been widely 
exploited as a general method for the preparation of allylic amines.119  One reason could be 
dimerization of the alkenylorganometallic reagent resulting in α-selective crotylation.120  Many 
examples of catalytic asymmetric121 and diastereoselective122 additions of vinyllithium or vinyl 
Grignard reagent to imines and imine derivatives have been reported, though these are usually 
simply scope of a particular nucleophilic addition methodology.  A number of examples of 
diastereoselective additions of a highly substituted alkenyllithium to sulfonylimines were 
reported by Braun and Opdenbusch; however, the allylic double bonds were immediately 
oxidatively cleaved to form amino acids.123  In some cases, diastereoselective addition of 
nucleophiles to imines for the preparation of analogues of ligands,124 peptides,125 sugars,126 or the 
antibiotic anisomycin,127 included one example of addition of vinyllithium or vinyl Grignard.  
Diastereoselective addition of vinylmagnesium bromide to a chiral α-hydroxy imine was a key 
step in the total synthesis of 4a,5-dihydrostreptazolin,128 and diastereoselective addition of vinyl-
lithium to a chiral oxime ether was the key step in the synthesis of CP-99,994.129  A related 
preparation of allylic amines, by catalytic asymmetric130 or diastereoselective131 1,2-addition of 
nucleophiles to α,β-unsaturated imines, has been reported.  Very few examples of racemic132 or 
asymmetric133 additions of vinylzinc reagents to imines have been reported. 
 Buchwald and co-workers have reported a zirconocene-mediated synthesis of allylic 
amines starting from alkynes and imines (Scheme 19).134  Lithiation of amine 80 and addition to 
Cp2ZrMeCl afforded, after loss of methane, azazirconacyclopropane 82.  Coupling of 82 with 
alkynes such as 1-hexyne formed allylic amines such as 84 after methanolysis of the Zr-C and 
Zr-N bonds.  The regioselectivity of alkyne coupling was excellent if one of the substituents in 
the 3- or 5-position of azazirconacyclopentene 83 was aromatic.  Yields ranged from 48 to 80% 
with examples of primary aliphatic and benzylic amines, and both terminal and internal alkynes.  
An asymmetric, auxiliary-based variant was subsequently reported.135  Whitby,136 Mori,137 and 
others138 have expanded this methodology, and the equivalent Ta-139 and Ti-mediated140 
transformations have been reported. 
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Scheme 19. Buchwald’s Zr-mediated synthesis of allylic amines.  
 
 Another synthesis of allylic amines involving zirconium was reported by Hauske and co-
workers (Scheme 20).141  Non-racemic propargylic amines were prepared and then the triple 
bond was hydrozirconated and functionalized via iodination or Ni(II)-catalyzed 1,4-addition.  
For example, valine-derived propargyl carbamate 86 was converted into vinyl iodide 87 in 
modest yield.  To demonstrate the scope of this transformation, seven simple amino acid 
derivatives were selected.  The derivatized allylic amines were isolated in only 20-54% yield. 
 
NHBoc Cp2ZrHCl; I2
NHBoc
ICHO
NHBoc (MeO)2P(O)CHN2
(76%) (51%)
85 86 87  
Scheme 20. Hydrozirconation of propargylic amines to form allylic amines.  
 
 A few methods for the construction of allylic amines using alkynes and imines, related to 
the research presented herein, have recently been reported.  The Zr-Zn transmetalation strategy 
described in the previous section was extended by Vallée and co-workers to the preparation of 
allylhydroxylamines, using nitrones as electrophiles (Scheme 21).142  For example treatment of 
nitrone 88 with hexenylzirconocene 6 in the presence of Et2Zn afforded hydroxylamine 89 in 
62% yield.  Both aliphatic and aromatic nitrones were used in this process.  The isolated yields 
for unfunctionalized, terminal and internal alkynes were in the range of 29-83%, whereas yields 
for functionalized alkynes ranged from 5-60%.  The same transformation using hydroboration in 
place of hydrozirconation was subsequently reported.143
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Scheme 21. Et2Zn-mediated addition of alkenyl zirconocenes to nitrones.  
 
 A Rh(I)-catalyzed addition of alkenyl zirconocenes to N-tosyl aldimines was reported by 
Kakuuchi, Taguchi and Hanzawa (Scheme 22).144  For example, addition of hexenylzirconocene 
6 to aldimine 90 in the presence of 2 mol% of the rhodium catalyst afforded sulfonamide 91 in 
near quantitative yield.  The authors suggest a transmetalation of the alkenyl group from Zr to Rh 
prior to 1,2-addition to the aldimine.  They observed no alkyl group transfer from substrates 
prepared by hydrozirconation of alkenes.  The hydrozirconation step was performed in CH2Cl2 
and then the solvent switched to dioxane prior to addition of the aldimine and Rh(I) catalyst to 
the reaction mixture.  Both aromatic and aliphatic aldimines as well as functionalized alkynes all 
formed the desired sulfonamides in high (58-99%) yield. 
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Scheme 22. Rhodium(I)-catalyzed addition of alkenyl zirconocenes to imines.  
 
 Water-accelerated carboalumination of alkynes is another effective method for the 
preparation of reactive alkenyl organometallics.145  Wipf, Nunes and Ribe showed that direct 
addition of vinyl alanes to enantiopure N-sulfinimines146 afforded trisubstituted allylic amines in 
high yield and good diastereoselectivity (Scheme 23).147  For example 93, the methylaluminated 
product derived from 1-octyne, was added to sulfinimine 92 affording sulfinamide 94 with an 
80% isolated yield and diastereomeric ratio of 20:1.  Functional group tolerance on the alkyne 
segment is not as broad for carboalumination as for hydrozirconation, nevertheless a range of 
unfunctionalized alkynes were used as well as a triisopropylsilyl ether-substituted terminal 
alkyne.  Aromatic, cinnamyl and cyclohexyl sulfinimines were used as substrates, with isolated 
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 yields ranging from 65-85%, and all diastereoselectivities were at least 6:1.  An alkyne 
carbocupration, imine-addition strategy has also been used to prepare allylic amines.148
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Scheme 23. Diastereoselective addition of alkenyl alanes to sulfinimines.  
 
 A three-component Ni(0)-catalyzed coupling of alkynes, organoboron reagents, and 
aldimines, forming tetrasubstituted allylic amines, was reported by Patel and Jamison (Scheme 
24).149  For example the reaction of alkyne 96, benzaldimine 95, and triethylborane, catalyzed by 
5 mol% of a Ni(0)/trialkylphosphine complex afforded allylic amines 97-99 in 78% combined 
yield.  The scope of this reaction was limited to internal alkynes and the regioselectivity of the 
double bond formed was high (9:1) only for alkyne substrates that included one aryl and one 
alkyl substituent.  When trialkylboranes were used, the reductive coupled product 99 was formed 
in ca. 10% yield; however, when boronic acids were used, only the alkylative coupled products 
(for example regioisomers 97 and 98) were isolated.  Both aromatic and aliphatic aldimines were 
used and the isolated yields of the product mixtures ranged from 30-98%. 
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Scheme 24. Racemic Ni-catalyzed reductive coupling of alkynes, boranes, and imines.  
 
 Recently, this reaction was extended to an asymmetric synthesis of allylic amines by 
using chiral phosphine 101 and alkylimines such as 100 (Scheme 25).150  Not only were most of 
the desired allylic amines obtained in good yield (42-95%) and high enantioselectivity (51-89% 
ee), but the undesired products of reductive coupling, such as 99, were avoided under these 
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 reaction conditions.  The enantioenriched allylic amines formed were oxidatively deprotected 
with no loss of enantiomeric purity to afford the corresponding primary amines.  No explanation 
for determination of the absolute stereochemistry of the allylic amines was given. 
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Scheme 25. Asymmetric Ni-catalyzed reductive coupling of alkynes, boranes, and imines.  
 
1.4. Diethylzinc Additions to Aldimines 
 Despite the vast body of knowledge for dialkylzinc (R2Zn) additions to aldehydes,151 the 
corresponding addition to aldimines has not been as widely studied due to their significantly 
lower electrophilicity.152  Most examples have been limited to the addition of strongly basic 
reagents such as Grignard reagents or alkyllithiums.  Katritzky and Harris reported the 
asymmetric addition of Et2Zn to N-(amidobenzyl)-benzotriazoles (masked N-acylimines) in up to 
76% ee in the presence of one equivalent of N,N-dibutylnorephedrine.153  Soai and co-workers 
soon afterwards reported that N-diphenylphosphinoylimines such as 104 were sufficiently active 
for R2Zn addition, and the easily deprotected phosphinamide products 106 could be prepared in 
up to 90% ee and recrystallized to higher enantiomeric purities (Scheme 26).154  Again, one 
equivalent of a norephedrine ligand was used.  Similar levels of enantiocontrol (84% ee and 76% 
isolated yield) were obtained when the same reaction was performed in neat Et2Zn.155
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HPh
PPh2
O
3 equiv Et2Zn
1 equiv 105,
toluene, 0 °C
(89%)
NHP(O)Ph2
Ph
104
(S)-106, 90% ee
1. H3O+
2. OH-
NH2
Ph
107
OHN
Ph
O
105
 
Scheme 26. Soai’s asymmetric addition of Et2Zn to N-diphenylphosphinoylimine 104.  
 
 Soai has subsequently developed polymer-156 and dendrimer-supported157 norephedrine 
ligands for use in this asymmetric transformation, and other groups have developed amino 
alcohols 108,158 109,159 110,160 111,161 112,162 and 113.163  A survey of results is presented in 
Table 1.  The isolated yields of 106 were in general high, normally within the range of 65-90%, 
and the reaction required at least three equivalents of Et2Zn.  Highest ee was achieved when one 
equivalent of the chiral ligand was used (compare Entries 1 with 2; 3 with 4; 5 with 6; and 10 
with 11 and 12).  The reaction times were long and usually required room temperature for 
acceptable rates.  Pericàs and co-workers developed an amino alcohol/silyl halide protocol that 
allowed performing the reaction at -20 °C, though no significant improvement in yield or ee was 
observed with the asymmetric ligands tested (Entry 7).  Recently, Beresford has found that using 
catalytic quantities of the natural alkaloid cinchonidine (113) as the amino alcohol and two 
equivalents of MeOH afforded α-ethylbenzylamine 106 with a similar yield and ee (entry 13) as 
when one equivalent of 113 was used (entry 10). 
N
Bn
CH2OH
N
Ph
Ph
OH
N OH
Ph
NH
Ph
OH
HO
Ph
N
O
Ph
N
OH
N
H
111
112
113 (cinchonidine)110
109108
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Table 1. Representative examples for asymmetric Et2Zn addition to 104. 
N
HPh
PPh2
O
3 equiv Et2Zn
L*, toluene
NHP(O)Ph2
Ph
104
106
 
Entry L* (Equiv) Temperature Yield (%) ee (%) Reference 
1 105 (1.0) 0 °C 89 90 (S) 154 
2 105 (0.5) 0 °C 69 85 (S) 154 
3 108 (1.0) rt 63 94 (R) 158a 
4 108 (0.5) rt 76 87 (R) 158a 
5 109 (1.0) rt 75 97 (S) 159c 
6 109 (0.5) rt 68 92 (S) 159c 
7a 110 (1.0) -20 °C 75 92 (S) 160b 
8b 111 (1.0) rt 92 97 (R) 161b 
9b 112 (1.0) rt 77 91 (S) 162a 
10c 113 (1.0) rt 76 93 (R) 163a 
11c 113 (0.5) rt 77 87 (R) 163a 
12c 113 (0.05) rt 50 69 (R) 163b 
13c 113 (0.2)d rt 70 93 (R) 163b 
a1 equiv TIPS-Cl added to the reaction mixture. b5 equiv Et2Zn 
used. c12 equiv Et2Zn used. d2 equiv MeOH added. 
 
 The process chemistry group at Bristol-Myers Squibb tested the asymmetric alkylation of 
N-diphenylphosphinoylimines during the large-scale synthesis of a candidate for the treatment of 
cystic fibrosis and rheumatoid arthritis, DMP 777 (Scheme 27).164  Alkylation of imine 114 with 
n-Pr2Zn in the presence of 1.5 equivalents of norephedrine-derived amino alcohol ent-105 was 
performed on a 30 mmol scale, affording (R)-115 in 67% conversion, but 50% isolated yield 
(after crystallization), and 89% ee.  Phosphinamide 115 was then deprotected using TFA/MeOH 
at reflux.  Ultimately, a diastereoselective hydrogenation of chiral ketimine 118 was selected to 
prepare large quantities of chiral amine 116, despite destruction of the chiral auxiliary in this 
process.  The phosphinimine alkylation method was undesirable due to the relatively low ee of 
89% obtained, and the need to use stoichiometric quantities of ent-105. 
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 N
H
Ph2P
O
O
n-Pr2Zn
1.5 equiv ent-105,
toluene/heptane, 0 °C
(50%)
NHP(O)Ph2
O
O
114
115, 89% ee
30% TFA
MeOH, reflux;
NaOH/toluene
(80%)
NH2
O
O
O
116, 90% ee
O
O
117
O
(R)-α-methylbenzylamine
0.55 equiv TiCl4,
Et3N, toluene, reflux O
O
NPh
118
NH3Cl
O
O
116•HCl, 99.0% ee
NH
O
O
N
O
O
O
N
N
Me
O
Et
Et
DMP 777
1. H2 (150 psi), cat. Ra-Ni,
    toluene/EtOH, rt
2. H2 (150 psi), cat. Pd-C,
    AcOH/toluene/EtOH, rt
3. HCl, i-PrOH/toluene, 20 °C
(60-70%)
 
Scheme 27. Comparison of asymmetric alkylation of N-diphenylphosphinoylimine 114 and 
diastereoselective hydrogenation by the process group at Bristol-Myers Squibb.  
 
 Tomioka and co-workers reported an asymmetric alkylation of N-tosylimines, catalyzed 
by Cu(OTf)2 and phosphine 119.165  Several other groups have subsequently investigated this 
Cu-catalyzed reaction, using ligands 122,166 123,167 124,168 and 125.169  A survey of their results 
(for alkylation of imines derived from aromatic aldehydes) is shown in Table 2.  Tomioka and 
co-workers improved their ligand’s selectivity by preparing 120 (for Et2Zn addition, entry 1) and 
121 (for Me2Zn and i-Pr2Zn addition, entries 2 and 3).  Charette and co-workers have developed 
ligand 122 for the alkylation of phosphinimines (entries 4-6), resulting in a superior process due 
to the significantly milder deprotection conditions of diphenylphosphinamides compared to 
sulfonamides.  High ee’s were reported for Et2Zn, Me2Zn and i-Pr2Zn additions to both aromatic 
and in situ generated aliphatic imines.  Hoveyda, Snapper and co-workers have successfully 
developed a Zr-catalyzed asymmetric addition of Et2Zn to imines derived from condensation of 
aryl aldehydes and o-anisidine, in the presence of as little as 0.1 mol% of peptide 126 (entry 
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 10).170  Dahmen and Bräse have reported that in situ generated N-formylimines can be alkylated 
by Et2Zn in the presence of catalytic quantities of paracyclophane amino alcohol 127 affording 
adducts in very high yield and enantioselectivity (entry 11).171
N
PPh2
O
R
R
R
R
R
R
119: R = H
120: R = Me
121: R = i-Pr
P
P
O
122
NHEt
NHP(S)Me2
123
NHP(S)Me2
NHEt
124
N
N N
O O
Ph Ph
125
OH
N
H
N
O
Ph
126
N
H
O
C4H9
N
PhOH
127  
 
Table 2. Representative examples for catalytic asymmetric R2Zn addition to aromatic imines. 
N
HPh
PG
cat. Metal, L*
NH(PG)
Ph R
R2Zn
 
Entry R (Equiv) PG Metal (mol%) L* (mol%) Yield (%) ee (%) Reference
1a Et (2) Ts Cu(OTf)2 (5) 120 (6.5) 97 96 (S) 165c 
2b Me (8) Ts Cu(OTf)2 (20) 121 (15) 97 87 (S) 165c 
3a i-Pr (2) Ts Cu(OTf)2 (20) 121 (15) 92c 78 (S) 165c 
4a Et (2) P(O)Ph2 Cu(OTf)2 (6) 122 (3) 96 98 (S) 166b 
5b Me (3) P(O)Ph2 CuOTf (5) 122 (5) 87 97 (S) 166b 
6a i-Pr (3) P(O)Ph2 Cu(OTf)2 (10) 122 (5) 84 95 (S) 166b 
7a Et (2) Ts CuBF4 (3) 123 (6) 93 86 (S) 167b 
8a Et (2) Ts CuClO4 (3) 124 (6) 92 68 (S) 168 
9d Et (4) Ts Cu(OTf)2 (10) 125 (12) 58 77 (S) 169 
10b Et (3) 2-C6H4OMe Zr(Oi-Pr)4 (20) 126 (0.1) 82 93 (S) 170a 
11e Et (6) CHO none 127 (2) 99 95 (R) 171 
aReaction in toluene at 0 °C. bReaction in toluene at rt. c5% of BnNHTs also isolated. dReaction 
in toluene at -20 °C. eReaction in hexane at 10 °C. 
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 1.5. Simmons-Smith Cyclopropanation 
 In the course of the research presented here, a one-pot imine vinylation/cyclopropanation 
was discovered.  The mechanism was thought to involve an allylic amide-directed Simmons-
Smith cyclopropanation.172  Cyclopropane amino acids are of considerable interest as many, such 
as (2S,1’S,2’S)-2-(carboxycyclopropyl)glycine (L-CCG-I)173,174 and (2S,4R)-hypoglycin A,175 
show biological activity.176  They are also increasingly used in the pharmaceutical industry, in 
active compounds such as BILN 206.177
H2N
HO2C
H
hypoglycin AL-CCG-I
H2N
HO2C CO2H
N
O
H
NO
O
O
H
N CO2H
O
N N
S H
NMeO
BILN 2061  
 Simmons and Smith discovered that the cyclopropanation of alkenes could be 
accomplished using the product of a zinc/copper couple and CH2I2.178  The active reagent was 
believed to be the electrophilic zinc carbenoid IZnCH2I.  Furukawa and co-workers found that a 
similar cyclopropanating reagent, presumably EtZnCH2I, could be formed by mixing Et2Zn and 
CH2I2.179  A number of metal/CH2X2 (X = halogen) combinations, with or without additional 
ligands, have been subsequently developed. b,180
 The Simmons-Smith reaction has gained wide use for the cyclopropanation of alkenes 
due to its tolerance of most common functional groups including alkynes, alcohols, ethers, 
aldehydes, ketones, and carboxylic acids and their derivatives.  Dihalides other than CH2I2, such 
as CH3CHI2, can be used to form trisubstituted cyclopropanes.181  CH2Cl2 is the solvent of choice 
for this reaction, since it is “non-basic, unreactive towards the zinc reagents, and polar enough to 
solubilize the substrates.” a 
 An important characteristic of the Simmons-Smith cyclopropanation is that it can be 
directed by allylic alcohols and ethers. ,182  For example, the more sterically hindered β-face of 
the allylic double bond of alcohol 128 was diastereoselectively and chemoselectively cyclo-
propanated using the Simmons-Smith reagent (Scheme 28).183
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HO
Zn/Cu, CH2I2
Et2O, DME, 65 °C
(85%)
HO
128 129  
Scheme 28. Alcohol-directed Simmons-Smith cyclopropanation.  
 
 (Z)-Disubstituted and trisubstituted allylic double bonds nearly always give very high 
syn-selectivities when cyclopropanated; however, selectivities with (E)-disubstituted double 
bonds are much lower, and highly reagent- and substituent-dependant.184  In some cases (E)-
disubstituted allylic ethers can favor anti-selectivity (Table 3).185  Two trends can be observed: 
as the size of R2 increases, syn-selectivity increases as well; however, the size of the R1 ether has 
the opposite effect, increasing anti-selectivity. 
 
Table 3. Substituent effects on syn/anti selectivity for (E)-disubstituted allylic ethers. 
OR1
R2Ph
OR1
R2Ph
OR1
R2Ph
+
CH2Cl2
EtZnCH2I (R1 = Me and Bn)
or CF3CO2ZnCH2I (R1 = TES)
 
Entry R1 R2 Yield (%) syn:anti Reference 
1 Me Me 95 39:61 185a 
2 Me Et 93 77:23 185a 
3 Me i-Pr 94 98:2 185a 
4 Bn Me 94 10:90 185a 
5 Bn Et 97 33:67 185a 
6 Bn i-Pr 82 95:5 185a 
7 TES Me 87 >1:99 185b 
8 TES Et 87 3:97 185b 
9 TES i-Pr 78 30:70 185b 
 
 Transition state models that explain these trends are shown in Figure 3.  The allylic A1,3-
strain of transition state I, normally used to explain syn-selectivity for allylic alcohol-directed 
cyclopropanation (i.e. R1 = H for the allylic alcohol substrate), decreases relative to the strain 
between the R1 and R2 groups in transition state II for sufficiently large R1 and small R2 groups.  
Allylic A1,3-strain is the dominant interaction for (Z)-allylic ethers. 
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Figure 3. Transition state models for anti- and syn-selective cyclopropanations 
of allylic ethers. a
 
 Amides can also be strong directing groups in the Simmons-Smith reaction, though there 
are very few published examples.  Cyclopentenylamide 130 was cyclopropanated exclusively syn 
to the amide, despite the presence of an allylic alcohol on the opposite face of the ring (Scheme 
29).186  Reversal of selectivity was observed when the fully N-protected cyclopentene 132 was 
subjected to the same reaction conditions.  The related cyclopropanation of α,β-unsaturated 
amides using SmI2/CH2I2 was proposed to involve co-ordination of Sm to the carbonyl 
oxygen.187
 Amines are normally not directing groups for Simmons-Smith cyclopropanation, likely 
due to competitive formation of zinc-complexed ammonium ylides.188  Aggarwal and co-workers 
have found that a suitably proximal hydroxyl group inhibited ylide formation between allylic 
amines and bis-iodomethylzinc, thus allowing cyclopropanation of the alkene (Scheme 30).189  
For example, pseudoephedrine-containing allylic amine 134 was cyclopropanated to afford 135 
as a single diastereomer in very high yield.  Tertiary amines were required, and no additional 
functional groups, such as alcohols or esters, were tolerated as substituents on the substrate.  The 
29 
 chiral auxiliary was removed in high yield by quaternizing the amine followed by heating with 
NaH. 
 
BnO
HO
NHAc
Et2Zn, CH2I2
CH2Cl2
(50%)
130
BnO
HO
NHAc
131
BnO
HO
N
132 133
Ac
Bn
BnO
AcO
N Ac
Bn
1. Et2Zn, CH2I2, CH2Cl2
2. Ac2O, Et3N,
    cat. DMAP, THF
(50%)
 
Scheme 29. Amide-directed Simmons-Smith cyclopropanation.  
NMe
OHPh
Ph
Zn(CH2I)2
CH2Cl2, 0 °C, 48 h
(95%)
NMe
OHPh
Ph
134 135, dr > 98:2
1. neat MeI
2. NaH, THF,
    reflux
(93%)
NMe2
Ph
136
 
Scheme 30. Amine-directed Simmons-Smith cyclopropanation.  
 
 Oshima and co-workers have combined the Zr-Zn transmetalation strategy with 
Simmons-Smith cyclopropanation conditions for a net synthesis of trans-disubstituted cyclo-
propanes from alkynes (Scheme 31).190  For example, hydrozirconation of 1-dodecyne and 
transmetalation with i-PrZnCl formed alkenylzinc reagent 139.  Addition of the Furukawa 
reagent to the reaction mixture, stirring at room temperature for 1 h, and quenching with 
deuterated acetic acid afforded cyclopropane 141 (via trans-cyclopropylzinc species 140).  Cu-
mediated allylation of 140 afforded the corresponding allyl-substituted cyclopropane. 
 Taguchi, Hanzawa and co-workers have reported another Zr-mediated synthesis of cyclo-
propanes.  They prepared cyclopropyl alcohols from vinyloxiranes by simply treating the 
substrate with Schwartz reagent in CH2Cl2 (Scheme 32).191  This reaction was very diastereo-
selective for cis-vinyloxirane 142, as C-cyclopropyl alcohol 145 was the only diastereomer 
isolated from the reaction mixture.  When the trans-vinyloxirane was used, the diastereomeric 
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 ratio of the anti,trans-cyclopropane (vs. anti,cis-) was 80:20.  The analogous hydrozirconation of 
vinylaziridines afforded C-cyclopropylalkylamines.  Allylic ethers have also been converted into 
cyclopropanes by the same mechanism, however, a Lewis acid was needed for deoxygenation.192
 
C10H21
Cp2ZrHCl
CH2Cl2
ClCp2Zr C10H21
i-PrZnCl
i-PrZn
C10H21
Et2Zn, CH2I2 RZn
C10H21
AcOD D
C10H21
141
137 138
140139
(65%)
 
Scheme 31. Zr-Zn transmetation/Simmons-Smith cyclopropanation.  
Ph
O Cp2ZrHCl
CH2Cl2
Ph
O
ZrCp2Cl
Ph
ClCp2ZrO NaHCO3
(98%) Ph
HO
142 143
144 145  
Scheme 32. Synthesis of C-cyclopropyl alcohols from vinyloxiranes using Schwartz reagent.  
31 
 2. Results and Discussion 
2.1. Synthesis of Allylic Amines193 
 The research project described here was initiated to extend the Zr-Zn methodology 
developed in the Wipf group to an asymmetric synthesis of allylic amines.  Optimization of a 
racemic transformation analogous to the allylic alcohol synthesis detailed in Scheme 6 was 
undertaken using 1-hexyne (30) and benzaldimine 104.  The hydrozirconation of terminal 
alkynes is very rapid in CH2Cl2 or THF at room temperature, thus initially the one-pot reaction 
was attempted in either of these two solvents (Table 4).  Standard conditions were as follows: 1.5 
equivalents of 30 were hydrozirconated with an equimolar quantity of Cp2ZrHCl.  Once the 
reaction mixture was homogeneous (~10 min), it was cooled to -78 °C, treated with 1.5 
equivalents of Me2Zn, rapidly warmed to room temperature, cannulated into a solution of 
aldimine 96, and stirred until TLC analysis showed consumption of the imine.  Performing the 
reaction under these standard conditions in CH2Cl2 yielded only 41% of the desired allylic amide 
146 after 18 h (entry 1).  The reaction time was decreased significantly by heating the reaction 
mixture to reflux (entry 2), though the isolated yield increased only to 59%.  Increasing the 
number of equivalents of reagents and heating at reflux (entries 3 and 4) had a detrimental effect 
on the yield (vide infra).  There was no trace of 1,2-addition in the absence of Me2Zn in CH2Cl2 
after 4 h (entry 5). 
 Under standard conditions in THF, only 54% of 146 was isolated after 36 h (Table 4, 
entry 6).  Either doubling the number of equivalents (entry 7), heating the reaction mixture (entry 
8), or both (entry 10) reduced the reaction time but did not increase the isolated yield.  The 
optimal conditions in THF consisted of heating the reaction mixture to 40 °C and using 2 
equivalents of all reagents, which gave a 65% yield of 146, based on aldimine 104, after 16 h 
(entry 9).  Additives such as TMS-Cl,194 MeOH  or an amino alcohol,  each of which accelerate 
Et2Zn addition to aldimines, did not improve the isolated yield or rate of reaction in CH2Cl2 or 
THF (entries 11-13). 
 The results in CH2Cl2 and THF were not promising, so toluene was investigated as the 
reaction solvent.  When the entire one-pot reaction, including hydrozirconation at 40 °C for 1 h, 
was performed in toluene, 59% of 146 was isolated (Table 4, entry 14).  However, when hydro-
zirconation was first performed in CH2Cl2 and then the solvent switched to toluene, gratifyingly 
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 a 76% yield of 146 was isolated after 2 h (entry 15).  When Me2Zn was omitted from the reaction 
mixture, again no addition product was observed (entry 16); however, a catalytic amount of 
Me2Zn resulted in nearly as high a yield as when using 1.5 equivalents of Me2Zn, though the 
reaction time was significantly increased (entry 17).  Again, additives such as MeOH or BnOH 
had no affect on the reaction yield (entries 18 and 19). 
 
Table 4. Imine addition optimization studies. 
C4H9
Cp2ZrHCl ClCp2Zr C4H9
N
HPh
PPh2
O
Me2Zn
NHP(O)Ph2
Ph C4H930 6
104
146  
Entry Equiv 6 Equiv Me2Zn
Solvent Temperature Time (h) Yield (%)a
1 1.5 1.5 CH2Cl2 rt 16 41 
2 1.5 1.5 CH2Cl2 reflux 16 59 
3 2.0 2.0 CH2Cl2 reflux 16 43 
4 3.0 3.0 CH2Cl2 reflux 16 11 
5 1.5 0 CH2Cl2 rt 4 0 
6 1.5 1.5 THF rt 36 54 
7 3.0 3.0 THF rt 16 50 
8 1.5 1.5 THF 30 °C 20 49 
9 2.0 2.0 THF 40 °C 16 65 
10 3.0 3.0 THF 40 °C 4 52 
11 1.5 1.5 CH2Cl2 rt 16 40b
12 1.5 1.5 CH2Cl2 reflux 16 64c
13 1.5 1.5 THF rt 36 45d
14 1.5 1.5 toluene rt 4 59 
15 1.5 1.5 toluenee rt 2 76 
16 1.5 0 toluenee rt 16 0 
17 1.5 0.2 toluenee rt 16 72 
18 1.5 1.5 toluenee rt 6 74c
19 1.5 1.5 toluenee rt 6 74f
aYields of isolated products are based on aldimine 104. b0.1 equiv of 
HO(CH2)2NMe2 was added. c0.5 equiv of MeOH was added. d1 equiv of 
TMS-Cl was added. eHydrozirconation was performed in CH2Cl2, which 
was subsequently removed in vacuo and replaced with toluene. f0.5 equiv of 
PhCH2OH was added. 
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  Using the optimized reaction conditions (Table 4, entry 15), the reaction scope was 
investigated (Table 5).  Trisubstituted alkene 147 was prepared in high yield from 3-hexyne 
(entry 2).  Functional groups on the alkyne such as silyl ethers (entry 3), silyl esters (entry 4), 
sulfonamides and carbamates (entry 5) were tolerated.  Bulky trimethylsilylacetylene did not 
yield any significant quantities of the desired allylic amide 155 (entry 6).  In contrast to Et2Zn 
addition to 104, electron-withdrawing groups on the benzaldimine did not affect the reaction 
(entry 7), whereas the presence of electron-donating groups significantly reduced the isolated 
yield (entry 8). 
 Other N-diphenylphosphinoylimines derived from non-enolizable aldehydes were 
prepared and subjected to these reaction conditions.  Thus α,β-unsaturated aldimines 160 and 
162 were converted to bis-allylic amides 161 and 163, and alkynlimine 164 was converted to 
propargylamide 165 in 85% yield (Table 5, entries 9-11).  The N-tosyl group was also suitable 
for activating benzaldimine 90 under these conditions (entry 12), and N-tosylimines 166, 168 and 
170, derived from enolizable aldehydes, formed amides 167, 169 and 171 (entries 13-15). 
 
Table 5. Synthesis of allylic amines using the Zr-Zn transmetalation methodology. 
Entry Alkyne Aldimine Allylic Amine Yield (%)
1 1-hexyne (30) 
N
HPh
PPh2
O
104  
NHP(O)Ph2
Ph C4H9
146  
76 
2 3-hexyne 104 
NHP(O)Ph2
Ph Et
Et
147  
72 
3 
OBDPS
148  
104 
NHP(O)Ph2
Ph
149
OBDPS
 
73 
4 
150
OTIPS
O
 
104 
NHP(O)Ph2
Ph
151
CO2TIPS
 
65 
5 N
152
CO2Et
Ts
 
104 
NHP(O)Ph2
Ph
153
N(Ts)CO2Et
 
59 
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 Table 5 (continued). Synthesis of allylic amines using the Zr-Zn transmetalation methodology. 
Entry Alkyne Aldimine Allylic Amine Yield (%)
6 
TMS
154  
104 
NHP(O)Ph2
Ph TMS
155  
< 10 
7 30 
N
H
PPh2
O
MeO2C
156
NHP(O)Ph2
C4H9
MeO2C
157  
84 
8 30 
N
H
PPh2
O
MeO
158  
NHP(O)Ph2
C4H9
MeO
159  
35 
9 30 
N
H
PPh2
O
Ph
160  
NHP(O)Ph2
C4H9Ph
161  
28 
10 30 
N
H
PPh2
O
Ph
162  
NHP(O)Ph2
C4H9Ph
163  
72 
11 30 
N
H
PPh2
O
Ph
164  
NHP(O)Ph2
C4H9
Ph
165  
85 
12 30 
N
HPh
Ts
90  
NHTs
Ph C4H9
91  
80 
13 30 
N
H
Ts
166
Ph
 
NHTs
C4H9
167
Ph
 
90 
14 30 
N
H
Ts
168  
NHTs
C4H9
169  
71 
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 Table 5 (continued). Synthesis of allylic amines using the Zr-Zn transmetalation methodology. 
Entry Alkyne Aldimine Allylic Amine Yield (%)
15 30 
N
H
Ts
170  
NHTs
C4H9
171  
81 
aReaction conditions: (i) 1.5 equiv of Cp2ZrHCl, 1.5 equiv of alkyne, CH2Cl2, rt, 10 min; 
(ii) 1.5 equiv of Me2Zn, toluene, -78 °C, 5 min; (iii) 1.0 equiv of aldimine, toluene, rt, 2-5 
h. bYields of isolated products are based on aldimines. 
 
 Like benzyl phosphinamide 106, the allylic phosphinamides prepared were easily 
deprotected under mild conditions.195  For example, anhydrous HCl in MeOH removed the 
diphenylphosphinoyl group of 172, and in one pot the allylic amine was reprotected as amide 
173, carbamate 174 or sulfonamide 175 (Scheme 33). 
 
NHP(O)Ph2
C3H7
C3H7
MeO2C
1. 2 N HCl, MeOH
2. R-Cl, cat. DMAP,
    (i-Pr)2NEt, CH2Cl2
NHR
C3H7
C3H7
MeO2C
NHCOPh
C3H7
C3H7
MeO2C
NHCO2Ph
C3H7
C3H7
MeO2C
NHSO2Ph
C3H7
C3H7
MeO2C
172
173 (84%) 174 (90%) 175 (77%)
 
Scheme 33. Facile one-pot deprotection and derivitization of allylic phosphinamide 172. 
 
 Several other aldimines were tested using the conditions of Table 5.  Carbamoylimines 
such as 175, and N-acetylimine 177 were significantly more reactive than phosphinimine 104 or 
sulfonimine 90 (vide infra).   All benzaldimines that did not have an activating (strongly 
withdrawing) group on nitrogen, including N-aryl imine 178, N-silyl imine 179, and oxime 180, 
were unreactive under the Zr-Zn transmetalation conditions. 
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N
HPh
TMS
MeO2C
H
N
OPh
176
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N
HPh
O
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2.2. Asymmetric Synthesis of Allylic Amines 
 Development of an asymmetric synthesis of 144, through the use of chiral amino alcohol 
or thiol promoters that were effective for the enantioselective allylic alcohol reaction detailed in 
Scheme 13, was unsuccessful.  Amino alcohol 55 and amino thiophenol 181 were used for the 
attempted ee optimization studies (Table 6).  Both were effective asymmetric catalysts for the 
Zr-Zn transmetalation/aldehyde addition reaction, and both can easily be prepared in large scale 
in two steps from inexpensive, commercially available starting materials. 
N
Me OH
55
SH
NMe2
Ph
Ph
181
 Optimization was performed for the addition of alkenylzirconocene 6 to imine 104.  
Using the standard conditions of toluene as the reaction solvent and performing the reaction at 
room temperature gave acceptable yields of 146 but less than 5% ee when 10 or 50 mol% of 55 
was added to the reaction mixture (Table 6, entries 1 and 2).  The same occured when amino 
thiol 181 was used with a reaction temperature of 0 °C (entries 3 and 4).  For phosphinimine 104, 
when the reaction was performed at -20 °C there was a significant drop in the rate of reaction, 
and only a very small ee was measured by chiral HPLC (entry 5). 
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 Table 6. Attempted asymmetric addition reactions with imine 104 and ligands 55 and 181. 
N
Ph H
PPh2
O
104
ClCp2Zr C4H9 6
Me2Zn, 55 or 181,
toluene, 16-48 h
NHP(O)Ph2
Ph C4H9
146
 
Entry Equiv Me2Zn 
L* Equiv L* Temperature Yield (%)a ee (%)b
1 1.2 55 0.1 rt 65 < 5 
2 1.2 55 0.5 rt 71 < 5 
3 1.5 181 0.1 0 °C 68 < 5 
4 1.5 181 0.5 0 °C 69 < 5 
5 1.5 181 0.1 -20 °C 39 10 
6 1.0 55 1.0 rt 0 - 
7 3.0 55 1.0 rt 66 24 
8 3.0 55 1.0 10 °C 75 23 
9 3.0 55 1.0 0 °C 27 29 
10 3.0 181 1.0 10 °C 56 34 
11 0.2 181 0.5 50 °C 56 18 
aYields of isolated products based on 104. bMeasured by chiral HPLC 
using a Chiracel OD or AD Column. 
 
 Though the reaction was largely unaffected by the presence of substoichiometric 
quantities of ligand when at least one equivalent of Me2Zn was used, addition of one equivalent 
of 55 to an equal amount of Me2Zn suppressed addition of alkenylzirconocene 6 to imine 104 
(Table 6, entry 6).  The use of stoichiometric quantities of 55 required 3 equivalents of Me2Zn 
for an acceptable isolated yield of 146, but the ee of the reaction was still not high (entry 7).  
Lowering the temperature did not significantly increase the ee, and once again reduced the rate 
of reaction (entries 8 and 9).  The highest ee of allylic phosphinamide 146 (34%) was achieved 
using three equivalents of Me2Zn, one equivalent of 181, and performing the reaction in toluene 
at 10 °C (entry 10).  The reaction could be forced to completion when equal or greater amounts 
of amino alcohol than Me2Zn were used, by heating to 50 °C.  However, when 0.2 equivalents of 
Me2Zn and 0.5 equivalents of 181 were used at 50 °C, the reaction ee was only 18% (entry 11).  
The observed ee’s, though low, were reproducible.  Repeating reactions using one equivalent of 
ligand that gave ee’s in the range of 20-30% gave a result that was within 5% ee of the originally 
measured value.  In every set of reaction conditions tested for an asymmetric synthesis of 146, 
38 
 where less than one equivalent of ligand but at least one equivalent of Me2Zn was used, the ee 
was always <10%. 
 Several other ligands were prepared and tested using the conditions of Table 6, entries 8 
and 10.  These included amino alcohols 108, b 112, b 127,196 182,  183,197 184,198 185,199 186,200 
187, and 188, alcohols 189 and 190, and amines 191-193.  In all cases, the ee was <30%.  
Pyridine 189 was prepared as a racemic mixture and then separated by semi-preparative chiral 
HPLC using a Chiralcel AD column.  The enantiomerically pure ligand (S)-189 was effective for 
Et2Zn addition to phosphinimine 104 using the conditions of Table 1 (α-ethylbenzylamine (S)-
106 was isolated in 74% yield with an ee of 93%), but was ineffective for the preparation of 
enantiomerically enriched allylic phosphinamide 146.  Based on the results of Scheme 14, 
alcohol 190 was also prepared as a racemic mixture and separated by chiral HPLC, but was also 
inneffective.  Diols 70,201 194 and 195202 were also tested, in combination with Ti(IV) reagents.  
Regardless of the conditions used, when Ti was present in the reaction mixture, the ee was zero.  
N-Tosylimine 90 was also completely ineffective, with only racemic product formed.  Using 
ZnCl2 in place of Me2Zn was also briefly investigated, however the ee’s were zero in all 
reactions tested. 
O
Ph
OH
Ph
OH
N
O
N
Bn
OH
Ph Ph
N OH
Ph
Ph
NHP(OMe)2HO
O HO NMe2
187 (quinine) 188 (cinchonine)
N
Me OH
N
OH
N
H
N
OH
N
H
OMe
182 [(-)-MIB] 183 184 185 186
189 190
OH
OH
OH
Ph Ph
OH
Ph Ph
O
O
NHP(O)Ph2
Ph
NHP(O)Ph2
NHP(O)Ph2
191 [(-)-sparteine] 194 [(+)-BINOL]
N
N
H
H
H
H
192 193 195
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  N-Carbamate, -amide, and -urea benzaldimines 176, 177, 197, 199, and 202 were 
significantly more reactive than phosphinimine 96, thus temperatures lower than those of Table 6 
could be investigated (Table 7).  Again, no ee higher than 35% was obtained.  The allylic amine 
derivatives were however typically isolated in higher yield. 
 
Table 7. Attempted asymmetric addition reactions with more reactive imines. 
N
Ph H
O
NHCOR
Ph C4H9
R
1.5 equiv Me2Zn, 10 mol% L*,
toluene, -30 °C
ClCp2Zr C4H9 6
imine
allylic amine
 
Entry R Imine L* Yield (%)a ee (%)b Allylic Amine 
1c Ot-Bu 176 55 81 22 196 
2 OEt 197 181 94 7 198 
3d OMe 199 55 86 6 200 
4 Me 177 181 44 1 201 
5 NMe2 202 181 69 6 203 
aYields of isolated products, based on imines. bMeasured by 
chiral HPLC using a Chiracel OD or AD Column. c1 equiv of 
Me2Zn used. d3 equiv of Me2Zn and 1 equiv of L* used, and 
reacted at -20 °C. 
 
 The benzaldimines 176, 177, 197, and 199 could be prepared in situ using the method of 
Dahmen and Bräse (Table 8).   The advantage of this method was the ease of preparation and the 
stability of the solid sulfonamide sulfones, compared to the aldimines which were all moisture-
sensitive oils.  However, as can be seen by comparing Table 7, entry 2 and Table 8, entry 1, the 
isolated yield of ethyl carbamate 198 was much lower using the in situ generated imine protocol.  
The isolated yield of acetamide 201 was very slightly increased (Table 7, entry 4 vs. Table 8, 
entry 2), likely due to the difficulty in handling the very unstable imine 177.  This approach was 
abandoned because no ee above 10% was obtained using in situ generated imines. 
 The highest ee achieved using an imine other than 104 was from addition to 199, in the 
presence of 1 equivalent of both Me2Zn and amino alcohol 55, which yielded 80% of allylic 
carbamate 200 in 32% ee (Scheme 34). 
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 Table 8. Attempted asymmetric addition reactions with in situ-generated imines. 
N
Ph H
O
6 NHCOR
Ph C4H9
R
Me2Zn, 10 mol% 55,
toluene, -20 °C
HN
SO2PhPh
R
O
Me2Zn
sulfonamide
sulfone
allylic amine
 
Entry R Sulfonamide Sulfone Yield (%)
a ee (%)b Allylic Amine 
1 OEt 204 51 5 198 
2 Me 205 48 6 201 
a Yields of isolated products, based on sulfones. b Measured by 
chiral HPLC using a Chiracel OD or AD Column. 
 
N
HPh
O
OMe
ClCp2Zr C4H9
1 equiv Me2Zn, 1 equiv 55,
toluene, -10 °C
(80%)
NHCO2Me
Ph C4H9
200, 32% ee
199
6
 
Scheme 34. Highest ee achieved for addition to an imine other than 104. 
 
 Following a recently published protocol,203 in situ generated acyliminium ions were used 
as electrophiles in the Zr-Zn transmetalation reaction, and found to be significantly more reactive 
than any other imines tested.  Quantitative formation of acyliminium chloride 206 took 15 min at 
room temperature in CH2Cl2 and could be monitored by TLC.  Treatment of 206 with hexenyl-
zirconocene 6 and an equivalent of Me2Zn resulted in very rapid 1,2-addition, though a 
significant amount of methyl addition also occurred.  When the reaction was performed at room 
temperature, 51% of the desired allylic amide 207 was isolated, as well as 32% of methyl-adduct 
208 (Scheme 35). 
 To avoid methyl transfer to acyliminium 206, ZnCl2 was successfully used in place of 
Me2Zn (Scheme 36).  During optimization of these reaction conditions, it was discovered that as 
little as 1 drop of a 1.0 M solution of ZnCl2 in Et2O was sufficient to catalyze the addition of 
hexenylzirconocene 6; after only a 15 min reaction time at 0 °C, 82% of 207 was isolated.  There 
was no addition when ZnCl2 was excluded from the reaction. 
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 N
HPh
OMe
178
AcCl
CH2Cl2
N
HPh
OMe
O
206
Cl
ClCp2Zr C4H9 6
1 equiv Me2Zn, CH2Cl2
N
Ph
OMe
O
C4H9
N
Ph
OMe
O
207 (51%) 208 (32%)
+
 
Scheme 35. Hexenylzirconocene 6 addition to acyliminium chloride 206 in the presence of 
stoichiometric Me2Zn. 
N
HPh
OMe
O
Cl
N
Ph
OMe
O
C4H9
206
6
2 mol% ZnCl2, CH2Cl2, 0 °C
(82%)
207  
Scheme 36. Hexenylzirconocene 6 addition to acyliminium chloride 206 in the presence of 
catalytic ZnCl2. 
 
 Despite the presence of a significantly more reactive electrophile and the high yield of 
addition product 207 with only 2 mol% of ZnCl2 added, no ee was obtained when the reaction 
was performed in the presence of chiral amino alcohols or thiols.  As previously, using an equal 
amount of ligand and ZnCl2 had a detrimental affect on the rate of reaction, whereas if more 
ZnCl2 than ligand was used only racemic product was formed.  Unlike all of the other imines 
tested; however, the addition of 6 to 206 was also catalyzed by Cu(I) salts (Scheme 37).  In the 
presence of 10 mol% of CuBr, allylic amide 207 was isolated in 86% yield after a 30 min 
reaction time at 0 °C. 
 All Cu(I) salts tested were almost equally effective, so CuCl was selected for asymmetric 
studies since Cp2ZrCl2 (the Zr complex formed after transmetalation in this case) is not highly 
soluble in CH2Cl2.  Several known asymmetric ligands for Cu-catalyzed reaction were tested, 
including 209-217 (Figure 4)  No ligand was found that delivered any enantioselectivity (<10% 
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 ee for each catalyst system tested), and again the rate of reaction was decreased upon addition of 
an external ligand to the reaction mixture. 
 
N
HPh
OMe
O
Cl
N
Ph
OMe
O
C4H9
206
6
10 mol% CuBr, CH2Cl2, 0 °C
(86%)
207  
Scheme 37. Hexenylzirconocene 6 addition to acyliminium chloride 206 in the presence of 
catalytic CuBr. 
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P
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PPh2
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Fe
PPh2
(t-Bu)2P
Bn Bn
N N
O O
PhPh
PPh2
PPh2
70-85% yld, 2-8% ee no reaction
181 209
215 [(R,R)-DIOP]
211 212 [(R,R)-Me-DuPHOS] 213
214 [(S)-BINAP]
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Figure 4. Ligands tested and ee’s obtained for the attempted 
Cu-catalyzed asymmetric synthesis of 207. 
 
 Lacking success using external chiral ligands for an asymmetric synthesis of allylic 
amines using the Zr-Zr transmetalation methodology, other strategies were explored.  Diastereo-
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 selective addition to chiral sulfinimine 92 was attempted; however, this aldimine was not 
sufficiently reactive, even at elevated temperatures (Scheme 38). 
 
no reactionN
Ph H
S
O
92
ClCp2Zr C4H9 6
Me2Zn, toluene, 40 °C
 
Scheme 38. Attempted diastereoselective addition to a chiral sulfinimine. 
 
 Several chiral phosphinamides were prepared and tested as potential substrates for 
diastereoselective addition of alkenylzirconocene 6 (Table 9).  The first imine tested was 
binaphthyl-phenyl phosphinimine 219, which was prepared as a single diastereomer (vide infra).  
Addition of 6 to this imine at room temperature afforded the desired allylic amide 220 with a 
modest diastereomeric ratio of 72:28 (entry 1).  The benzaldimines of known phosphinamides 
221204 and 224205 were then tested and identical diastereoseletivities of 69:31 were obtained for 
both (entries 2 and 3).  Since there was no change in selectivity for all three substrates tested, it 
was assued that the bulky R group was not as hoped involved in stereodifferentiation, instead the 
constant dr of 7:3 was due to the difference in size between the phenyl and oxygen substituents 
on phosphorous. 
 Preliminary molecular modeling showed that ortho-substituted phenyl rings blocked one 
face of the aldimine and oriented the oxygen away from the C=N double bond.  A series of novel 
phosphinamides were prepared to test the modeling findings.  Though the first two imines tested, 
227 and 230, had poorer selectivities of nearly 1:1 (Table 9, entries 4-6), the reaction was much 
slower, and imine 227 required 40 °C for an isolated yield of 68%.  In these cases, due to the 
lower rate of reaction, it appeared that the transition state was more crowded thus the model 
appeared to be correct.  Imines 233 and 236 were then tested (entries 7 and 8).  In both cases a 
reaction temperature of 40 °C was required, and the diastereoselectivity was increased, though it 
was still much too low to be useful.  Imine 239 showed no improvement over 233 (entry 9). 
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 Table 9. Diastereoselective addition to chiral phosphinimines. 
O
P
NH2R
Ph
PhCHO
TiCl4, Et3N,
CH2Cl2
primary
amide
O
P
NR
Ph
Ph
H
imine
ClCp2Zr C4H9 6
Me2Zn, toluene
O
P
N
H
R
Ph
Ph
allylic amide
C4H9
 
Entry Primary Amide R Imine Yield
a Allylic
Amide Temperature Yield
b dr 
1 218 
 
219 16% 220 rt 76% 72:28
2 221 
 
222 35% 223 rt 53% 69:31
3 224 t-Bu not isolated -- 225 rt 32% 69:31
4 226 not isolated -- 227 rt 51% 57:43
5 226 
 
not 
isolated -- 227 40 °C 68% 54:46
6 228 
TMS
 
229 87% 230 rt 70% 51:49
7 231 
Ph
 
232 82% 233 40 °C 89% 65:35
8 234 
 
235 97% 236 40 °C 86% 59:41
9 237 
 
238 88% 239 45 °C 87% 63:37
aIsolated yields of Imines. bIsolated yields of Allylic Amides. 
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  The imines were prepared using the method of Jennings and Lovely,206 and initially 
isolated, with difficulty, by precipitation.  Imines 225 and 227 could not be isolated by this 
method, and so they were used as crude mixtures of imine and benzaldehyde.  Imines 230, 233, 
236, and 239 were purified by column chromatography after it was discovered that unlike 
diphenylphosphinamide 104, these imines were stable on deactivated SiO2. 
 Binaphthyl-phenyl phosphinimine 219 was prepared from the known phosphinic acid 
241207 in three steps (Scheme 39).  Thermal opening of phosphole oxide 240 with NaOH was 
very low yielding.  The subsequent one-pot acid chloride formation and amidation was nearly 
quantitative.  Imine formation afforded a 64:38 mixture of diastereomers, and fortunately, 
crystalization from CH2Cl2/hexanes afforded an x-ray quality (Appendix A) single crystal that 
was characterized and tested in the diastereoselective addition. 
 
P
O
Ph
1. NaOH, 280 °C
2. H3O+
240
P
OH
O
Ph
241
1. (COCl)2, cat. DMF,
    CH2Cl2
2. liq. NH3, CH2Cl2
(19%)
P
NH2
O
Ph
218
PhCHO
TiCl4, Et3N,
CH2Cl2
P
N
O
Ph
242
Ph
H
P
N
O
Ph
219
Ph
H
+
219:242 = 1.8:1
recrystalize from
CH2Cl2/hexanes
(16%) P N
O
Ph
219
Ph
H
ClCp2Zr C4H9 6
Me2Zn, toluene, rt
(76%)
P
N
H
O
Ph
220, dr = 72:28
Ph
C4H9
 
Scheme 39. Synthesis and of binaphthyl-phenyl phosphinimine 219. 
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  The novel phosphinamides 243, 246, 248, 250, and 252 were prepared by adapting the 
literature procedure used for mesityl-phenyl phosphinamide 221 (Table 10).   Aryl Grignard 
addition to ClP(OEt)2 was followed by mild acid-promoted rearrangement to afford ethyl 
phosphinates with a characteristic P-H coupling of ~550 Hz.  Only 244 (R = t-Bu) was isolated 
(entry 1), in all other cases the crude material was used in the subsequent Pd-catalyzed coupling 
with iodobenzene.  Phosphinates 245, 247, 249, 251, and 253 were isolated in modest to high 
yield.  For entries 2-5, a three-step, high yielding sequene of dealkylation, acid chloride 
formation, and amidation was used for ester to amide conversion.  Non-racemic phosphinamide 
221 has been prepared by treating its corresponding acid chloride with one enantiomer of α-
methylbenzylamine, separating the resulting diastereomers by chromatography on SiO2, and 
removal of the benzylic group by hydrogenation.   This resolution strategy was not explored here 
since no highly diastereoselective alkenylzirconocene addition was found. 
 
Table 10. Synthesis of novel aryl-phenyl phosphinamides. 
O
P
OEt
H
R
1. Mg, THF; ClP(OEt)2
2. 0.1 N HCl, THF
R
Br
cat. Pd(OAc)2 + dppf,
Et3N, MeCN, 70 °C
iodobenzene
O
P
OEt
Ph
R
1. TMS-Br, CH2Cl2; MeOH
2. (COCl)2, cat. DMF, CH2Cl2
3. liq. NH3, CH2Cl2
O
P
NH2
Ph
R
primary amide
aryl bromide
aryl-phenyl
phosphinate
aryl
phosphinate
 
Entry Aryl Bromide R 
Aryl 
Phosphinate Yield
a Aryl-Phenyl
Phosphinate Yield
b Primary
Amide Yield
c
1 243 t-Bu 244 95% 245 60% 226 --- 
2 246 TMS not isolated -- 247 28% 228 88% 
3 248 Ph not isolated -- 249 82% 231 95% 
4 250 1-adamantyl not isolated -- 251 48% 234 61% 
5 252 p-tolyl not isolated -- 253 54% 237 87% 
aIsolated yield of Aryl Phosphinates. bIsolated yield of Aryl-Phenyl Phosphinates. cIsolated 
yield of Primary Amides. 
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  For the conversion of ester 245 to amide 226, a known one-step protocol using NaNH2 
was followed,  but the yield was low and the reaction was not clean (Scheme 40).  This appraoch 
failed completely for the conversion of 247 to 228, so the three-step sequence shown in Table 10 
was used for all other substrates. 
 
P
OEt
O
Ph
NaNH2, NH3
THF, -35 °C
(27%)
P
NH2
O
Ph
245 226  
Scheme 40. One-step synthesis of phosphinamide 226. 
 
 Known aryl bromides 243,208 246,209 and 250210 were prepared according to literature 
procedures.  Tolyl-substituted bromobenzene 252 was prepared by Suzuki coupling of 4-methyl-
phenylboronic acid (255) with 1,2-dibromobenzene (Scheme 41). 
 This diastereolective addition strategy was abandonded since the diastereoselectivities 
obtained were not promising, and preparation of the chiral phosphinimines required up to eight 
chemical steps, not including the needed resolution should the method be used for the synthesis 
of non-racemic allylic amines. 
 
Br
BuLi, THF, -78 °C;
cat. Pd(PPh3)4,
K2CO3, DME/H2O, reflux
(69%)
Br
Br 256
Br
254
252
B(OMe)3; H3O+
B(OH)2
255
 
Scheme 41. Synthesis of aryl bromide 252. 
 
2.3. Synthesis of C-Cyclopropylalkylamines  
 While investigating the alkenylzinc addition to aldimines in CH2Cl2 (Table 4), it was 
observed that increasing the number of equivalents of the organometallic reagents when 
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 performing the reaction at reflux reduced the isolated yield of the desired allylic amide 146.  This 
was due to formation of a second phosphinamide, cyclopropane 257 (Scheme 42).  Only the 
amino cyclopropane with anti-configuration (determined by X-ray analysis of benzyl derivative 
268, Appendix B) was identified by 1H NMR analysis of the crude reaction mixture.  By 
repeating the reaction in CD2Cl2, bis-deuterated cyclopropane 258 was formed, whereas 257 
remained the major product formed if Me2Zn was replaced with Et2Zn, thus the origin of the new 
cyclopropyl carbon was shown to be the solvent. 
 
30
3 equiv
1. 3 equiv Cp2ZrHCl, CH2Cl2
2. 3 equiv Me2Zn
3. 104, reflux, 1 h
NHP(O)Ph2
Ph C4H9
257 (29%)
dr > 20:1
+
Ph C4H9
146 (43%)
NHP(O)Ph2
30
3 equiv
1. 3 equiv Cp2ZrHCl, CD2Cl2
2. 3 equiv Me2Zn
3. 104, reflux
(34%)
C4H9
Ph2(O)PNH
Ph C4H9
258
D
D
 
Scheme 42. Unexpected formation of amino cyclopropane 257. 
 
 Allowing the reaction to continue for a longer period of time increased the yield of 257 
and decreased that of 146 (Table 11, Entry 2).  Lowering the number of equivalents of the 
organometallic reagents reduced the yield of 257, even after prolonged reaction times (Entries 3 
and 4).  Even as little as 10 equivalents of CH2Cl2 added to a reaction performed in toluene 
resulted in formation of substantial quantities of 257, though heating was necessary to keep the 
reaction time under 24 h (Entries 5 and 6).  Whenever CH2Cl2 was used, 257 was not the only 
product formed, thus, in order to increase the yield and rate of the reaction, CH2I2 was added to 
the reaction mixture, resulting in the isolation of 257 in 74% yield (Entry 7). 
 The scope of the optimized reaction conditions (Table 11, entry 7) is shown in Table 12.  
Silyl ether, silyl ester, sulfonamide, and carbamate functional groups were again tolerated on the 
alkyne moiety (entries 2-4).211  Alkynylimine 164 was converted into propargylamine 262212 in 
modest yield (entry 5); however, the α,β-unsaturated imines 159 and 161 gave only complex 
mixtures of mono- and bis-cyclopropanated amides.  Use of N-tosylimine 90 in place of 104 
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 retained the excellent diastereoselectivity displayed by all reactions thus far (entry 6); however, 
with alkylimines 166 and 170, the diastereoselectivity was lower (entries 7 and 8). 
 
Table 11. C-Cyclopropylalkylamine reaction optimization. 
N
PPh2
O
HPh
104
ClCp2Zr C4H9 6
Me2Zn
NHP(O)Ph2
Ph C4H9
257
+
Ph C4H9
NHP(O)Ph2
146
 
Entry Equiv 6 and Me2Zn 
Solvent Temperature Time (h) Yield 257a Yield 146a
1 3.0 CH2Cl2 reflux 1 29% 43% 
2 3.0 CH2Cl2 reflux 16 58% 11% 
3 2.0 CH2Cl2 reflux 16 18% 43% 
4 1.2 CH2Cl2 reflux 16 4% 42% 
5 3.0 tolueneb rt 36 43% 26% 
6 3.0 tolueneb 40 °C 16 49% 19% 
7 3.0 CH2Cl2c reflux 3 74% --- 
aYields of isolated products based on 104. b10 equiv CH2Cl2 added to reaction 
mixture. c5 equiv CH2I2 added to the reaction mixture after 1 h. 
 
Table 12. Synthesis of C-cyclopropylalkylamines. 
Entry Alkyne Aldimine C-Cyclopropylalkylaminea,b Yieldc dr 
1 1-hexyne (30) 104 
NHP(O)Ph2
Ph C4H9
257  
74% 97:3d
2 148 104 
NHP(O)Ph2
Ph
259
OBDPS
 
68% 98:2d
3 150 104 
NHP(O)Ph2
Ph
260
CO2TIPS
 
71% >95:5e
4 152 104 
NHP(O)Ph2
Ph
261
N(Ts)CO2Et
 
45% >95:5e
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 Table 12 (continued). Synthesis of C-cyclopropylalkylamines. 
Entry Alkyne Aldimine C-Cyclopropylalkylaminea,b Yieldc dr 
5 30 164 
NHP(O)Ph2
C4H9
262
Ph
 
60% >95:5e
6 30 90 Ph C4H9
263
NHTs
 
66% >95:5e
7 30 166 C4H9
264
NHTs
Ph
 
67% 87:13e
8f 30 170 C4H9
265
NHTs
 
62% 40:60e,g
9 3-hexyne 104 
NHP(O)Ph2
Ph Et
Et
266  
46% 96:4d
10h,i 30 104 
NHP(O)Ph2
Ph C4H9
267
CH3
H
 
52% >95:5e,j
11k 30 104 257 91% >95:5e
aOnly the major isomer is shown. bReaction conditions: (i) 3 equiv of Cp2ZrHCl, 
3 equiv of alkyne, CH2Cl2, rt, 10 min; (ii) 3 equiv of Me2Zn, CH2Cl2, -78 °C, 5 
min; (iii) 1 equiv of aldimine, CH2Cl2, reflux, 1-2 h; (iv) 5 equiv of CH2I2, 
CH2Cl2, reflux, 2-12 h. cYields of isolated products are based on aldimines. 
dDetermined by HPLC analysis of the crude reaction mixture. eDetermined by 1H 
NMR analysis of the crude reaction mixture. fAdditional Me2Zn (3 equiv) and 
CH2I2 (10 equiv) were added to the reaction mixture. gMajor diastereomer was not 
assigned. hEt2Zn (6 equiv) and CH3CHI2 (12 equiv) were added to the reaction 
mixture. iHydrozirconation was performed in THF, and the solvent exchanged to 
(CH2Cl)2 for the remainder of the reaction. jRelative stereochemistry determined 
by x-ray analysis of a derivative (Appendix C). k1 equiv of PhCH2OH was added 
to the reaction mixture. 
 
 1,1,2-Trisubstituted cyclopropanes could be prepared in modest yield using internal 
alkynes in the hydrozirconation step (Table 12, entry 9), and 1,2,3-trisubstituted cyclopropanes 
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 could also be prepared using CH3CHI2 in place of CH2I2 (entry 10).  Using I2C(CH3)2213
2 2
2 2
 afforded 
only trace amounts of the desired tetrasubstituted cyclopropane.  When either of these 1,1-
diiodoalkanes were used in place of CH I , hydrozirconation had to be performed in a solvent 
other than CH Cl , otherwise 257 was the major product formed.  The isolated yield of 257 was 
increased to 91% when one equivalent of benzyl alcohol was added to the reaction mixture 
(entry 11). 
 The C-cyclopropylalkylphosphinamides produced could be easily deprotected  in 
quantitative yield in anhydrous methanol and acid (Scheme 43).  Upon acylation, benzamide 268 
(used for X-ray analysis to determine the relative stereochemistry, Appendix B) was formed in 
99% yield from 257. 
 
1. 1 N HCl, MeOH
2. (PhCO)2O, i-Pr2NEt,
    cat. DMAP, CH2Cl2
NHCOPh
Ph C4H9
(99%)
268
NHP(O)Ph2
Ph C4H9
257
 
Scheme 43. Deprotection of phosphinamide 257. 
 
 The anti-configuration was observed for the major diastereomer of all C-cyclopropyl-
alkylamines but 265.  The stereochemistry of 259-261 and 266 were assigned by analogy to 257.  
Deprotection and N-tosylation of 257 afforded 263, confirming an identical relative 
configuration for the major diastereomers of N-phosphinoyl and N-sulfonyl amides (Scheme 44). 
 
1. 1 N HCl, MeOH
2. TsCl, Et3N,
    cat. DMAP, CH2Cl2
NHTs
Ph C4H9
(72%)
263
NHP(O)Ph2
Ph C4H9
257
 
Scheme 44. Relative stereochemistry determination of 263 by chemical correlation to 257. 
 
 The relative stereochemistry of 264 was determined by chemical correlation (Scheme 
45).  Known allylic alcohol 270  was prepared using the Zr-Zn transmetalation/aldehyde addition 
reaction.  Simmons-Smith cyclopropanation of 270 with the Furukawa reagent afforded an 86:14 
mixture of easily separable diastereomers, with the major isomer assigned a syn-relative 
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 stereochemistry based on literature precedent.   Mitsunobu substitution of the secondary alcohol 
of syn-271 with DPPA214 gave a 78:22 mixture of diastereomeric azides.  The major epimer was 
assigned as the SN2 product (anti relative stereochemistry), since subjecting the minor 
diastereomer from Simmons-Smith cyclopropanation (anti-271) to the Mitsunobu reaction 
afforded the azides as a 15:85 mixture of diastereomers, favoring the syn-stereoisomer (Scheme 
46).215  Reduction of the mixture of azides followed by N-tosylation and epimer separation by 
chromatography on SiO2 afforded 264 in 66% overall yield. 
 
O
H
ClCp2Zr C4H9 6
Me2Zn, CH2Cl2
(84%)
OH
Ph Ph C4H9
Et2Zn, CH2I2
CH2Cl2
(90%)
OH
Ph C4H9
2. DPPA, DEAD,
    PPh3, THF
N3
Ph C4H9
269 270 271, dr = 86:14
1. diastereomer
    separation
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272, dr = 78:22
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    10% Pd/C, THF
2. TsCl, Et3N,
    cat. DMAP, CH2Cl2
3. diastereomer
    separation
(66%)
NHTs
Ph C4H9
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Scheme 45. Relative stereochemistry determination of 264 by an alternate synthesis. 
OH
Ph C4H9
anti-271
DEAD, PPh3, THF
(58%)
N3
Ph C4H9
272, dr = 15:85
DPPA
 
Scheme 46. Mitsunobu reaction on anti-271. 
 
 The relative configuration of 262 was determined chemically by reduction, deprotection, 
and tosylation to give 264 (Scheme 47). 
 
1. 1 atm H2,
    10% Pd/C, THF
2. HCl, MeOH
3. TsCl, Et3N,
    cat. DMAP, CH2Cl2
(68%)
NHTs
Ph C4H9
264
NHP(O)Ph2
C4H9
262
Ph
 
Scheme 47. Relative stereochemistry determination of 262 by chemical correlation to 264. 
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 A Simmons-Smith-type cyclopropanation was postulated to explain the formation of 257 
(Figure 5).  Hydrozirconation of 1-hexyne followed by transmetalation with Me2Zn afforded 
alkenylzinc 31.  Addition to aldimine 104 resulted in metalated allylic amide 273, which reacted 
with CH2Cl2 to give zinc carbenoid 274.  Intramolecular cyclopropanation of 274 gave anti-
cyclopropane 257.  No reaction occurred in the absence of Me2Zn.  TLC analysis of the reaction 
mixture clearly showed formation of allylic amide 146 prior to formation of cyclopropane 257, 
and there was no addition of a cyclopropylzinc species (prepared according to the conditions of 
Scheme 31)  to imine 104. 
 
1. Cp2ZrHCl
2. Me2Zn
CH2Cl2
C4H9
30
MeZn
C4H9
31
N
HPh
PPh2
O
(104)
Ph2(O)PN
Ph C4H9
ZnMe
273
Ph2(O)PN
Ph C4H9
ZnCH2Cl
274
Ph2(O)PN
Ph C4H9
ZnCl
275
H2O NHP(O)Ph2
Ph C4H9
257  
Figure 5. Proposed mechanism for formation of C-cyclopropylalkylamide 257. 
 
 No cyclopropane was formed in CH2Cl2 at reflux if the aldimine 104 was replaced with 
benzaldehyde, or if the alkenylzinc species was generated by a hydroboration, B-Zn trans-
metalation216 (even in the presence of CH2I2, see Scheme 52) or carboalumination, Al-Zn 
transmetalation strategy (Scheme 48).  Simmons-Smith cyclopropanation of allylic 
phosphinamide 146 afforded 257 as a 71:29 (anti:syn) mixture of diastereomers, and allylic 
sulfonamide 91 afforded 263 as an 81:19 (anti:syn) mixture of diastereomers.  In both cases the 
diastereoselectivity was significantly lower than for the one-pot alkenylzirconocene 
addition/cyclopropanation.  Thus, both the zirconocene complex and the aldimine may play a 
role in the reaction mechanism. 
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 1. 1 equiv BH3•THF, CH2Cl2
2. 3 equiv Me2Zn
3. 104, reflux, 16 h
(50%)
1. 3 equiv Cp2ZrHCl, CH2Cl2
2. 3 equiv Me2Zn
3. PhCHO, reflux, 48 h
(90%)
1-hexyne
(3 equiv)
OH
Ph C4H9
33
3-hexyne
(3 equiv)
NHP(O)Ph2
Ph Et
147
Et
1. 2 equiv AlMe3, cat. Cp2ZrCl2,
    1 equiv H2O, CH2Cl2
2. 3 equiv Me2Zn
3. 104, reflux, 16 h
(54%)
1-hexyne
(3 equiv)
Ph2(O)PNH
Ph C4H9
276
 
Scheme 48. Unsuccessful attempts to obtain cyclopropanation products 
in aldehyde or imine additions. 
 
 The high level of diastereoselectivity for anti-257 can be rationalized using the allylic 
ether-directed cyclopropanation model a (Figure 6).  Transition state III, normally invoked to 
explain syn-selective allylic alcohol directed cyclopropanation, minimizes allylic A1,3 strain.  
Transition state IV instead minimizes steric interactions of the phenyl substituent with the bulky 
phosphinoyl protecting group on nitrogen.  The zirconocene complex could act as a Lewis acid,  
activating the halomethyl zinc carbenoid, and forming a significantly larger cyclopropanation 
reagent via a bridged Zr-Zn complex,217 which increases anti-selectivity compared to the (Zr-
free) cyclopropanations of allylic amides 91 and 146. 
 The isolated yield of allylic amide 276, prepared by carboalumination/Al-Zn trans-
metalation/imine addition was improved to 73% using the optimized addition conditions 
(toluene, room temperature), and the one-pot aldimine vinylation/cyclopropanation to form the 
corresponding 1,2,2-trisubstituted cyclopropane 278 was achieved using the optimized 
conditions for this transformation (Scheme 49).  A mixture of 276 and 278 was obtained, and the 
cyclopropane 278 was formed as a 9:1 mixture of diastereomers.  In this case, Me2Zn was not 
necessary for cyclopropanation.  Pure 278 was prepared by Simmons-Smith cyclopropanation of 
276, affording 278 as a single diastereomer. The relative stereochemistry of the isomer was 
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 identical to that of the major diastereomer in the one-pot vinylation/cyclopropanation, and was 
assigned as syn based on literature precedent.  
 
H2C
Ph
N
H P(O)Ph2
H
Zn
X
Cl
transition state III
synclinal
H
C4H9
H2C
H
N
H P(O)Ph2
Ph
Zn
X
Cl
allylic
A1,3-strain
transition state IV
H
C4H9
syn-257
ZrCp2Me
ZrCp2Me
NHP(O)Ph2
Ph C4H9
anti-257
NHP(O)Ph2
Ph C4H9
 
Figure 6. Transition state models for cyclopropanation of allylic amide 274. 
 
2.4. Synthesis of Homoallylic Amines218 
 Interestingly, the order of addition of reactants for the optimized C-cyclopropylalkyl-
amine synthesis proved to be crucial for product formation.  Addition of CH2I2 to the reaction 
mixture prior to imine 104 lead to a switch from the expected cyclopropylamide 257 to homo-
allylic amide 279, in 58% yield and 5:1 diastereoselectivity, favoring the syn-isomer (Scheme 
50).219  This yield was slightly increased by lowering the temperature, but the effect on diastereo-
selectivity was minimal. 
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dr = 88:12
C4H9
30
2 equiv AlMe3
cat. Cp2ZrCl2,
1 equiv H2O,
CH2Cl2
C4H9
Me2Al
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N
HPh
PPh2
O
104
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N
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PPh2
O
104
1. 277, Me2Zn,
    CH2Cl2, reflux
2. CH2I2
276 (46%)
+
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dr = 90:10
N
HPh
PPh2
O
104
1. 277, toluene
2. CH2I2
276 (32%)
+
Ph2(O)PNH
Ph C4H9
Ph2(O)PNH
Ph C4H9
276
Ph2(O)PNH
Ph C4H9
Ph2(O)PNH
Ph C4H9
Ph2(O)PNH
Ph C4H9
 
Scheme 49. Tandem carboalumination, aldimine additions with and without cyclopropanation. 
1. 3 equiv Cp2ZrHCl, CH2Cl2
2. 3 equiv Me2Zn
3. 5 equiv CH2I2
4. 104, reflux
NHP(O)Ph2
Ph
C4H9
(58%, dr = 83:17) syn-279 (major)
NHP(O)Ph2
Ph
C4H9
anti-279
+C4H9
30
3 equiv
 
Scheme 50. Unexpected formation of homoallylic amide 279. 
 
 The reaction scope is illustrated in Table 13.  Some functional groups on the alkyne 
segment, such as silyl ethers (Entry 3) did not interfere with the reaction; however, the use of 
silyl esters or internal alkynes resulted in both lower yield and reduced diastereoselectivity 
(Entries 4 and 2).  Electron-donating and -withdrawing groups on the aldimine were tolerated 
and had no effect on product ratios (Entries 5 and 6).  N-Tosylimines such as 90 and 166 were 
also suitable substrates, though 90 resulted in decreased diastereoselectivity (Entry 7), whereas 
166 provided the homoallylated product 286 in excellent diastereoselectivity.  Trace amounts of 
the corresponding C-cyclopropylalkylamines (e.g. 257 for Entry 1) were the only identifiable 
side products. 
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 Table 13. Synthesis of homoallylic amines. 
Entry Alkyne Aldimine Homoallylic Amidea,b Yield (%)c drd
1 1-hexyne (30) 104 
Ph
NHP(O)Ph2
C4H9
279  
71 85:15 
2 3-hexyne 104 Ph
Et
280
EtPh2(O)PNH
 
49 75:25 
3 148 104 Ph
NHP(O)Ph2
OBDPS
281  
72 85:15 
4 150 104 Ph
NHP(O)Ph2
CO2TIPS
282  
48 62:38 
5 148 156 
NHP(O)Ph2
OBDPS
MeO2C
283
69 85:15 
6 30 158 
NHP(O)Ph2
C4H9
284
MeO
 
79 83:17 
7 148 90 Ph
NHTs
OBDPS
285  
81 60:40 
8 148 166 
NHTs
OBDPS
Ph
286  
87 >95:5 
aOnly the major isomer is shown. bReaction conditions: (i) 3 equiv of Cp2ZrHCl, 3 
equiv of alkyne, CH2Cl2, rt, 10 min; (ii) 4 equiv of Me2Zn, CH2Cl2, -78 °C, 5 min; (iii) 
5 equiv CH2I2, 1 equiv of aldimine, CH2Cl2, rt, 2-12 h. cYields of isolated products are 
based on aldimines. dDetermined by 1H NMR analysis of the crude reaction mixture. 
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  The assignment of the relative stereochemistry of these addition products was first based 
on the coupling constant analysis of lactams 287, formed by hydrolysis and cyclization of homo-
allylic amides 282 (Scheme 51), and later confirmed by an X-ray analysis of anti-287 (Appendix 
D).  1H coupling constants of anti- and syn-287 were characteristic for 1,2-diaxial and gauche 
relationships and were in good agreement with literature values.220
 
1. 1 N HCl, MeOH
2. DEPC, Et3N,
    CH2Cl2
(56%)
NH
H
H
Ph
O
1. 1 N HCl, MeOH
2. DEPC, Et3N,
    CH2Cl2
(69%)
NH
H
Ph
H
O
J = 9.3 Hz
J = 4.9 Hz
NHP(O)Ph2
Ph
(CH2)2CO2TIPS
syn-282
NHP(O)Ph2
Ph
(CH2)2CO2TIPS
anti-282
anti-287
syn-287  
Scheme 51. Assignment of homoallylic amine stereochemistry. 
 
 A rationalization of the formation of the homoallylic product is shown in Figure 7.  First, 
hydrozirconation of 1-hexyne followed by transmetalation with Me2Zn afforded alkenylzinc 31.  
Rapid reaction of 31 with CH2I2 formed, after [1,2]-shift, allylic zinc 289, which added to 
aldimine 104 to form the observed homoallylic amide 279.221  A similar vinyl zinc to allyl zinc 
homologation mechanism was proposed by Marek and co-workers in their four-component 
coupling of alkynyl sulfoxides, organocopper reagents, electrophiles (aldehydes or aldimines) 
and bis(iodomethyl)zinc.222  A closed transition state is likely for this reaction and minimization 
of allylic strain explains the preference for syn-configuration.  Indirect support for a preferred 
cyclic transition state came from the dependence of the diastereoselectivity on the nature of the 
pseudoaxial imine substituents: the bulkier aromatic aldimines significantly eroded syn-
selectivity versus an aliphatic chain (Table 13, Entries 7 and 8).  Attempts to prepare the 
analogous homoallylic alcohols by replacing aldimines with aldehyde substrates were 
unsuccessful, and furthermore, efforts to prepare 280 using a B-Zn transmetalation strategy  have 
also failed (Scheme 52).  In either case, only allylic products were formed, and thus once again 
both the aldimine and a zirconocene complex may be important in the mechanism. 
59 
  
Ph
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2. Me2Zn
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C4H9
CH2I2
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C4H9
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I
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N
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Ph2(O)P
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Figure 7. Proposed mechanism for formation of homoallylic amide syn-279. 
1. 1 equiv BH3•THF, CH2Cl2
2. 3 equiv Me2Zn
3. 5 equiv CH2I2
4. 104, rt
(50%)
NHP(O)Ph2
Ph Et
Et
1. 1.5 equiv Cp2ZrHCl, CH2Cl2
2. 1.5 equiv Me2Zn
3. 5 equiv CH2I2
4. PhCHO, 0 °C
(88%)
OH
Ph C4H9
147
33
1-hexyne
(3 equiv)
3-hexyne
(3 equiv)
 
Scheme 52. Unsuccessful one-pot vinylzinc homologation/electrophile allylation. 
 
2.5. Application of an Alternate Preparation of Alkenylzirconocenes 
 Application of Takahashi’s protocol for generating vinylzirconocenes (oxidative insertion 
of Cp2Zr into a vinyl halide) to the optimized reaction conditions developed for allylic amide, C-
cyclopropylalkylamine and homoallylic amide syntheses produced yet another unexpected result.  
Upon addition of Me2Zn to vinylzirconocene 292, followed by imine 104, homoallylic amide 
293 was the major product isolated, not the expected allylic amide 294 (Scheme 53).  A similar 
result was obtained when CH2I2 was added (last) to the reaction mixture.  Again homoallylic 
amide 293 was the major product formed, with cyclopropane 295 isolated in only 14% yield. 
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THF
ZrCp2Br
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(4 equiv)
1. 4 equiv Me2Zn,
    toluene
2. 104, rt
NHP(O)Ph2
Ph
NHP(O)Ph2
Ph
+
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NHP(O)Ph2
Ph
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N
HPh
PPh2
O
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1. 292, Me2Zn
    CH2Cl2, reflux
2. CH2I2, reflux
NHP(O)Ph2
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+
293 (42%)  
Scheme 53. Allylic amine and amino cyclopropane syntheses using Takahashi’s protocol. 
 
 Mechanistic insight was obtained by quenching the reaction mixture with deuterated 
acetic acid (Scheme 54).  In this case, bis-deuterated homoallylic amide 296 was isolated, in a 
very similar yield to 293. 
 
Ph
294 (26%)
N
HPh
PPh2
O
104
1. 292, Me2Zn
    toluene
2. CD3CO2D
+
NHP(O)Ph2
Ph
296 (46%)
D
D
NHP(O)Ph2
 
Scheme 54. Effect of a deuterium quench on the unexpected homoallylic amide 293. 
 
 The bis-deuterated product 296 supported a zirconocycle precursor; a possible 
mechanism is shown in Figure 8.  Oxidative insertion of Cp2Zr into 2-bromopropene afforded 
alkenylzirconocene 292.  Ligand exchange on 292 with a second equivalent of Cp2ZrBu2 resulted 
in 297, which could eliminate butane to form propyne complexed to Cp2Zr (298).  Alternatively 
ligand exchange could have occurred with Me2Zn, followed by elimination of methane.  
Takahashi and co-workers have postulated this type of mechanism, by purposely treating 292 
with a second equivalent of Cp2ZrBu2.223  In their case, bis-zirconocene complex 300 was 
isolated and characterized.  In the present case, however, addition of Me2Zn and imine 104 to the 
reaction mixture could result in oxidative cyclization of the propyne-Cp2Zr complex 298 and 
allylic amide 302 (formed by a Zr-Zn transmetalation on 292 or 297, followed by addition to 
imine 104).  Deuterolysis of both C-Zr bonds of zirconacycle 303 would give the product with 
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 correct deuterium substitution.  Attempts to optimize or minimize the yield of 293 were 
unsuccessful, as were attempts to intercept the proposed mechanism with external alkynes. 
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Figure 8. Proposed mechanism for formation of homoallylic amide 296. 
 
 Under the optimized homoallylic amide reaction conditions shown in Table 13, 304 was 
formed in 75% yield, and no trace of 293 was detected in the reaction mixture (Scheme 55). 
 
Ph2(O)PNH
Ph
304
N
HPh
PPh2
O
104
ZrCp2Cl 292
CH2I2, Me2Zn, CH2Cl2
(75%)
 
Scheme 55. Homoallylic amine synthesis using Takahashi’s protocol. 
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 3. Conclusions 
 The Zr-Zn transmetalation, aldehyde addition methodology developed in the Wipf group 
has been extended to the synthesis of allylic amines. b  The use of toluene as a reaction solvent 
was required to obtain high yields and low reaction times.  N-phosphinoyl-, N-sulfonoyl-, and N-
carbamoylimines were excellent substrates for this transformation. 
 Many chiral ligands were tested for asymmetric catalysis, but minimal ee was achieved.  
A successful asymetric synthesis of allylic amines by alkenylzirconocene addition to imines will 
likely require conditions where transmetalation must take place with a chiral organometallic 
complex that will subsequently add to the imine or imine derivative without a significant 
decrease in reaction rate.  No such conditions were found in this study. 
 A novel three-component C-cyclopropylalkylamine synthesis was discovered while 
attempting to perform the allylic amine synthesis in CH2Cl2.  The mechanism of this trans-
formation is not fully understood, however this is the first reported example of a high-yielding 
Simmons-Smith cyclopropanation with CH2Cl2 as the carbene precursor.  This reaction was 
optimized by adding CH2I2 to the reaction mixture once all imine was consumed.   Addition of 
CH2I2 prior to imine substrate resulted in homoallylic amine formation.  
 Takahashi’s alkenylzirconocene protocol was applied to the allylic amine, C-cyclo-
propylalkylamine and homoallylic amine syntheses, allowing formation of products regio-
isomeric to those derived from hydrozirconation of terminal alkynes.  A novel homoallylic amide 
was formed, believed to result from a zirconacyclopentene intermediate. 
 The amides prepared in Table 5, Table 12, and Table 13 were screened for acticvity 
against the estrogen receptor ERα.  Cyclopropane 261 was found to be an antagonist comparable 
to tamoxifen (the first clinically successful antiestrogen) of 17β-estradiol (E2)-induced 
transcription (IC50 of 11 µM) in cell based and protein-ligand displacement assays.  
 In summary, the multi-component reaction of alkenylzirconocenes, imines, Me2Zn and 
CH2I2 can form three different amide products, depending simply on the order of addition of 
reagents (Figure 9).  Due to the functional group tolerance of both Zr and Zn chemistry, libraries 
of nitrogen-containing alkenes and cyclopropanes with many common functional groups can be 
rapidly prepared using inexpensive starting materials. 
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Figure 9. Diversity-oriented synthesis224 of imine addition products. 
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 4. Experimental Part 
 All moisture-sensitive reactions were performed using syringe-septum cap techniques 
under an N2 or Ar atmosphere and all glassware was dried in an oven at 140 °C for 1 h prior to 
use.  Reactions carried out at -78 °C employed a CO2-acetone bath.  THF was distilled over 
sodium/benzophenone ketyl, and CH2Cl2, toluene and Et3N were distilled from CaH2.  Me2Zn, 
Me3Al, TsNH2, CH2I2, N,N-dimethylurea, Pd(OAc)2, dppf, and 2-bromobiphenyl were purchased 
from Aldrich Company.  Cp2ZrCl2 was purchased from Boulder Scientific.  (R,R)-DIOP (215) 
was purchased from Strem Chemical.  Cp2ZrHCl,225 CH3CHI2,226 P,P-diphenylphosphin-amide,  
imines 90,  104,  158,  168,227 170,  176,228 177,229 178,230 197,  and 199,  alkyne 148,  allylic 
phosphinamide 172,231 and ligands 55,  56,  and 181,232 were prepared according to literature 
procedures. 
 Reactions were monitored by TLC analysis (EM Science pre-coated silica gel 60 F254 
plates, 250 µm layer thickness) and visualization was accomplished with a 254 nm UV light and 
by staining with a PMA solution (5 g of phosphomolybdic acid in 100 mL of 95% EtOH), p-
anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 mL of conc. H2SO4 in 
100 mL of 95% EtOH), Vaughn’s reagent (4.8 g of (NH4)6Mo7O24•4 H2O and 0.2 g of Ce(SO4)2 
in 100 mL of a 3.5 N H2SO4 solution) or a KMnO4 solution (1.5 g of KMnO4 and 1.5 g of K2CO3 
in 100 mL of a 0.1% NaOH solution).  Flash chromatography on SiO2 or deactivated SiO2 (1% 
Et3N in mobile phase) was used to purify the crude reaction mixtures. 
 Melting points were determined using a Laboratory Devices Mel-Temp II.  Infrared 
spectra were determined on a Nicolet Avatar 360 FT-IR spectrometer.  1H and 13C NMR spectra 
were obtained on a Bruker Avance 300 instrument in CDCl3 unless otherwise noted.  Chemical 
shifts were reported in parts per million with the residual solvent peak used as an internal 
standard.  1H NMR spectra were run at 300 MHz and are tabulated as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet, m = multiplet), number 
of protons, and coupling constant(s).  13C NMR spectra were run at 76 MHz using the proton-
decoupled pulse sequence with a d1 of 4 s, and are tabulated by observed peak for compounds 
146-148, 151, 153, 156, 157, 159-165, 249, 257-262, 266, 267, 276, 278-284, 293-296, and 304, 
and by chemical shift for all other compounds.  Mass spectra were obtained on a Micromass 
Autospec double focusing instrument. 
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 NHP(O)Ph2
Ph C4H9
146  
 (E)-N-(1-Phenylhept-2-enyl)-P,P-diphenylphosphinamide (146). General Protocol A.  
A suspension of 208 mg (0.807 mmol) of Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 105 µL 
(0.914 mmol) of 1-hexyne, stirred for 5 min, and concentrated in vacuo.  A solution of the 
residue in 2 mL of toluene was cooled to -78 °C, treated with 380 µL (0.760 mmol) of Me2Zn 
(2.0 M solution in toluene), warmed to room temperature over a period of 5 min and cannulated 
into a suspension of 155 mg (0.508 mmol) of imine 104 in 2 mL of toluene.  The mixture was 
stirred at room temperature for 2 h, quenched with saturated NH4Cl, diluted with EtOAc, washed 
with 1 N HCl and brine, dried (MgSO4), and concentrated in vacuo.  The residue was chromato-
graphed on deactivated SiO2 (1:9, hexanes/EtOAc containing 1% Et3N) to yield 151 mg (76%) 
of 146 as a colorless solid: mp 139-140 °C (EtOAc/hexane); IR (KBr) 3127, 2952, 2922, 2859, 
1456, 1437, 1194, 1182, 1121, 1109, 722, 695 cm-1; 1H NMR δ 8.00-7.93 (m, 2 H), 7.89-7.82 
(m, 2 H), 7.55-7.23 (m, 11 H), 5.69 (ddt, 1 H, J = 15.3, 6.2, 1.2 Hz), 5.53 (dtd, 1 H, J = 15.3, 6.6, 
1.1 Hz), 4.83 (td, 1 H, J = 9.4, 6.4 Hz), 3.34 (dd, 1 H, J = 9.4, 6.2 Hz), 2.01 (q, 2 H, J = 6.4 Hz), 
1.34-1.26 (m, 4 H), 0.90 (t, 3 H, J = 7.0 Hz); 13C NMR δ 143.03, 142.96, 133.73, 133.39, 132.45, 
132.29, 132.17, 132.06, 132.01, 131.67, 128.44, 128.37, 128.21, 127.10, 126.92, 56.87, 31.77, 
31.12, 22.19, 13.88; EIMS m/z 389 (M+, 15), 332 (19), 306 (25), 216 (98), 201 (92), 188 (100), 
172 (35), 143 (55), 129 (87), 115 (35), 91 (33), 77 (60); HRMS (EI) m/z calcd for C25H28NOP 
389.1909, found 389.1906. 
 Representative attempted asymmetric preparation of 146 (catalytic ligand). 
A suspension of 77.0 mg (0.299 mmol) of Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 40.0 
µL (0.348 mmol) of 1-hexyne, stirred for 5 min, and concentrated in vacuo.  A solution of the 
residue in 1 mL of toluene was cooled to -78 °C, treated with 150 µL (0.300 mmol) of Me2Zn 
(2.0 M solution in toluene), warmed to room temperature over a period of 5 min and cannulated 
into a suspension of 76.0 mg (0.249 mmol) of imine 104 and 7.0 mg (0.026 mmol) of ligand 55 
in 1 mL of toluene.  The mixture was stirred at room temperature for 16 h, quenched with 
saturated NH4Cl, diluted with EtOAc, washed with H2O, saturated NaHCO3 and brine, dried 
(MgSO4), filtered through Florisil, and concentrated in vacuo.  The residue was chromato-
graphed on deactivated SiO2 (1:9, hexanes/EtOAc containing 1% Et3N) to yield 63 mg (65%) of 
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 146 as a colorless solid.  The enantioselectivity was measured by chiral HPLC using a Chiracel 
OD column (12% i-PrOH in hexanes, 1.0 mL/min, RT = 5.1 and 6.9 min): 2% ee. 
 Representative attempted asymmetric preparation of 146 (stoichiometric ligand). 
A suspension of 85.0 mg (0.330 mmol) of Cp2ZrHCl in 1 mL of CH2Cl2 was treated with 40.0 
µL (0.348 mmol) of 1-hexyne, stirred for 5 min, and concentrated in vacuo.  A solution of the 
residue in 1 mL of toluene was cannulated into a suspension, cooled to -78 °C, of 50.0 mg (0.164 
mmol) of imine 104, 44.0 mg (0.163 mmol) of ligand 55, and 250 µL (0.500 mmol) of Me2Zn 
(2.0 M solution in toluene) in 1 mL of toluene.  The mixture was stirred at 10 °C for 24 h, 
quenched with saturated NH4Cl, diluted with EtOAc, washed with 1 N HCl and brine, dried 
(MgSO4), filtered through Florisil, and concentrated in vacuo.  The residue was chromato-
graphed on deactivated SiO2 (1:4, hexanes/EtOAc containing 1% Et3N) to yield 48 mg (75%) of 
146 as a colorless solid.  The enantioselectivity was measured by chiral HPLC using a Chiracel 
OD column (12% i-PrOH in hexanes, 1.0 mL/min, RT = 5.1 and 6.8 min): 23% ee. 
NHP(O)Ph2
Ph Et
Et
147  
 (E)-N-(2-Ethyl-1-phenylpent-2-enyl)-P,P-diphenylphosphinamide (147).  According 
to the General Protocol A, 205 mg (0.795 mmol) of Cp2ZrHCl, 105 µL (0.924 mmol) of 3-
hexyne, 380 µL (0.760 mmol) of Me2Zn (2.0 M solution in toluene), and 153 mg (0.501 mmol) 
of imine 104 (4 h reaction time) afforded 140 mg (72%) of 147 as a colorless solid: mp 129-130 
°C (EtOAc/hexane); IR (KBr) 3165, 2959, 2931, 2872, 1436, 1187, 1179, 1107, 727, 696 cm-1; 
1H NMR δ 8.00-7.93 (m, 2 H), 7.91-7.83 (m, 2 H), 7.54-7.21 (m, 11 H), 5.56 (t, 1 H, J = 7.2 Hz), 
4.76 (t, 1 H, J = 10.8 Hz), 3.29 (dd, 1 H, J = 10.1, 6.2 Hz), 2.19-2.07 (m, 3 H), 1.77 (dq, 1 H, J = 
14.5, 7.5 Hz), 1.06 (t, 3 H, J = 7.5 Hz), 0.73 (t, 3 H, J = 7.6 Hz); 13C NMR δ 142.53, 142.48, 
140.94, 140.87, 133.50, 133.40, 132.49, 132.36, 132.13, 132.01, 131.80, 131.75, 131.70, 131.66, 
128.56, 128.34, 128.20, 128.16, 127.44, 127.04, 59.11, 21.86, 20.84, 14.43, 13.49; EIMS m/z 
389 (M+, 15), 306 (20), 218 (55), 201 (88), 188 (100), 143 (33), 129 (15), 91 (27), 77 (29); 
HRMS (EI) m/z calcd for C25H28NOP 389.1909, found 389.1905. 
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 (E)-N-{5-[(tert-Butyldiphenylsilyl)oxy]-1-phenylpent-2-enyl}-P,P-diphenylphos-
phinamide (149).  According to the General Protocol A, 205 mg (0.795 mmol) of Cp2ZrHCl, 
300 mg (0.972 mmol) of alkyne 148, 380 µL (0.760 mmol) of Me2Zn (2.0 M solution in 
toluene), and 153 mg (0.501 mmol) of imine 104 (12 h reaction time) afforded 226 mg (73%) of 
149 as a colorless solid: mp 118-119 °C (EtOAc/hexane); IR (KBr) 3131, 3052, 2928, 2857, 
1457, 1438, 1428, 1192, 1111, 1088, 740, 723, 698 cm-1; 1H NMR δ 8.00-7.93 (m, 2 H), 7.90-
7.83 (m, 2 H), 7.70-7.67 (m, 4 H), 7.52-7.25 (m, 17 H), 5.80 (dd, 1 H, J = 15.4, 6.0 Hz), 5.57 
(dtd, 1 H, J = 15.3, 6.8, 1.2 Hz), 4.86 (td, 1 H, J = 9.4, 6.2 Hz), 3.68 (t, 2 H, J = 6.6 Hz), 3.33 
(dd, 1 H, J = 9.6, 6.3 Hz), 2.32 (q, 2 H, J = 6.6 Hz), 1.07 (s, 9 H); 13C NMR δ 142.63, 142.56, 
135.47, 133.77, 133.69, 133.58, 133.29, 132.25, 132.19, 132.12, 132.06, 131.86, 131.74, 131.69, 
131.65, 131.58, 129.50, 128.69, 128.43, 128.37, 128.20, 127.55, 127.15, 126.99, 63.27, 56.69, 
35.48, 26.75, 19.11; EIMS m/z 600 ([M-CH3]+, 3), 558 (82), 201 (24), 199 (32), 143 (24), 91 
(20), 77 (37), 61 (100); HRMS (EI) m/z calcd for C38H39NO2PSi [M-CH3] 600.2488, found 
600.2465. 
150
OTIPS
O
 
 O-Triisopropylsilyl-4-pentynoate (150).  According to a literature procedure, a solution 
of 1.17 g (11.9 mmol) of 4-pentynoic acid in 25 mL of CH2Cl2 was treated with 2.29 g (11.9 
mmol) of TIPS-Cl and 0.812 g (11.9 mmol) of imidazole.  The mixture was stirred at room 
temperature for 2 h, filtered through Celite, washed with 1 N HCl and brine, dried (MgSO4), and 
concentrated in vacuo.  The residue was Kugelrohr distilled to yield 3.04 g (100%) of 150 as a 
colorless oil: IR (neat) 3315, 2945, 2870, 1722, 1466, 1372, 1268, 1191, 1068, 1015 cm-1; 1H 
NMR δ 2.62-2.57 (m, 2 H), 2.52-2.45 (m, 2 H), 1.96 (t, 1 H J = 2.6 Hz), 1.35-1.23 (m, 3 H), 1.07 
(d, 18 H, J = 7.2 Hz); 13C NMR δ 171.64, 82.71, 68.90, 34.90, 17.71, 14.67, 11.87; EIMS m/z 
211 ([M-C3H7]+, 100), 155 (18), 131 (22), 103 (47); HRMS (EI) m/z calcd for C11H19O2Si [M-
C3H7] 211.1154, found 211.1158. 
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 (E)-O-Triisopropylsilyl-6-(diphenylphosphinyl)amino-6-phenylhex-4-enoate (151). 
According to the General Protocol A, 260 mg (1.01 mmol) of Cp2ZrHCl, 285 mg (1.10 mmol) of 
alkyne 150, 500 µL (1.00 mmol) of Me2Zn (2.0 M solution in toluene), and 153 mg (0.501 
mmol) of imine 104 (12 h reaction time) afforded 184 mg (65%) of 151 as a colorless oil: IR 
(neat) 3167, 2945, 2868, 1718, 1464, 1437, 1186, 1123, 1110 cm-1; 1H NMR δ 7.94-7.77 (m, 4 
H), 7.50-7.19 (m, 11 H), 5.70 (dd, 1 H, J = 15.3, 6.2 Hz), 5.51 (dt, 1 H, J = 15.5, 5.8 Hz), 4.79 
(dt, 1 H, J = 9.2, 6.6 Hz), 3.30 (dd, 1 H, J = 9.1, 6.1 Hz), 2.53-2.23 (m, 4 H), 1.30-1.10 (m, 3 H), 
1.02 (d, 18 H, J = 7.2 Hz); 13C NMR δ 172.81, 142.65, 132.88, 132.28, 132.19, 132.07, 131.74, 
130.40, 128.53, 128.43, 128.27, 127.27, 126.93, 56.90, 35.11, 27.58, 17.72, 11.86; EIMS m/z 
561 (M+, 8), 518 (40), 361 (41), 346 (25), 330 (58), 301 (17), 218 (52), 201 (100), 158 (20), 143 
(24), 128 (29), 115 (37), 103 (41); HRMS (EI) m/z calcd for C33H44NO3PSi 561.2828, found 
561.2849. 
N
152
CO2Et
Ts
 
 O-Ethyl-N-but-3-ynyl-N-[(4-methylphenyl)sulfonyl]carbamate (152).  According to a 
literature procedure,233 a solution of 5.39 g (20.5 mmol) of PPh3 and 2.50 g (10.3 mmol) of 
TsNHCO2Et234 in 100 mL of THF was treated with 520 µL (6.85 mmol) of 3-butyn-1-ol and 
2.70 mL (17.1 mmol) of DEAD, stirred at room temperature for 16 h, and concentrated in vacuo.  
The residue was chromatographed on SiO2 (80:20, hexanes/EtOAc) to yield 1.95 g (96%) of 152 
as a colorless solid: mp 63-65 °C (EtOAc/hexane); IR (KBr) 3307, 2993, 2941, 2121, 1734, 
1353, 1329, 1268, 1168, 1028, 964, 866, 812, 769, 741, 657 cm-1; 1H NMR δ 7.83 (d, 2 H, J = 
8.4 Hz), 7.30 (d, 2 H, J = 8.1 Hz), 4.13 (q, 2 H, J = 7.1 Hz), 4.00 (dd, 2 H, J = 8.0, 7.0 Hz), 2.64 
(td, 2 H, J =7.5, 2.7 Hz), 2.42 (s, 3 H), 2.02 (t, 1 H, J = 2.7 Hz), 1.18 (t, 3 H, J = 7.1 Hz); 13C 
NMR δ 152.06, 144.67, 136.44, 129.31, 128.37, 80.17, 70.53, 63.52, 45.26, 21.62, 19.91, 13.96; 
EIMS m/z 295 (M+, 4), 256 (31), 184 (58), 155 (100), 91 (89); HRMS (EI) calcd for C14H17NO4S 
295.0878, found 295.0892. 
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 (E)-O-Ethyl-N-{5-[(diphenylphosphinyl)amino]-5-phenylpent-3-enyl}-N-[(4-methyl-
phenyl)sulfonyl]carbamate (153).  According to the General Protocol A, 205 mg (0.795 mmol) 
of Cp2ZrHCl, 253 mg (0.857 mmol) of alkyne 152, 380 µL (0.760 mmol) of Me2Zn (2.0 M 
solution in toluene), and 153 mg (0.501 mmol) of imine 104 (12 h reaction time) afforded 177 
mg (59%) of 153 as a colorless solid: mp 159-160 °C (EtOAc/hexane); IR (KBr) 3168, 3064, 
2960, 2871, 1736, 1436, 1370, 1359, 1277, 1186, 1160, 1125, 970, 726, 702, 679 cm-1; 1H NMR 
δ 7.99-7.92 (m, 2 H), 7.89-7.80 (m, 4 H), 7.53-7.44 (m, 4 H), 7.41-7.35 (m, 2 H), 7.33-7.24 (m, 7 
H), 5.85 (dd, 1 H, J = 15.4, 5.8 Hz), 5.54 (dtd, 1 H, J = 15.4, 7.1, 1.3 Hz), 4.84 (td, 1 H, J = 9.6, 
6.0 Hz), 4.09 (q, 2 H, J = 7.1 Hz), 3.85 (t, 2 H, J = 7.3 Hz), 3.52 (dd, 1 H, J = 9.5, 6.8 Hz), 2.50-
2.44 (m, 2 H), 2.44 (s, 3 H), 1.15 (t, 3 H, J = 7.1 Hz); 13C NMR δ 152.08, 144.97, 142.35, 
142.28, 136.69, 135.19, 135.13, 133.62, 133.15, 132.28, 132.15, 132.03, 131.91, 131.76, 131.72, 
131.69, 131.66, 131.43, 129.19, 128,43, 128.35, 128.26, 128.20, 127.47, 127.19, 127.00, 63.24, 
56.47, 46.40, 32.63, 21.54, 13.92; EIMS m/z 602 (30), 401 (63), 358 (25), 346 (41), 332 (15), 
230 (31), 218 (17), 201 (100), 158 (50), 155 (30), 91 (53), 77 (19); HRMS (EI) calcd for 
C33H35N2O5PS 602.2004, found 602.2004. 
N
H
PPh2
O
MeO2C
156  
 Methyl 4-[(diphenylphosphinylimino)methyl]benzoate (156). General Protocol B.  
According to a literature procedure,  a suspension of 1.50 g (6.91 mmol) of P,P-diphenyl-
phosphinamide, 1.25 g (7.61 mmol) of methyl 4-formylbenzoate, and 3.00 mL (20.8 mmol) of 
Et3N in 15 mL of CH2Cl2 was cooled to 0 °C, treated dropwise with a solution of 3.50 mL (3.50 
mmol) of TiCl4 (1.0 M solution in CH2Cl2) in 5 mL of CH2Cl2 over 10 min, warmed to room 
temperature and stirred for 1 h.  The mixture was poured into 150 mL of Et2O,235 stirred for 5 
min, filtered through a pad of Florisil, and concentrated in vacuo.  The residue was precipitated 
from CH2Cl2 with hexanes to yield 1.19 g (47%) of 156 as a colorless solid: mp 143-145 °C 
(CH2Cl2/hexanes); IR (KBr) 3226, 3060, 3037, 1725, 1613, 1568, 1438, 1280, 1203, 1127, 1107, 
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 861, 834, 766, 750, 729, 697 cm-1; 1H NMR δ 9.34 (d, 1 H, J = 31.7 Hz), 8.15-8.12 (m, 2 H), 
8.06-8.03 (m, 2 H), 7.96-7.89 (m, 4 H), 7.48-7.36 (m, 6 H), 3.91 (s, 3 H); 13C NMR δ 172.62, 
172.52, 166.09, 139.22, 138.89, 134.15, 133.20, 131.91, 131.88, 131.76, 131.63, 131.53, 131.41, 
129.95, 129.85, 128.55, 128.38, 128.26, 52.40; EIMS m/z 363 (M+, 24), 201 (100); HRMS (EI) 
m/z calcd for C21H18NO3P 363.1024, found 363.1018. 
NHP(O)Ph2
C4H9
MeO2C
157  
 (E)-Methyl 4-{1-[(diphenylphosphinyl)amino]hept-2-enyl}benzoate (157).  According 
to the General Protocol A, 103 mg (0.399 mmol) of Cp2ZrHCl, 51.0 µL (0.444 mmol) of 1-
hexyne, 190 µL (0.380 mmol) of Me2Zn (2.0 M solution in toluene), and 94.0 mg (0.259 mmol) 
of imine 156 (1 h reaction time) afforded 97 mg (84%) of 157 as a colorless solid: mp 129-130 
°C (EtOAc/hexane); IR (KBr) 3122, 2956, 2928, 2872, 1722, 1437, 1276, 1194, 1109, 724, 695   
cm-1; 1H NMR δ 8.01-7.90 (m, 4 H), 7.85-7.78 (m, 2 H), 7.56-7.34 (m, 8 H), 5.68 (ddt, 1 H, J = 
15.3, 6.2, 1.2 Hz), 5.51 (dtd, 1 H, J = 15.3, 6.6, 1.1 Hz), 4.87 (td, 1 H, J = 9.7, 6.3 Hz), 3.93 (s, 3 
H), 3.42 (dd, 1 H, J = 9.4, 6.4 Hz), 2.01 (q, 2 H, J = 6.7 Hz), 1.34-1.24 (m, 4 H), 0.89 (t, 3 H, J = 
7.0 Hz); 13C NMR δ 166.83, 148.10, 148.04, 133.37, 133.18, 133.11, 132.26, 132.14, 132.02, 
131.88, 131.83, 131.79, 131.66, 131.40, 131.08, 131.02, 129.77, 128.91, 128.47, 128.43, 128.31, 
128.26, 126.98, 56.59, 52.03, 31.78, 31.05, 22.17, 13.86; EIMS m/z 447 (M+, 3), 246 (15), 230 
(21), 201 (21), 141 (19), 129 (35), 87 (100), 84 (45); HRMS (EI) m/z calcd for C27H30NO3P 
447.1963, found 447.1961. 
NHP(O)Ph2
C4H9
MeO
159  
 (E)-N-[1-(4-Methoxyphenyl)hept-2-enyl]-P,P-diphenylphosphinamide (159). 
According to the General Protocol A, 195 mg (0.756 mmol) of Cp2ZrHCl, 95.0 µL (0.827 mmol) 
of 1-hexyne, 380 µL (0.760 mmol) of Me2Zn (2.0 M solution in toluene), and 149 mg (0.444 
mmol) of imine 158 (4 h reaction time) afforded 65 mg (35%) of 159 as a colorless oil: IR (thin 
film) 2957, 2929, 2871, 2836, 1604, 1511, 1439, 1251, 1175, 1127, 1035, 986, 755, 721, 697  
cm-1; 1H NMR δ 7.95-7.78 (m, 4 H), 7.50-7.32 (m, 6 H), 7.24-7.19 (m, 2 H), 6.85-6.80 (m, 2 H), 
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 5.63 (dd, 1 H, J = 15.3, 6.1 Hz), 5.48 (dtd, 1 H, J = 15.3, 6.7, 1.0 Hz), 4.74 (td, 1 H, J = 9.5, 6.1 
Hz), 3.77 (s, 3 H), 3.20 (dd, 1 H, J = 9.2, 6.2 Hz), 2.00-1.93 (m, 2 H), 1.29-1.22 (m, 4 H), 0.86 (t, 
3 H, J = 7.0 Hz); 13C NMR δ 158.63, 135.27, 135.20, 133.73, 133.49, 132.33, 132.20, 132.07, 
132.01, 131.84, 131.78, 131.74, 131.70, 131.66, 128.41, 128.24, 128.12, 113.95, 113.79, 56.32, 
55.23, 31.79, 31.19, 22.23, 13.91; EIMS m/z 419 (M+, 6), 336 (24), 218 (42), 202 (92), 173 
(100), 159 (48); HRMS (EI) m/z calcd for C26H30NO2P 419.2014, found 419.2007. 
N
H
PPh2
O
Ph
160  
 (2E)-N-(3-Phenylallylidene)-P,P-diphenylphosphinamide (160).  According to the 
General Protocol B, 2.00 g (9.21 mmol) of P,P-diphenylphosphinamide, 1.50 mL (11.9 mmol) of 
trans-cinnamaldehyde, 4.00 mL (28.7 mmol) of Et3N, and 600 µL (5.47 mmol) of TiCl4 afforded 
1.39 g (46%) of 160 as a colorless solid: mp 142-143 °C (CH2Cl2/hexanes); IR (KBr) 3065, 
3020, 1629, 1591, 1438, 1207, 1125, 1106, 869, 802, 757, 727, 703, 694 cm-1; 1H NMR δ 9.04 
(dd, 1 H, J = 31.7, 9.0 Hz), 7.93-7.86 (m, 4 H), 7.56-7.34 (m, 12 H), 7.10 (ddd, J = 15.8, 9.0, 2.1 
Hz); 13C NMR δ 174.83, 174.72, 150.57, 134.60, 133.69, 132.02, 131.72, 131.68, 131.55, 
131.43, 130.75, 128.98, 128.79, 128.50, 128.41, 128.34, 128.22; EIMS m/z 331 (M+, 7), 201 
(48), 130 (100), 77 (52); HRMS (EI) m/z calcd for C21H18NOP 331.1126, found 331.1114. 
NHP(O)Ph2
C4H9Ph
161  
 (E)-N-[1-(2-Phenylvinyl)hept-2-enyl]-P,P-diphenylphosphinamide (161).  According 
to the General Protocol A, 200 mg (0.776 mmol) of Cp2ZrHCl, 100 µL (0.870 mmol) of 1-
hexyne, 750 µL (1.50 mmol) of Me2Zn (2.0 M solution in toluene), and 165 mg (0.498 mmol) of 
imine 160 (4 h reaction time) afforded 57 mg (28%) of 161 as a colorless solid: mp 141-142 °C 
(Et2O/hexane); IR (KBr) 3089, 2954, 2923, 2855, 1438, 1200, 1183, 1122, 1109, 965, 747, 723, 
696 cm-1; 1H NMR δ 7.96-7.88 (m, 4 H), 7.52-7.37 (m, 6 H), 7.33-7.19 (m, 5 H), 6.42 (dd, 1 H, J 
= 15.9, 1.1 Hz), 6.23 (dd, 1 H, J = 15.4, 6.5 Hz), 5.60-5.57 (m, 2 H), 4.39-4.36 (m, 1 H), 3.01 
(dd, 1 H, J = 9.5, 5.9 Hz), 2.04-1.98 (m, 2 H), 1.34-1.25 (m, 4 H), 0.88 (t, 3 H, J = 7.0 Hz); 13C 
NMR δ 136.85, 133.81, 133.77, 132.59, 132.42, 132.39, 132.29, 132.26, 132.09, 132.05, 131.90, 
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 131.40, 131.33, 130.78, 130.71, 130.35, 128.62, 128.57, 128.45, 127.65, 126.60, 54.96, 32.05, 
31.36, 22.36, 14.06; EIMS m/z 415 (M+, 26), 358 (55), 216 (48), 214 (100), 201 (83), 199 (32), 
155 (43), 124 (22), 91 (37), 77 (34); HRMS (EI) m/z calcd for C27H30NOP 415.2065, found 
415.2105. 
N
H
PPh2
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162  
 (2E)-N-(2-Methyl-3-phenylallylidene)-P,P-diphenylphosphinamide (162).  According 
to the General Protocol B, 2.00 g (9.21 mmol) of P,P-diphenylphosphinamide, 1.50 mL (10.7 
mmol) of α-methylcinnamaldehyde, 4.00 mL (28.7 mmol) of Et3N, and 600 µL (5.47 mmol) of 
TiCl4 afforded 1.47 g (46%) of 162 as a colorless solid: mp 153-154 °C (CH2Cl2/hexanes); IR 
(KBr) 3049, 3026, 2952, 2883, 1603, 1443, 1437, 1196, 1128, 1108, 1021, 887, 846, 754, 729, 
706, 693 cm-1; 1H NMR δ 8.98 (d, 1 H, J = 31.2 Hz), 7.96-7.89 (m, 4 H), 7.49-7.34 (m, 11 H), 
7.22 (s, 1 H), 2.28 (s, 3 H); 13C NMR δ 177.91, 177.81, 148.09, 137.74, 137.40, 135.62, 134.16, 
132.48, 131.61, 131.55, 131.42, 129.94, 129.07, 128.53, 128.45, 128.29, 12.43; EIMS m/z 345 
(M+, 43), 201 (85), 144 (100), 77 (75); HRMS (EI) m/z calcd for C22H20NOP 345.1283, found 
345.1278. 
NHP(O)Ph2
C4H9Ph
163  
 (E)-N-[1-(1-Methyl-2-phenylvinyl)hept-2-enyl]-P,P-diphenylphosphinamide (163). 
According to the General Protocol A, 195mg (0.756 mmol) of Cp2ZrHCl, 100 µL (0.870 mmol) 
of 1-hexyne, 380 µL (0.760 mmol) of Me2Zn (2.0 M solution in toluene), and 173 mg (0.501 
mmol) of imine 162 (4 h reaction time) afforded 154 mg (72%) of 163 as a colorless oil: IR (thin 
film) 3176, 3054, 2954, 2927, 2855, 1437, 1192, 1124, 1109, 972, 916, 748, 724, 697 cm-1; 1H 
NMR δ 8.11-8.03 (m, 4 H), 7.65-7.53 (m, 6 H), 7.49-7.33 (m, 5 H), 6.50 (s, 1 H), 5.79 (dtd, 1 H, 
J = 15.3, 6.4, 1.0 Hz), 5.66 (dd, 1 H, J = 15.4, 5.7 Hz), 4.42 (td, 1 H, J = 9.4, 5.7 Hz), 3.28 (dd, 1 
H, J = 9.2, 5.9 Hz), 2.19-2.13 (m, 2 H), 1.98 (s, 3 H), 1.68-1.41 (m, 4 H), 1.03 (t, 3 H, J = 7.1 
Hz); 13C NMR δ 138.74, 138.68, 137.58, 133.78, 133.52, 132.52, 132.31, 132.19, 132.16, 
132.07, 132.03, 131.79, 131.72, 130.36, 130.29, 128.86, 128.62, 128.52, 128.44, 128.38, 128.27, 
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 128.21, 127.96, 126.32, 126.26, 60.17, 31.86, 31.18, 22.17, 14.82, 13.89; EIMS m/z 429 (M+, 
16), 32 (21), 358 (61), 228 (86), 218 (49), 201 (100), 155 (19), 91 (19), 77 (29); HRMS (EI) m/z 
calcd for C28H32NOP 429.2222, found 429.2238. 
N
H
PPh2
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164  
 N-(3-Phenylprop-2-ynylidene)-P,P-diphenylphosphinamide (164).  A solution of 2.20 
mL (20.0 mmol) of phenylacetylene in 50 mL of THF was cooled to -40 °C, treated with 12.5 
mL (20.0 mmol) of n-BuLi (1.6 M solution in hexanes), stirred at -40 °C for 10 min, treated with 
3.10 mL (40.0 mmol) of DMF, warmed to room temperature over 30 min, and stirred for 30 min.  
The mixture was quenched by pouring into a biphasic mixture of 10.0 g (73.4 mmol) of KH2PO4 
in 90 mL of H2O and 100 mL of MTBE at 0 °C.236  The organic layer was separated, washed 
with H2O, dried (MgSO4), concentrated in vacuo and filtered through a pad of SiO2 (9:1, 
hexanes/EtOAc).  The residue (2.10 g, 81%) was used in the next step without further 
purification.  According to the General Protocol B, 1.50 g (6.91 mmol) of P,P-diphenyl-
phosphinamide, 1.35 g (10.4 mmol) of the crude aldehyde, 3.00 mL (21.5 mmol) of Et3N, and 
450 µL (4.10 mmol) of TiCl4 afforded 914 mg (40%) of 164 as a yellow solid: mp 109-110 °C 
(CH2Cl2/hexanes); IR (KBr) 3056, 2199, 1585, 1439, 1214, 1124, 1109 cm-1; 1H NMR δ 8.72 (d, 
1 H, J = 31.2 Hz), 7.90-7.86 (m, 4 H), 7.60-7.37 (m, 11 H); 13C NMR δ 158.12, 132.88, 132.03, 
131.68, 131.56, 131.06, 130.72, 128.60, 128.44, 120.45, 100.65, 88.38, 87.90; EIMS m/z 329 
(M+, 30), 216 (30), 201 (74), 130 (32), 102 (42), 77 (100); HRMS (EI) m/z calcd for C21H16NOP 
329.0970, found 329.0960. 
NHP(O)Ph2
C4H9
Ph
165  
 (E)-N-(1-Phenethynylhept-2-enyl)-P,P-diphenylphosphinamide (165).  According to 
the General Protocol A, 195 mg (0.756 mmol) of Cp2ZrHCl, 95.0 µL (0.827 mmol) of 1-hexyne, 
380 µL (0.760 mmol) of Me2Zn (2.0 M solution in toluene), and 165 mg (0.501 mmol) of imine 
164 (2 h reaction time) afforded 176 mg (85%) of 165 as a colorless oil: IR (neat) 3144, 2957, 
2928, 2853, 1592, 1490, 1438, 1190, 1124, 1110, 1058 cm-1; 1H NMR δ 8.09-8.02 (m, 2 H), 
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 7.98-7.90 (m, 2 H), 7.56-7.37 (m, 9 H), 7.35-7.30 (m, 2 H), 5.95 (dtd, 1 H, J = 15.1, 6.8, 1.5 Hz), 
5.71 (ddt, 1 H, J = 15.2, 5.2, 1.3 Hz), 4.75 (td, 1 H, J = 9.0, 5.2 Hz), 3.42 (dd, 1 H, J = 9.4, 7.5 
Hz), 2.10-2.03 (m, 2 H), 1.40-1.29 (m, 4 H), 0.91 (t, 3 H, J = 7.1 Hz); 13C NMR δ 133.63, 
132.96, 132.52, 132.40, 131.87, 131.75, 131.53, 131.17, 128.79, 128.41, 128.24, 128.07, 126.62, 
122.75, 88.44, 84.86, 45.04, 31.40, 30.97, 22.10, 13.76; EIMS m/z 413 (M+, 17), 370 (24), 356 
(13), 216 (56), 212 (39), 201 (100), 196 (25), 167 (27), 154 (46), 124 (33), 115 (29), 91 (24), 77 
(83); HRMS (EI) m/z calcd for C27H28NOP 413.1909, found 413.1902. 
NHTs
Ph C4H9
91  
 (E)-N-(1-Phenylhept-2-enyl)-S-(4-methylphenyl)sulfonamide (91).  According to the 
General Protocol A, 195 mg (0.756 mmol) of Cp2ZrHCl, 95.0 µL (0.827 mmol) of 1-hexyne, 380 
µL (0.760 mmol) of Me2Zn (2.0 M solution in toluene), and 130 mg (0.501 mmol) of imine 90 (4 
h reaction time) afforded 138 mg (80%) of 91 as a colorless oil: IR (neat) 3272, 3030, 2956, 
2927, 2858, 1454, 1433, 1328, 1161, 1094, 1043, 1027, 970, 932, 813, 749, 699, 668 cm-1; 1H 
NMR δ 7.65-7.61 (m, 2 H), 7.24-7.12 (m, 7 H), 5.48-5.34 (m, 2 H), 5.18 (d, 1 H, J = 7.4 Hz), 
4.89 (dd, 1 H, J = 7.3, 5.2 Hz), 2.37 (s, 3 H), 1.90-1.84 (m, 2 H), 1.24-1.14 (m, 4 H), 0.83 (t, 3 H, 
J = 6.9 Hz); 13C NMR δ 142.92, 140.27, 137.83, 133.72, 129.25, 128.64, 128.40, 127.37, 127.18, 
126.90, 59.52, 31.66, 30.87, 22.11, 21.40, 13.83; EIMS m/z 343 (M+, 4), 286 (40) 188 (90), 172 
(29), 155 (44), 144 (21), 129 (32), 117 (46), 104 (39), 91 (100), 77 (21), 65 (30); HRMS (EI) m/z 
calcd for C20H25NO2S 343.1606, found 343.1607. 
N
H
Ts
166
Ph
 
 N-(3-Phenylpropylidene)-S-(4-methylphenyl)sulfonamide (166).  According to a 
literature procedure,  a solution of 1.85 g (11.3 mmol) of sodium benzenesulfinate, 1.71 g (10.0 
mmol) of TsNH2, and 1.32 mL (10.0 mmol) of hydrocinnamaldehyde in 30 mL of 50% formic 
acid was stirred at room temperature for 16 h, diluted with 20 mL of H2O, filtered and rinsed 
with H2O and pentane.  The filter cake was dissolved in 75 mL of CH2Cl2 and stirred with 75 mL 
of saturated NaHCO3 for 2 h.  The organic layer was separated and the aqueous layer extracted 
with CH2Cl2.  The combined organic layers were dried (MgSO4), and concentrated in vacuo.  
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 The residue was precipitated from CH2Cl2 with hexanes to yield 2.03 g (71%) of 166 as a 
colorless solid: mp 61-63 °C (CH2Cl2/hexanes); IR (KBr) 3271, 3030, 2938, 1634, 1613, 1494, 
1453, 1318, 1159, 1091, 784, 705, 682 cm-1; 1H NMR δ 8.67 (t, 1 H, J = 4.0 Hz), 7.81 (d, 2 H, J 
= 8.3 Hz), 7.38-7.15 (m, 7 H), 3.02-2.96 (m, 2 H), 2.91-2.85 (m, 2 H), 2.49 (s, 3 H); 13C NMR δ 
177.36, 144.69, 139.53, 134.36, 129.75, 128.58, 128.25, 128.09, 126.41, 37.30, 30.53, 21.61; 
EIMS m/z 287 (M+, 4), 171 (12), 155 (25), 132 (100), 105 (16), 91 (20); HRMS (EI) m/z calcd 
for C16H17NO2S 287.0980, found 287.0979. 
NHTs
C4H9
167
Ph
 
 (E)-N-(1-Phenethylhept-2-enyl)-S-(4-methylphenyl)sulfonamide (167).  According to 
the General Protocol A, 195 mg (0.756 mmol) of Cp2ZrHCl, 95.0 µL (0.827 mmol) of 1-hexyne, 
380 µL (0.760 mmol) of Me2Zn (2.0 M solution in toluene), and 144 mg (0.501 mmol) of imine 
166 (5 h reaction time) afforded 168 mg (90%) of 167 as a colorless oil: IR (neat) 3166, 3058, 
2955, 2924, 2855, 1490, 1438, 1189, 1124, 1110, 1070, 755, 723, 692 cm-1; 1H NMR δ 7.73-7.69 
(m, 2 H), 7.27-7.06 (m, 7 H), 5.30 (dtd, 1 H, J = 15.3, 6.7, 0.8 Hz), 5.07 (ddt, 1 H, J = 15.3, 7.4, 
1.4 Hz), 4.84 (d, 1 H, J = 8.0 Hz), 3.73 (qn, 1 H, J = 7.2 Hz), 2.65-2.50 (m, 2 H), 2.39 (s, 3 H), 
1.83-1.69 (m, 4 H), 1.20-1.10 (m, 4 H), 0.84 (t, 3 H, J = 6.9 Hz); 13C NMR δ 142.97, 141.28, 
138.18, 133.23, 129.39, 128.80, 128.34, 128.31, 127.19, 125.83, 55.77, 37.67, 31.69, 31.65, 
30.94, 22.09, 21.43, 13.86; EIMS m/z 371 (M+, 2), 314 (4), 288 (4), 267 (100), 216 (71), 200 
(97), 155 (60), 143 (60), 139 (33), 117 (37), 105 (93); HRMS (EI) m/z calcd for C22H29NO2S 
371.1919, found 371.1913. 
NHTs
C4H9
169  
 (E)-N-(1-Isopropylhept-2-enyl)-S-(4-methylphenyl)sulfonamide (169).  According to 
the General Protocol A, 390 mg (1.51 mmol) of Cp2ZrHCl, 190 µL (1.65 mmol) of 1-hexyne, 
750 µL (1.50 mmol) of Me2Zn (2.0 M solution in toluene), and 113 mg (0.502 mmol) of imine 
168 (4 h reaction time) afforded 111 mg (72%) of 169 as a colorless oil: IR (neat) 3278, 2961, 
2926, 2873, 1467, 1437, 1323, 1162, 1096, 1041, 972, 814, 667 cm-1; 1H NMR δ 7.75 (d, 2 H, J 
= 8.3 Hz), 7.27 (d, 2 H, J = 8.6 Hz), 5.21 (dt, 1 H, J = 15.6, 6.6), 5.05 (ddt, 1 H, J = 15.3, 7.6, 1.3 
76 
 Hz), 4.98 (d, 1 H, J = 8.5 Hz), 3.53 (td, 1 H, J = 7.8, 5.7 Hz), 2.42 (s, 3 H), 1.81-1.67 (m, 3 H), 
1.23-1.05 (m, 4 H), 0.87 (t, 6 H, J = 6.5 Hz), 0.85 (t, 3 H, J = 7.0 Hz); 13C NMR δ 142.66, 
138.32, 133.33, 129.19, 127.15, 126.87, 61.58, 32.99, 31.65, 30.94, 22.01, 21.34, 18.33, 18.14, 
13.79; EIMS m/z 308 ([M-H]+, 1), 266 (90), 226 (59), 155 (86), 139 (29), 111 (39), 91 (100); 
HRMS (EI) m/z calcd for C17H26NO2S [M-H] 308.1684, found 308.1687. 
NHTs
C4H9
171  
 (E)-N-(1-Cyclohexylhept-2-enyl)-S-(4-methylphenyl)sulfonamide (171).  According to 
the General Protocol A, 97.0 mg (0.376 mmol) of Cp2ZrHCl, 50.0 µL (0.435 mmol) of 1-hexyne, 
190 µL (0.380 mmol) of Me2Zn (2.0 M solution in toluene), and 66.0 mg (0.249 mmol) of imine 
170 (2 h reaction time) afforded 70 mg (81%) of 171 as a colorless solid: mp 102-103 °C 
(Et2O/hexanes); IR (KBr) 3287, 2921, 2851, 1439, 1326, 1151, 1090, 1044 cm-1; 1H NMR δ 
7.70-7.67 (m, 2 H), 7.24-7.21 (m, 2 H), 5.13 (dt, 1 H, J = 15.3, 6.4 Hz), 4.99 (ddt, 1 H, J = 15.3, 
7.6, 1.2 Hz), 4.63 (d, 1 H, J = 8.5 Hz), 3.49 (td, 1 H, J = 8.0, 6.1 Hz), 2.38 (s, 3 H), 1.77-1.56 (m, 
7 H), 1.37-1.26 (m, 1 H), 1.21-1.01 (m, 7 H), 0.99-0.86 (m, 2 H), 0.81 (t, 3 H, J = 7.0 Hz); 13C 
NMR δ 142.78, 138.43, 133.32, 129.28, 127.28, 127.22, 61.10, 42.83, 31.73, 31.03, 28.92, 
28.83, 26.28, 25.99, 22.12, 21.43, 13.87; EIMS m/z 349 (M+, 1), 266 (100), 155 (48), 91 (84); 
HRMS (EI) m/z calcd for C20H31NO2S 349.2076, found 349.2074. 
NHCOPh
C3H7
C3H7
MeO2C
173  
 (E)-Methyl 4-(1-benzoylamino-2-propylhex-2-enyl)benzoate (173).  A solution of 48.0 
mg (0.101 mmol) of phosphinamide 172 in 5.7 mL of a 2 N solution of HCl(g) in MeOH 
(prepared by treating 5 mL of MeOH with 0.7 mL of acetyl chloride at 0 °C and stirring at room 
temperature for 30 min) was stirred at room temperature for 12 h, concentrated in vacuo, 
dissolved in 5 mL of CH2Cl2, and concentrated in vacuo.  A solution of the residue in 1 mL of 
CH2Cl2 was treated with 27.0 µL (0.233 mmol) of PhCOCl, 60.0 µL (0.344 mmol) of (i-Pr)2NEt, 
and 2.0 mg (0.016 mmol) of DMAP.  The mixture was stirred at room temperature for 1 h, 
concentrated to ~0.5 mL by rotary evaporation, and chromatographed on SiO2 (80:20, hexanes/ 
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 EtOAc) to afford 32 mg (84%) of 173 as a colorless oil: IR (thin film) 3571, 3311, 2959, 2869, 
1725, 1637, 1525, 1277, 1107 cm-1; 1H NMR δ 8.01 (d, 2 H, J = 8.4 Hz), 7.80 (d, 2 H, J = 8.4 
Hz), 7.55-7.38 (m, 5 H), 6.42 (d, 1 H, J = 8.0 Hz), 5.81 (d, 1 H, J = 8.1 Hz), 5.33 (t, 1 H, J = 7.1 
Hz), 3.91 (s, 3 H), 2.18-1.92 (m, 4 H), 1.53-1.31 (m, 4 H), 0.92 (t, 3 H, J = 7.3 Hz), 0.89 (t, 3 H, 
J = 7.4 Hz); 13C NMR δ 166.83, 166.40, 146.27, 138.81, 134.38, 131.63, 129.84 (2 C), 129.26, 
129.10, 128.65 (2 C), 127.34 (2 C), 126.93 (2 C), 57.84, 52.02, 31.77, 29.82, 22.82, 22.14, 14.20, 
13.83; EIMS m/z 379 (M+, 46), 336 (59), 322 (56), 105 (100), 77 (48); HRMS (EI) m/z calc’d for 
C24H29NO3 379.2147, found 379.2143. 
NHCO2Ph
C3H7
C3H7
MeO2C
174  
 (E)-Methyl 4-(1-phenoxycarbonylamino-2-propylhex-2-enyl)benzoate (174). 
A solution of 44.0 mg (0.0925 mmol) of phosphinamide 172 in 5.7 mL of a 2 N solution of 
HCl(g) in MeOH (prepared by treating 5 mL of MeOH with 0.7 mL of acetyl chloride at 0 °C 
and stirring at room temperature for 30 min) was stirred at room temperature for 12 h, 
concentrated in vacuo, dissolved in 5 mL of CH2Cl2, and concentrated in vacuo.  A solution of 
the residue in 1 mL of CH2Cl2 was treated with 55.0 µL (0.316 mmol) of (i-Pr)2NEt, 26.0 µL 
(0.207 mmol) of ClCO2Ph, and 2.0 mg (0.016 mmol) of DMAP.  The mixture was stirred at 
room temperature for 1 h, concentrated to ~0.5 mL by rotary evaporation, and chromatographed 
on SiO2 (80:20, hexanes/EtOAc) to afford 33 mg (90%) of 174 as a colorless oil: IR (thin film) 
3336, 2957, 2869, 1723, 1524, 1490, 1281, 1207, 1112, 1018 cm-1; 1H NMR δ 8.03 (d, 2 H, J = 
8.3 Hz), 7.46-7.12 (m, 7 H), 5.40-5.36 (m, 3 H), 3.93 (s, 3 H), 2.14-2.04 (m, 3 H), 1.96-1.86 (m, 
1 H), 1.46-1.34 (m, 4 H), 0.92 (t, 3 H, J = 7.3 Hz), 0.91 (t, 3 H, J = 7.3 Hz); 13C NMR δ 166.77, 
150.96, 145.99, 138.44, 129.85 (2 C), 129.51, 129.38, 129.22 (2 C), 127.20 (2 C), 125.31, 121.45 
(2 C), 120.86, 52.03, 31.43, 29.75, 22.78, 22.05, 14.14, 13.80; EIMS m/z 395 (M+, 2), 364 (8), 
301 (23), 259 (100), 227 (22), 214 (45), 170 (24), 141 (34), 128 (34), 94 (95), 77 (63); HRMS 
(EI) m/z calc’d for C24H29NO4 395.2097, found 395.2101. 
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 NHSO2Ph
C3H7
C3H7
MeO2C
175  
 (E)-Methyl 4-(1-Benzenesulfonylamino-2-propylhex-2-enyl)benzoate (175). 
A solution of 43.0 mg (0.0904 mmol) of phosphinamide 172 in 5.7 mL of a 2 N solution of 
HCl(g) in MeOH (prepared by treating 5 mL of MeOH with 0.7 mL of acetyl chloride at 0 °C 
and stirring at room temperature for 30 min) was stirred at room temperature for 12 h, 
concentrated in vacuo, dissolved in 5 mL of CH2Cl2, and concentrated in vacuo.  A solution of 
the residue in 1 mL of CH2Cl2 was treated with 53.0 µL (0.304 mmol) of (i-Pr)2NEt, 26.0 µL 
(0.204 mmol) of PhSO2Cl, and 2.0 mg (0.016 mmol) of DMAP.  The mixture was stirred at room 
temperature for 1 h, concentrated to ~0.5 mL by rotary evaporation, and chromatographed on 
SiO2 (80:20, hexanes/EtOAc) to afford 29 mg (77%) of 175 as a colorless oil: IR (thin film) 
3285, 2957, 2873, 1723, 1447, 1442, 1329, 1280, 1163, 1110 cm-1; 1H NMR δ 7.85 (d, 2 H, J = 
8.4 Hz), 7.74 (d, 2 H, J = 8.1 Hz), 7.52-7.46 (m, 1 H), 7.41-7.35 (m, 2 H), 7.17 (d, 2 H, J = 8.3 
Hz), 5.19-5.12 (m, 2 H), 4.96 (d, 1 H, J = 7.7 Hz), 3.90 (s, 3 H), 1.92-1.70 (m, 4 H), 1.30-1.12 
(m, 4 H), 0.81 (t, 3 H, J = 7.3 Hz), 0.77 (t, 3 H, J = 7.3 Hz); 13C NMR δ 166.70, 144.98, 140.53, 
137.74, 132.42, 130.08, 129.57 (2 C), 129.24, 128.76 (2 C), 127.25 (2 C), 127.09 (2 C), 61.76, 
52.02, 30.88, 29.70, 22.54, 21.94, 14.06, 13.75; EIMS m/z 415 (M+, 1), 384 (1), 372 (1), 340 (1), 
304 (16), 274 (19), 258 (17), 141 (31), 132 (20), 77 (100); HRMS (EI) m/z calc’d for 
C23H29NO4S 415.1817, found 415.1819. 
MeO2C
H
N
OPh
180  
 Methyl 4-(phenoxyiminomethyl)benzoate (180).  According to a literature 
procedure,237 a solution of 400 mg (2.75 mmol) of O-phenylhydroxylamine hydrochloride and 
361 mg (2.20 mmol) of methyl 4-formylbenzoate in 10 mL of pyridine was stirred at room 
temperature for 12 h, and concentrated in vacuo.  The residue was dissolved in EtOAc, washed 
with saturated CuSO4, H2O and brine, dried (MgSO4), and concentrated in vacuo.  The residue 
was chromatographed on SiO2 (4:1, hexanes/EtOAc) to yield 533 mg (95%) of 180 as a pale 
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 yellow solid: mp 61-63 °C (EtOAc/hexane); IR (thin film) 1720, 1591, 1489, 1435, 1285, 1215, 
1115, 935, 768, 746, 698, 687 cm-1; 1H NMR δ 8.45 (s, 1 H), 8.11 (dt, 2 H, J = 8.3, 1.7 Hz), 7.80 
(dt, 2 H, J = 8.2, 1.6 Hz), 7.40-7.34 (m, 2 H), 7.28 (d, 2 H, J = 7.9 Hz), 7.08 (t, 1 H, J = 7.2 Hz), 
3.96 (s, 3 H); 13C NMR δ 166.44, 159.20, 150.50, 135.65, 131.72, 130.02 (2 C), 129.38 (2 C), 
127.44 (2 C), 122.67, 114.57 (2 C), 52.32; EIMS m/z 255 (M+, 19), 162 (25), 130 (38), 94 (100); 
HRMS (EI) m/z calcd for C15H13NO3 255.0895, found 255.0893. 
N OH
Ph
189  
 Phenyl(pyridin-2-yl)methanol (189).238  A solution of 890 µL (9.36 mmol) of 2-
pyridinecarboxaldehyde in 20 mL of THF was cooled to 0 °C and treated dropwise with a 
solution of 3.70 mL (11.1 mmol) of PhMgBr (3.0 M solution in Et2O) in 20 mL of THF.  The 
mixture was stirred at 0 °C for 3 h, quenched with saturated NH4Cl and extracted with 1N HCl 
(2x).  The aqueous extracts were basified with K2CO3 to pH 8, extracted with Et2O (2x), washed 
with brine, dried (MgSO4), and concentrated in vacuo to afford 1.21 g (70%) of 189 as a 
colorless solid: 1H NMR δ 8.57 (s, 1 H), 7.62 (t, 1 H, J = 7.6 Hz), 7.41-7.27 (m, 5 H), 7.22-7.15 
(m, 2 H), 5.77 (s, 1 H), 5.16 (bs, 1 H).  Approximately 600 mg of racemic 189 was separated by 
HPLC on a Chiracel AD semi-preparative column (solvent system: 15% i-PrOH in hexanes; flow 
rate: 10 mL/min).  (R)-Enantiomer: Rt 16.0 min; 99.9% ee (HPLC chiracel AD analytical 
column, 15% i-PrOH in hexanes, 1.0 mL/min); αD -156 (CHCl3, c = 1.00), lit.239 -163 (CHCl3, c 
= 0.4).  (S)-Enantiomer: Rt 19.5 min; 99.9% ee (HPLC chiracel AD analytical column, 15% i-
PrOH in hexanes, 1.0 mL/min); αD +158 (CHCl3, c = 1.00), lit.  +163 (CHCl3, c = 0.4). 
NHP(O)Ph2
Ph
(S)-106  
 (S)-N-(1-Phenylpropyl)-P,P-diphenylphosphinamide (106).162  A solution of 75.0 mg 
(0.246 mmol) of imine 104, 46.0 mg (0.248 mmol) of (S)-189, and 670 µL (0.737 mmol) of 
Et2Zn (1.1 M solution in toluene) in 1 mL of toluene was stirred at room temperature for 48 h.  
The mixture was quenched with saturated NH4Cl, extracted with CH2Cl2 (2x), washed with 
brine, dried (MgSO4), and concentrated in vacuo.  The residue was purified by preparative TLC 
(EtOAc) to yield 61 mg (74%) of (S)-106 as a colorless solid: 1H NMR δ 7.87 (ddt, 2 H, J = 
80 
 11.9, 6.6, 1.6 Hz), 7.76 (ddt, 2 H, J = 12.1, 6.9, 1.5 Hz), 7.52-7.38 (m, 4 H), 7.35-7.20 (m, 5 H), 
7.16 (dt, 2 H, J = 6.5, 1.6 Hz), 4.16-4.05 (m, 1 H), 3.27 (t, 1 H, J = 7.5 Hz), 2.09-1.95 (m, 1 H), 
1.91-1.77 (m, 1 H), 0.79 (t, 3 H, J = 7.4 Hz).  The enantioselectivity was measured by chiral 
HPLC using a Chiracel OD column (15% i-PrOH in hexanes, 1.0 mL/min, RT = 5.7 and 6.9 
min): 93% ee. 
O
Ph
OH
Ph
190  
 (Tetrahydro-2H-pyran-2-yl)diphenylmethanol (190).  A suspension of 1.23 g (50.6 
mmol) of Mg in 40 mL of THF was cooled to 0 °C and treated with 5.30 mL (50.3 mmol) of 
bromobenzene.  The mixture was stirred at room temperature for 30 min, heated at reflux for 1 h, 
cooled to 0 °C, treated dropwise with a solution of 2.00 g (12.6 mmol) of ethyl tetrahydro-2H-
pyran-2-carboxylate240 in 10 mL of THF, slowly warmed to room temperature over 16 h, 
quenched with cold saturated NH4Cl then 1 N HCl, and extracted with Et2O (3x). The combined 
extracts were washed with H2O and brine, dried (MgSO4) and concentrated in vacuo.  The 
residue was chromatographed on SiO2 (9:1, hexanes/EtOAc) to yield 2.34 g (69%) of 190 as a 
pale yellow solid: mp 95-96 °C (Et2O/hexane); IR (thin film) 3479, 2935, 2856, 1492, 1448, 
1330, 1172, 1090, 1048, 873, 748, 697 cm-1; 1H NMR δ 7.57-7.53 (m, 2 H), 7.42-7.16 (m, 8 H), 
4.24 (dd, 1 H, J = 10.7, 1.9 Hz), 4.10-4.04 (m, 1 H), 3.62 (td, 1 H, J = 11.0, 3.5 Hz), 3.24 (s, 1 
H), 1.88-1.83 (m, 1 H), 1.67-1.39 (m, 4 H), 1.14-1.09 (m, 1 H); 13C NMR δ 146.52, 143.86, 
127.94 (2 C), 127.90 (2 C), 126.83 (2 C), 126.68, 126.47, 125.80 (2 C), 80.19, 79.19, 68.75, 
25.83, 24.89, 23.31; EIMS m/z 250 ([M-H2O]+, 11), 206 (18), 183 (35), 160 (32), 131 (59), 124 
(100), 105 (42), 91 (43), 77(52); HRMS (EI) m/z calcd for C18H20O2 [M-H2O] 250.1358, found 
250.1360.  Approximately 500 mg of racemic 190 was separated by HPLC on a Chiracel AD 
semi-preparative column (solvent system: 1.2% i-PrOH in hexanes; flow rate: 10 mL/min).  
Enantiomer 1: Rt 19.5 min; 93.4% ee (HPLC chiracel AD analytical column, 1.2% i-PrOH in 
hexanes, 1.0 mL/min); αD +170 (CHCl3, c = 0.88).  Enantiomer 2: Rt 22.0 min; 86.7% ee (HPLC 
chiracel AD analytical column, 1.2% i-PrOH in hexanes, 1.0 mL/min); αD -146 (CHCl3, c = 
0.14). 
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 NHBoc
Ph C4H9
196  
 (E)-O-tert-Butyl-N-(1-phenylhept-2-enyl)carbamate (196).  A suspension of 95.0 mg 
(0.368 mmol) of Cp2ZrHCl in 1 mL of CH2Cl2 was treated with 50.0 µL (0.435 mmol) of 1-
hexyne, stirred at room temperature for 5 min, and concentrated in vacuo.  A solution of the 
residue in 1 mL of toluene was treated with 5.3 mg (0.027 mmol) of amino thiol 56,  cooled to  -
50 °C, and treated with 190 µL (0.380 mmol) of Me2Zn (2.0 M solution in toluene).  The mixture 
was slowly warmed from -50 °C to -30 °C over 1 h, treated with a solution of 51.0 mg (0.248 
mmol) of imine 176 in 1 mL of toluene, stirred at -30 °C for 12 h, quenched with saturated 
NaHCO3, diluted with Et2O, filtered through Celite, washed with H2O and brine, dried (MgSO4), 
filtered through Florisil, and concentrated in vacuo.  The residue was chromato-graphed on SiO2 
(9:1, hexanes/EtOAc) to yield 58 mg (81%) of 196 as a colorless solid: mp 39-40 °C 
(EtOAc/hexanes); IR (thin film) 3332, 2961, 2927, 1699, 1495, 1366, 1248, 1171, 700 cm-1; 1H 
NMR δ 7.34-7.20 (m, 5 H), 5.66-5.50 (m, 2 H), 5.21 (bs, 1 H), 4.89 (bs, 1 H), 2.04 (q, 2 H, J = 
6.4 Hz), 1.42 (s, 9 H), 1.37-1.20 (m, 4 H), 0.87 (t, 3 H, J = 7.1 Hz); 13C NMR δ 154.97, 142.04, 
132.45, 129.73, 128.43, 127.10, 126.73, 79.42, 56.10, 31.83, 31.21 28.31, 22.13, 13.84; EIMS 
m/z 289 (M+, 1), 233 (56), 176 (100), 132 (86); HRMS (EI) m/z calcd for C18H27NO2 289.2042, 
found 289.2047.  The enantioselectivity was measured by chiral HPLC using a Chiracel OD 
column (0.1% i-PrOH in hexanes, 1.0 mL/min, RT = 13.1 and 14.3 min): 22% ee. 
NHCO2Et
Ph C4H9
198  
 (E)-O-Ethyl-N-(1-phenylhept-2-enyl)carbamate (198).  A suspension of 220 mg (0.853 
mmol) of Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 115 µL (1.00 mmol) of 1-hexyne, 
stirred at room temperature for 10 min, and concentrated in vacuo.  A solution of the residue in 1 
mL of toluene was cannulated into a cold (-30 °C) solution of 10.2 mg (0.0563 mmol) of amino 
thiol 181, and 420 µL (0.840 mmol) of Me2Zn (2.0 M solution in toluene) in 1 mL of toluene.  
The mixture was stirred at -30 °C for 30 min, treated with a solution of 100 mg (0.564 mmol) of 
imine 197 in 1 mL of toluene, stirred at -30 °C for 12 h, quenched with saturated NH4Cl, diluted 
with EtOAc, washed with 1 N HCl and brine, dried (MgSO4), filtered through Florisil, and 
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 concentrated in vacuo.  The residue was chromatographed on SiO2 (4:1, hexanes/EtOAc) to yield 
138 mg (94%) of 198 as a colorless oil: IR (thin film) 3324, 2959, 2925, 1698, 1528, 1245, 1074, 
1040, 969, 699 cm-1; 1H NMR δ 7.38-7.24 (m, 5 H), 5.70-5.54 (m, 2 H), 5.28 (bs, 1 H), 5.00 (bs, 
1 H), 4.13 (q, 2 H, J = 7.1 Hz), 2.07 (q, 2 H, J = 6.5 Hz), 1.42-1.29 (m, 4 H), 1.24 (t, 3 H, J = 7.1 
Hz), 0.90 (t, 3 H, J = 7.1 Hz); 13C NMR δ 155.75, 141.76, 132.76, 129.44, 128.55 (2 C), 127.31, 
126.79 (2 C), 60.90, 56.42, 31.88, 31.21, 22.19, 14.56, 13.90; ESIMS m/z 300 ([M+K]+, 100), 
284 ([M+Na]+, 78); HRMS (ESI) m/z calcd for C16H23NO2Na [M+Na] 284.1626, found 
284.1640.  The enantioselectivity was measured by chiral HPLC using a Chiracel OD column 
(3.5% i-PrOH in hexanes, 1.0 mL/min, RT = 7.2 and 12.6 min): 7% ee. 
 Preparation of 198 using a modified General Protocol A (in situ imine formation). 
A suspension of 161 mg (0.624 mmol) of Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 80.0 µL 
(0.696 mmol) of 1-hexyne, stirred at room temperature for 10 min, and concentrated in vacuo.  A 
solution of the residue in 1 mL of toluene was cannulated into a cold (-20 °C) solution of 100 mg 
(0.313 mmol) of sulfonamide 204,241 8.4 mg (0.031 mmol) of amino alcohol 55, and 240 µL 
(0.420 mmol) of Me2Zn (2.0 M solution in toluene) in 2 mL of toluene.  The mixture was stirred 
at -20 °C for 6 h, quenched with saturated NH4Cl, diluted with EtOAc, washed with 1 N HCl and 
brine, dried (MgSO4), diluted in hexanes, filtered through Florisil, and concentrated in vacuo.  
The residue was chromatographed on SiO2 (4:1, hexanes/EtOAc) to yield 42 mg (51%) of 198 as 
a colorless oil.  The enantioselectivity was measured by chiral HPLC using a Chiracel OD 
column (3.5% i-PrOH in hexanes, 1.0 mL/min, RT = 5.6, 12.6 min): 5% ee. 
NHCO2Me
Ph C4H9
200  
 (E)-O-Methyl-N-(1-phenylhept-2-enyl)carbamate (200).  A suspension of 127 mg 
(0.492 mmol) of Cp2ZrHCl in 1 mL of THF was treated with 60.0 µL (0.522 mmol) of 1-hexyne, 
stirred at room temperature for 15 min, and concentrated in vacuo.  A solution of the residue in 1 
mL of toluene was cannulated into a cold (-40 °C) solution of 27.0 mg (0.165 mmol) of imine 
199, 44.0 mg (0.163 mmol) of amino alcohol 55, and 250 µL (0.500 mmol) of Me2Zn (2.0 M 
solution in toluene) in 1 mL of toluene.  The mixture was stirred at -20 °C for 12 h, quenched 
with saturated NH4Cl, diluted with EtOAc, washed with 1 N HCl and brine, dried (MgSO4), and 
concentrated in vacuo.  The residue was chromatographed on SiO2 (4:1, hexanes/EtOAc) to yield 
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 35 mg (86%) of 200 as a colorless oil: IR (thin film) 3324, 2959, 2929, 1707, 1527, 1453, 1248, 
1069, 1021, 970, 774, 699 cm-1; 1H NMR δ7.37-7.24 (m, 5 H), 5.68-5.54 (m, 2 H), 5.29 (bs, 1 
H), 5.07 (bs, 1 H), 3.68 (s, 3 H), 2.07 (q, 2 H, J = 6.4 Hz), 1.42-1.28 (m, 4 H), 0.90 (t, 3 H, J = 
7.0 Hz); 13C NMR δ 156.13, 141.72, 132.82, 129.46, 128.53 (2 C), 127.30, 126.74 (2 C), 56.64, 
52.08, 31.82, 31.20, 22.14, 13.80; EIMS m/z 247 (M+, 13), 190 (74), 147 (42), 143 (50), 129 
(84), 115 (65), 105 (100), 91 (34), 77 (58); HRMS (EI) m/z calcd for C15H21NO2 247.1572, 
found 247.1578.  The enantioselectivity was measured by chiral HPLC using a Chiracel OD 
column (5% i-PrOH in hexanes, 1.0 mL/min, RT = 8.5, 15.0 min): 6% ee. 
NHAc
Ph C4H9
201  
 (E)-N-(1-Phenylhept-2-enyl)acetamide (201).  A suspension of 100 mg (0.388 mmol) 
of Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 50.0 µL (0.435 mmol) of 1-hexyne, stirred at 
room temperature for 10 min, and concentrated in vacuo.  A solution of the residue in 1.5 mL of 
toluene was cooled to -30 °C, and treated with 5.0 mg (0.028 mmol) of amino thiol 181 and 200 
µL (0.400 mmol) of Me2Zn (2.0 M solution in toluene).  The mixture was stirred for 30 min at    
-30 °C, treated with a solution of 42.0 mg (0.285 mmol) of imine 177 in 0.5 mL of toluene, 
stirred at -30 °C for 12 h, quenched with saturated NH4Cl, diluted with EtOAc, washed with 1 N 
HCl and brine, dried (MgSO4), filtered through Florisil, and concentrated in vacuo.  The residue 
was chromatographed on SiO2 (1:1, hexanes/EtOAc) to yield 29 mg (44%) of 201 as a colorless 
oil: IR (thin film) 3279, 2957, 2927, 1652, 1538, 1372, 1292, 970, 698 cm-1; 1H NMR δ 7.37-
7.23 (m, 5 H), 5.95 (bd, 1 H, J = 7.1 Hz), 5.64-5.55 (m, 3 H), 2.06 (q, 2 H, J = 7.0 Hz), 2.01 (s, 3 
H), 1.41-1.25 (m, 4 H), 0.89 (t, 3 H, J = 7.1 Hz); 13C NMR δ 168.92, 141.44, 132.86, 128.91, 
128.55 (2 C), 127.33, 126.98 (2 C), 54.59, 31.88, 31.19, 23.37, 22.20, 13.88; ESIMS m/z 270 
([M+K]+, 28), 254 ([M+Na]+, 100); HRMS (ESI) m/z calcd for C15H21NONa [M+Na] 254.1521, 
found 254.1527.  The enantioselectivity was measured by chiral HPLC using a Chiracel OD 
column (10% i-PrOH in hexanes, 1.0 mL/min, RT = 6.8 and 7.8 min): 1% ee. 
 Preparation of 200 using a modified General Protocol A (in situ imine formation). 
A suspension of 161 mg (0.624 mmol) of Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 80.0 µL 
(0.696 mmol) of 1-hexyne, stirred at room temperature for 10 min, and concentrated in vacuo.  A 
solution of the residue in 1 mL of toluene was cannulated into a cold (-20 °C) solution of 91.0 
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 mg (0.314 mmol) of sulfonamide 205,242 8.4 mg (0.0312 mmol) of amino alcohol 55, and 240 µL 
(0.420 mmol) of Me2Zn (2.0 M solution in toluene) in 2 mL of toluene.  The mixture was stirred 
at -20 °C for 12 h, quenched with saturated NH4Cl, diluted with EtOAc, washed with 1 N HCl 
and brine, dried (MgSO4), filtered through Florisil, and concentrated in vacuo.  The residue was 
chromatographed on SiO2 (1:1, hexanes/EtOAc) to yield 35 mg (48%) of 201 as a colorless oil.  
The enantioselectivity was measured by chiral HPLC using a Chiracel OD column (1.0 mL/min, 
10% i-PrOH in hexanes, RT = 6.4 and 8.0 min): 6% ee. 
NHCONMe2
Ph C4H9
203  
 (E)-1,1-Dimethyl-3-(1-phenylhept-2-enyl)urea (203).  A solution of 3.00 g (34.0 mmol) 
of 1,1-dimethylurea, 5.0 mg (0.026 mmol) of TsOH·H2O, and 3.50 mL (34.4 mmol) of PhCHO 
in 50 mL of toluene was heated at reflux with a Dean-Stark trap for 16 h, and concentrated in 
vacuo.  The residue was purified by Kugelrohr distillation (80 °C, ~1 atm) to afford 4.49 g (75%) 
of a pale yellow oil which was an 86:14 mixture of imine 202 to 1,1-dimethylurea.  This mixture 
was used without further purification in the subsequent reaction.  A suspension of 110 mg (0.427 
mmol) of Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 55.0 µL (0.479 mmol) of 1-hexyne, 
stirred at room temperature for 5 min, and concentrated in vacuo.  A solution of the residue in 2 
mL of toluene was cooled to -30 °C, and treated with 5.1 mg (0.028 mmol) of amino thiol 181 
and 210 µL (0.420 mmol) of Me2Zn (2.0 M solution in toluene).  The mixture was stirred for 30 
min at -30 °C, treated with a solution of 50.0 mg (0.244 mmol) of imine 202 (86% purity) in 0.5 
mL of toluene, stirred at -30 °C for 12 h, quenched with saturated NH4Cl, diluted with EtOAc, 
washed with 1 N HCl and brine, dried (MgSO4), filtered through Florisil, and concentrated in 
vacuo.  The residue was chromatographed on SiO2 (3:2, hexanes/EtOAc) to yield 44 mg (69%) 
of 203 as a colorless solid: mp 65-66 °C (EtOAc/hexanes); IR (thin film) 3330, 2925, 1631, 
1527, 1376, 1214, 969, 698 cm-1; 1H NMR δ 7.36-7.23 (m, 5 H), 5.66-5.59 (m, 2 H), 5.49 (bd, 1 
H, J = 5.5 Hz), 4.63 (bd, 1 H, J = 7.3 Hz), 2.93 (s, 6 H), 2.10-2.03 (m, 2 H), 1.42-1.28 (m, 4 H), 
0.89 (t, 3 H, J = 7.0 Hz); 13C NMR δ 157.46, 142.90, 132.38, 130.47, 128.46 (2 C), 127.01, 
126.95 (2 C), 55.95, 36.19 (2 C), 31.92, 31.31, 22.22, 13.83; EIMS m/z 260 (M+, 7), 172 (33), 
143 (59), 129 (100), 115 (37), 91 (30); HRMS (EI) m/z calcd for C16H24N2O 260.1889, found 
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 260.1888.  The enantioselectivity was measured by chiral HPLC using a Chiracel OD column 
(5% i-PrOH in hexanes, 1.0 mL/min, RT = 13.4 and 15.0 min): 6% ee. 
N
Ph
OMe
O
C4H9
N
Ph
OMe
O
207 208
+
 
 (E)-N-(4-Methoxyphenyl)-N-(1-phenylhept-2-enyl)acetamide (207) and N-(4-meth-
oxyphenyl)-N-(1-phenylethyl)acetamide (208).  A solution of 100 mg (0.473 mmol) of imine 
178 in 2 mL of toluene was cooled to 0 °C, treated with 35.0 µL (0.492 mmol) of AcCl, warmed 
to room temperature and stirred for 1 h.  Separately, a suspension of 183 mg (0.710 mmol) of 
Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 90.0 µL (0.783 mmol) of 1-hexyne, stirred at 
room temperature for 15 min, concentrated in vacuo, and dissolved in 2 mL of toluene.  The two 
solutions were combined at room temperature, cooled to 0 °C, and treated with 240 µL (0.480 
mmol) of Me2Zn (2.0 M solution in toluene).  The mixture was warmed to room temperature, 
stirred for 12 h, quenched with saturated NH4Cl, diluted with EtOAc, washed with 1 N HCl and 
brine, dried (MgSO4), and concentrated in vacuo.  The residue was chromatographed on SiO2 
(2:1, hexanes/EtOAc) to yield 82 mg (51%) of 207 and 41 mg (32%) of 208 as brown oils.  207: 
IR (thin film) 2957, 2927, 2858, 1658, 1511, 1383, 1295, 1250, 1033, 975, 837, 733, 701 cm-1; 
1H NMR δ 7.31-7.13 (m, 5 H), 6.76 (bs, 4 H), 6.50 (d, 1 H, J = 8.7 Hz), 5.83 (dt, 1 H, J = 15.2, 
6.6 Hz), 5.56 (dd, 1 H, J = 15.3, 8.7 Hz), 3.77 (s, 3 H), 2.06 (q, 2 H, J = 6.6 Hz), 1.79 (s, 3 H), 
1.44-1.24 (m, 4 H), 0.88 (t, 3 H, J = 7.1 Hz); 13C NMR δ 170.25, 158.96, 140.62, 135.50, 132.71, 
131.12 (2 C), 128.15 (2 C), 127.96 (2 C), 127.03, 126.57, 113.88 (2 C), 59.96, 55.21, 31.98, 
31.05, 23.02, 22.06, 13.73; ESIMS m/z 360 ([M+Na]+, 100), 338 ([M+H]+, 13); HRMS (ESI) m/z 
calcd for C22H27NO2Na [M+Na] 360.1939, found 360.1931.  208: IR (thin film) 2974, 2937, 
1653, 1510, 1454, 1387, 1315, 1292, 1248, 1032, 835, 700 cm-1; 1H NMR δ 7.29-7.17 (m, 5 H), 
6.76 (bs, 4 H), 6.29 (q, 1 H, J = 7.2 Hz), 3.78 (s, 3 H), 1.77 (s, 3 H), 1.40 (d, 3 H, J = 7.2 Hz); 
13C NMR δ 170.53, 159.08, 141.25, 131.65, 131.26 (2 C), 128.10 (2 C), 128.01 (2 C), 127.31, 
113.93 (2 C), 55.29, 51.73, 23.25, 17.07; ESIMS m/z 292 ([M+Na]+, 100), 270 ([M+H]+, 18); 
HRMS (ESI) m/z calcd for C17H19NO2Na [M+Na] 292.1313, found 292.1313. 
 Preparation of 207 using catalytic ZnCl2.  A solution of 100 mg (0.473 mmol) of imine 
178 in 2 mL of toluene was cooled to 0 °C, treated with 35.0 µL (0.492 mmol) of AcCl, warmed 
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 to room temperature and stirred for 15 min.   Separately, a suspension of 185 mg (0.717 mmol) 
of Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 90.0 µL (0.783 mmol) of 1-hexyne and stirred 
at room temperature for 10 min.  The two solutions were combined at room temperature, cooled 
to 0 °C, and treated with 10.0 µL (0.0100 mmol) of ZnCl2 (1.0 M solution in Et2O).  The mixture 
was stirred at 0 °C for 10 min, quenched with saturated NH4Cl, diluted with EtOAc, washed with 
1 N HCl and brine, dried (MgSO4), and concentrated in vacuo.  The residue was chromato-
graphed on SiO2 (2:1, hexanes/EtOAc) to yield 131 mg (82%) of 207 as a brown oil. 
 Preparation of 207 using catalytic CuBr.  A solution of 100 mg (0.473 mmol) of imine 
178 in 2 mL of toluene was cooled to 0 °C, treated with 35.0 µL (0.492 mmol) of AcCl, warmed 
to room temperature and stirred for 15 min.   Separately, a suspension of 185 mg (0.717 mmol) 
of Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 90.0 µL (0.783 mmol) of 1-hexyne and stirred 
at room temperature for 10 min.  The two solutions were combined at room temperature, cooled 
to 0 °C, and treated with 5.0 mg (0.035 mmol) of CuBr.  The mixture was stirred at 0 °C for 30 
min, quenched with saturated NH4Cl, diluted with EtOAc, washed with 1 N HCl and brine, dried 
(MgSO4), and concentrated in vacuo.  The residue was chromatographed on SiO2 (2:1, hexanes/ 
EtOAc) to yield 137 mg (86%) of 207 as a brown oil. 
 Representative attempted asymmetric preparation of 207 using Cu catalysis. 
A suspension of 50.0 mg (0.237 mmol) of imine 178, 1.9 mg (0.019 mmol) of CuCl, and 12.0 
mg (0.0241 mmol) of (R,R)-DIOP (215) in 1 mL of toluene was cooled to 0 °C, treated with 17.0 
µL (0.239 mmol) of AcCl, warmed to room temperature and stirred for 15 min.   Separately, a 
suspension of 90.0 mg (0.349 mmol) of Cp2ZrHCl in 1 mL of CH2Cl2 was treated with 45.0 µL 
(0.392 mmol) of 1-hexyne and stirred at room temperature for 10 min.  The two solutions were 
combined at room temperature, stirred for 12 h, quenched with with 1 N HCl, extracted with 
EtOAc, washed with brine, dried (MgSO4), and concentrated in vacuo.  The residue was 
chromatographed on SiO2 (2:1, hexanes/EtOAc) to yield 57 mg (71%) of 207 as a brown oil.  
The enantioselectivity was measured by chiral HPLC using a Chiracel AD column (5% i-PrOH 
in hexanes, 1.0 mL/min, RT = 13.6 and 15.3 min): 3% ee. 
87 
 P
NH2
O
Ph
218  
 P-2-(1,1’-Binaphthyl)-P-phenylphosphinamide (218).  A mixture of 1.34 g (3.56 
mmol) of phosphole oxide 240  and 500 mg (12.5 mmol) of crushed NaOH was slowly heated at 
280 °C over 3 h.   The mixture was stirred at 280 °C for 2 h, cooled to room temperature, and 
partitioned between CH2Cl2 and 2 N NaOH.  The aqueous layer was separated, cooled to 0 °C, 
acidified to pH 4 with conc. HCl, and filtered.  The filter cake was dissolved in CH2Cl2, dried 
(MgSO4), and concentrated in vacuo.  A solution of the residue in 20 mL of CH2Cl2 was cooled 
to 0 °C, treated with 600 µL (6.88 mmol) of (COCl)2 and 2 drops of DMF, stirred at 0 °C for 2 h, 
at room temperature for 1 h, and concentrated in vacuo.  A solution of the residue in 40 mL of 
CH2Cl2 was cooled to -78 °C, treated with 10 mL of NH3, slowly warmed to room temperature 
over 12 h, filtered and concentrated in vacuo.  The residue was chromatographed on SiO2 (95:5, 
CH2Cl2/MeOH) to yield 261 mg (19%) of 218 as a colorless foam: mp 105-107 °C 
(MeOH/CH2Cl2); IR (thin film) 3407, 3217, 3053, 1591, 1436, 1184, 1120, 902, 824, 802, 783, 
744, 692 cm-1; 1H NMR δ 7.69-7.61 (m, 8 H), 7.56-7.40 (m, 12 H); EIMS m/z 393 (M+, 64), 375 
(33), 277 (51), 252 (100), 77 (15); HRMS (EI) m/z calcd for C26H20NOP 393.1283, found 
393.1275. 
P
N
O
Ph
219
Ph
H
 
 N-Benzylidene-P-2-(1,1’-binaphthyl)-P-phenylphosphinamide (219).  According to 
the General Protocol B, 220 mg (0.559 mmol) of phosphinamide 218, 230 µL (1.65 mmol) of 
Et3N, 90.0 µL (0.885 mmol) of PhCHO, and 35.0 µL (0.319 mmol) of TiCl4 afforded a 1.8:1 
mixture of diastereomers.  The mixture was recrystallized from CH2Cl2/hexanes to yield 42 mg 
(16%) of 219 as a colorless solid: mp 204-205 °C (CH2Cl2/hexanes); IR (thin film) 3055, 1618, 
1577, 1196, 1113, 852, 831, 752, 690 cm-1; 1H NMR δ 8.47 (d, 1 H, J = 33.2 Hz), 7.94-7.00 (m, 
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 23 H); ESIMS m/z 504 ([M+Na]+, 62), 482 ([M+H]+, 100); HRMS (ESI) m/z calcd for 
C33H25NOP [M+H] 482.1674, found 482.1652. 
P
N
H
O
Ph
220
Ph
C4H9
 
 (E)-P-2-(1,1’-Binaphthyl)-P-phenyl-N-(1-phenylhept-2-enyl)phosphinamide (220). 
According to the General Protocol A, 28.0 mg (0.109 mmol) of Cp2ZrHCl, 15.0 µL (0.131 
mmol) of 1-hexyne, 27.0 mg (0.0561 mol) of imine 219, and 50.0 µL (0.100 mmol) of Me2Zn 
(2.0 M solution in toluene) afforded 24 mg (76%) of 220 as an (inseparable) 72:28 mixture of  
diastereomers: IR (thin film) 3381, 3207, 3055, 2954, 2924, 2858, 1452, 1439, 1184, 1113, 1026, 
972, 783, 746, 696 cm-1; 1H NMR δ 8.01-6.83 (m, 23 H), 5.17-5.04 (m, 1.7 H), 4.91 (dtd, 0.3 H, 
J = 15.3, 6.6, 1.4 Hz), 4.50 (td, 0.7 H, J = 9.4, 4.2 Hz), 4.39 (td, 0.3 H, J = 9.9, 5.7 Hz), 2.88-
2.79 (m, 1 H), 1.93-1.75 (m, 2 H), 1.24-1.08 (m, 4 H), 0.83 (t, 3 H, J = 6.8 Hz); ESIMS m/z 588 
([M+Na]+, 70), 566 ([M+H]+, 100); HRMS (ESI) m/z calcd for C39H37NOP [M+H] 566.2613, 
found 566.2621. 
P
N
O
Ph
Ph
H
222  
 N-Benzylidene-P-mesityl-P-phenylphosphinamide (222).  According to the General 
Protocol B, 500 mg (1.93 mmol) of P-mesityl-P-phenylphosphinamide (221),  290 µL (2.85 
mmol) of PhCHO, 810 µL (5.81 mmol) of Et3N, and 120 µL (1.09 mmol) of TiCl4 afforded 235 
mg (35%) of 222 as a colorless solid: mp 166-167 °C (CH2Cl2/hexanes); IR (thin film) 3441, 
3058, 2969, 2931, 1610, 1575, 1449, 1435, 1197, 1116, 850, 821, 753, 691, 645 cm-1; 1H NMR δ 
9.32 (d, 1 H, J = 32.8 Hz), 7.97-7.93 (m, 2 H), 7.73-7.66 (m, 2 H), 7.55-7.37 (m, 6 H), 6.88-6.87 
(m, 2 H), 2.53 (s, 6 H), 2.26 (s, 3 H); EIMS m/z 347 (M+, 100), 270 (26), 256 (20), 243 (68), 106 
(85), 91 (32), 77 (22); HRMS (EI) m/z calcd for C22H22NOP 347.1439, found 347.1443. 
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223  
 (E)-P-Mesityl-P-phenyl-N-(1-phenylhept-2-enyl)phosphinamide (223).  According to 
the General Protocol A, 95.0 mg (0.368 mmol) of Cp2ZrHCl, 50.0 µL (0.435 mmol) of 1-hexyne, 
190 µL (0.380 mmol) of Me2Zn, and 87.0 mg (0.250 mmol) of imine 222 afforded 57 mg (53%) 
of 223 as an (inseparable) 69:31 mixture of diastereomers: mp 122-125 °C (EtOAc/hexanes); IR 
(thin film) 3204, 2957, 2927, 2854, 1607, 1453, 1435, 1176, 1116, 748, 696 cm-1; 1H NMR δ 
7.75-7.67 (m, 1.4 H), 7.60-7.53 (m, 0.6 H), 7.46-7.15 (m, 8 H), 6.87 (d, 0.6 H, J = 3.7 Hz), 6.80 
(d, 1.4 H, J = 3.7 Hz), 5.77 (dd, 0.7 H, J = 15.3, 6.2 Hz), 5.66-5.54 (m, 1 H), 5.42 (dt, 0.3 H, J = 
15.3, 6.6 Hz), 5.08 (td, 0.3 H, J = 8.9, 7.1 Hz), 4.97 (td, 0.7 H, J = 9.2, 6.4 Hz), 3.19 (t, 0.3 H, J 
= 9.1 Hz), 3.13 (t, 0.7 H, J = 8.9 Hz), 2.45 (s, 1.8 H), 2.35 (s, 4.2 H), 2.28 (s. 0.9 H), 2.26 (s, 2.1 
H), 2.05 (q, 1.4 H, J = 6.7 Hz), 1.86 (q, 0.6 H, J = 6.7 Hz), 1.40-1.26 (m, 2.8 H), 1.23-1.14 (m, 
1.2 H), 0.89 (t, 2.1 H, J = 7.1 Hz), 0.83 (t, 0.9 H, J = 6.8 Hz); ESIMS m/z 454 ([M+Na]+, 100), 
432 ([M+H]+, 75); HRMS (ESI) m/z calcd for C28H34NOPNa [M+Na] 454.2276, found 
454.2280. 
P
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225  
 (E)-P-(tert-Butyl)-P-phenyl-N-(1-phenylhept-2-enyl)phosphinamide (225). According 
to the General Protocol B, 500 mg (2.54 mmol) of P-(tert-butyl)-P-phenylphosphinamide (224),  
1.17 mL (8.39 mmol) of Et3N, 390 µL (3.84 mmol) of PhCHO, and 150 µL (1.34 mmol) of TiCl4 
afforded a 1.6:1 mixture of imine and PhCHO, which was used without further purification in the 
subsequent reaction.  According to the General Protocol A, 390 mg (1.51 mmol) of Cp2ZrHCl, 
200 µL (1.74 mmol) of 1-hexyne, 500 µL (1.00 mmol) of Me2Zn, and 200 mg (0.571 mmol) of 
crude imine (81% purity) afforded 67 mg (32%) of 225 as an (inseparable)  69:31 mixture of 
diastereomers: IR (thin film) 3228, 2060, 2954, 2929, 2862, 1687, 1475, 1437, 1165, 1113, 1057, 
748, 700 cm-1; 1H NMR δ 7.88-7.81 (m, 0.6 H), 7.64-7.58 (m, 1.4 H), 7.51-7.35 (m, 2 H), 7.33-
7.13 (m, 6 H), 5.71 (ddt, 0.7 H, J = 15.4, 5.4, 1.3 Hz), 5.52-5.37 (m, 1.3 H), 4.79 (td, 0.3 H, J = 
8.8, 5.7 Hz), 4.70 (td, 0.7 H, J = 9.5, 5.3 Hz), 2.98-2.89 (m, 1 H), 1.98 (q, 1.4 H, J = 7.0 Hz), 
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 1.89 (q, 0.6 H, J = 6.2 Hz), 1.36-1.18 (m, 4 H), 1.12 (d, 6.3 H, J = 14.8 Hz), 1.09 (d, 2.7 H, J = 
14.8 Hz), 0.85-0.80 (m, 3 H); ESIMS m/z 392 ([M+Na]+, 68), 370 ([M+H]+, 100); HRMS (ESI) 
m/z calcd for C23H33NOP [M+H] 370.2300, found 370.2290. 
O
P
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244  
 Ethyl (2-tert-butylphenyl)phosphinate (244).  According to a literature procedure,243 a 
suspension of 220 mg (9.05 mmol) of Mg in 10 mL of THF was treated with a solution of 2.00 g 
(9.38 mmol) of ortho-bromo-tert-butybenzene (243)  in 10 mL of THF.  The reaction was 
initiated with 2 drops of (CH2Br)2, and the mixture was heated at reflux for 2 h, cooled to room 
temperature, treated with a solution of 910 µL (5.66 mmol) of ClP(OEt)2 (90% purity) in 10 mL 
of THF, heated at reflux for 2 h, cooled to room temperature, diluted with 30 mL of dioxane, 
filtered through Celite, and concentrated in vacuo.  Kugelrohr distillation (120 °C, ~1 atm) of the 
residue afforded a colorless oil that was dissolved in 10 mL of THF, treated with 20 mL of 0.1 M 
HCl, stirred at 50 °C for 4 h, cooled to room temperature and extracted with CH2Cl2 (4x).  The 
combined organic extracts were dried (MgSO4) and concentrated in vacuo to yield 1.21 g (95%) 
of 244 as a colorless oil: IR (thin film) 2966, 2906, 2870, 1475, 1433, 1365, 1192, 1122, 1024, 
960, 762 cm-1; 1H NMR δ 7.90 (d, 1 H, J = 566 Hz), 7.95-7.86 (m, 1 H), 7.55-7.43 (m, 2 H), 
7.33-7.27 (m, 1 H), 4.24-4.04 (m, 2 H), 1.49 (s, 9 H), 1.33 (t, 3 H, J = 7.1 Hz); 13C NMR δ 
153.88 (d, 1 C, J = 10.2 Hz), 133.00 (d, 1 C, J = 13.9 Hz), 132.55 (s, 1 C), 128.70 (d, 1 C, J = 
126 Hz), 127.09 (d, 1 C, J = 12.8 Hz), 125.67 (d, 1 C, J = 14.7 Hz), 62.36 (d, 1 C, J = 6.1 Hz), 
37.04 (s, 1 C), 32.32 (s, 3 C), 16.10 (d, 1 C, J = 6.4 Hz); EIMS m/z 226 (M+, 52), 211 (43), 183 
(80), 156 (58), 147 (100), 115 (49), 91 (77), 84 (42), 77 (54); HRMS (EI) m/z calcd for 
C12H19O2P 226.1123, found 226.1124. 
O
P
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245  
 Ethyl (2-tert-butylphenyl)phenylphosphinate (245).  According to a literature 
procedure,  a suspension of 1.00 g (4.42 mmol) of ethyl phosphinate 244, 30.0 mg (0.134 mmol) 
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 of Pd(OAc)2, 320 mg (0.577 mmol) of dppf, 1.23 mL (8.82 mmol) of Et3N, and 490 µL (4.38 
mmol) of iodobenzene in 25 mL of MeCN was stirred at 70 °C for 24 h.  The mixture was cooled 
to room temperature, diluted with EtOAc, filtered through Celite, and concentrated in vacuo.  
The residue was chromatographed on SiO2 (50:50, hexanes/EtOAc) to yield 800 mg (60%) of 
245 as an orange oil: IR (thin film) 2960, 2902, 2870, 1473, 1439, 1228, 1122, 1030, 947, 746, 
696 cm-1; 1H NMR δ 7.95-7.87 (m, 1 H), 7.70-7.57 (m, 3 H), 7.47-7.34 (m, 4 H), 7.26-7.20 (m, 1 
H), 4.12-4.02 (m, 2 H), 1.53 (s, 9 H), 1.32 (t, 3 H, J = 7.1 Hz); 13C NMR δ 156.53 (d, 1 C, J = 
10.1 Hz), 136.11 (d, 1 C, J = 9.8 Hz), 134.37 (d, 1 C, J = 136 Hz), 131.93 (s, 1 C), 131.39 (s, 1 
C), 131.33 (d, 2 C, J = 9.9 Hz), 128.70 (d, 1 C, J = 128. Hz), 128.21 (d, 2 C, J = 13.1 Hz), 
127.65 (d, 1 C, J = 13.0 Hz), 125.08 (d, 1 C, J = 12.6 Hz), 60.73 (d, 1 C, J = 5.5 Hz), 37.22 (s, 1 
C), 32.20 (s, 3 C), 16.33 (d, 1 C, J = 3.4 Hz); EIMS m/z 302 (M+, 71), 287 (61), 259 (39), 217 
(27), 202 (34), 163 (28), 141 (31), 115 (44), 91 (55), 77 (100); HRMS (EI) m/z calcd for 
C18H23O2P 302.1436, found 302.1444. 
P
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226  
 P-(2-tert-Butylphenyl)-P-phenylphosphinamide (226).  According to a literature 
procedure,204 a solution of 200 mg (8.70 mmol) of Na in 30 mL of NH3 was stirred at -35 °C for 
1 h, treated with a solution of 760 mg (2.51 mmol) of ethyl phosphinate 245 in 10 mL of THF, 
stirred at -35 °C for 5 h and slowly warmed to room temperature over 12 h.  The mixture was 
quenched with solid NH4Cl then wet THF, poured into 1 N HCl, and extracted with CH2Cl2 (3x).  
The combined extracts were dried (MgSO4) and concentrated in vacuo.  The residue was 
chromatographed on SiO2 (50:50, hexanes/Et2O) to yield 187 mg (27%) of 226 as a colorless 
solid: mp 139-140 °C (Et2O, hexanes); IR (thin film) 3225, 3078, 2954, 1567, 1475, 1436, 1194, 
1118, 893, 762, 750, 735, 695 cm-1; 1H NMR δ 7.91 (ddd, 1 H, J = 16.1, 7.8, 1.5 Hz), 7.79-7.72 
(m, 2 H), 7.61-7.56 (m, 1 H), 7.48-7.35 (m, 4 H), 7.21-7.15 (m, 1 H), 3.05 (bs, 2 H), 1.57 (s, 9 
H); 13C NMR δ 156.63 (d, 1 C, J = 9.3 Hz), 136.70 (d, 1 C, J = 128.4 Hz), 136.63 (d, 1 C, J = 
11.9 Hz), 131.78 (s, 1 C), 131.40 (d, 2 C, J = 9.2 Hz), 131.34 (s, 1 C), 131.01 (d, 1 C, J = 116.8 
Hz), 128.43 (d, 2 C, J = 12.8 Hz), 127.79 (d, 1 C, J = 12.1 Hz), 125.20 (d, 1 C, J = 13.1 Hz), 
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 37.51 (s, 1 C), 32.46 (s, 3 C); EIMS m/z 273 (M+, 90), 258 (100), 241 (45), 199 (50), 163 (28), 
91 (20), 77 (32); HRMS (EI) m/z calcd for C16H20NOP 273.1283, found 273.1283. 
P
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Ph
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227  
 (E)-P-(2-tert-Butylphenyl)-P-phenyl-N-(1-phenylhept-2-enyl)phosphinamide (227). 
According to the General Protocol B, 166 mg (0.607 mmol) of phosphinamide 226, 320 µL (1.84 
mmol) of (i-Pr)2NEt, 100 µL (0.984 mmol) of PhCHO, and 40.0 µL (0.365 mmol) of TiCl4 
afforded the crude imine, which was used without further purification in the subsequent reaction.  
According to the General Protocol A, 46.0 mg (0.178 mmol) of Cp2ZrHCl, 23.0 µL (0.200 
mmol) of 1-hexyne, 90.0 µL (0.180 mmol) of Me2Zn (2.0 M solution in toluene), and 32.4 mg 
(0.0896 mmol) of crude imine at a reaction temperature of 40 °C afforded 27 mg (68%) of 227 as 
an (inseparable) 54:46 mixture of diastereomers: IR (thin film) 3213, 2922, 2870, 1589, 1435, 
1197, 1113, 1051, 1028, 970, 924, 739, 702 cm-1; 1H NMR δ 7.94-7.55 (m, 4 H), 7.49-7.04 (m, 
10 H), 5.75-5.44 (m, 2 H), 4.94-4.82 (m, 1 H), 2.99-2.89 (m, 1 H), 2.04-1.96 (m, 2 H), 1.61 (s, 
4.9 H), 1.55 (s, 4.1 H), 1.30-1.15 (m, 4 H), 0.89-0.82 (m, 3 H); ESIMS m/z 468 ([M+Na]+, 84), 
446 ([M+H]+, 100); HRMS (ESI) m/z calcd for C29H37NOP [M+H] 446.2613, found 446.2603. 
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247  
 Ethyl [2-(trimethylsilyl)phenyl]phenylphosphinate (247).  According to a literature 
procedure,  a suspension of 190 mg (7.82 mmol) of Mg in 10 mL of THF was treated with a 
solution of 1.75 g (7.64 mmol) of (2-bromophenyl)trimethylsilane (246)  in 10 mL of THF.  The 
reaction was initiated with 2 drops of 1,2-dibromoethane, and the mixture was heated at reflux 
for 4 h, cooled to room temperature, treated with a solution of 1.23 mL (7.65 mmol) of 
ClP(OEt)2 (90% purity) in 10 mL of THF, heated at reflux for 12 h, cooled to room temperature, 
diluted with 30 mL of dioxane, filtered through Celite, and concentrated in vacuo.  Kugelrohr 
distillation (110 °C, ~1 atm) of the residue afforded a colorless oil that was dissolved in 10 mL 
of THF, treated with 20 mL of 0.1 M HCl, stirred at 60 °C for 6 h, cooled to room temperature 
and extracted with CH2Cl2 (4x).  The combined organic extracts were dried (MgSO4) and 
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 concentrated in vacuo.  A suspension of the residue, 33.0 mg (0.147 mmol) of Pd(OAc)2, 164 mg 
(0.296 mmol) of dppf, 770 µL (4.42 mmol) of (i-Pr)2NEt, and 400 µL (3.57 mmol) of iodo-
benzene in 25 mL of MeCN was stirred at 70 °C for 18 h.  The mixture was cooled to room 
temperature, diluted with EtOAc, filtered through Florisil, and concentrated in vacuo.  The 
residue was chromatographed on SiO2 (30:70, hexanes/EtOAc) to yield 646 mg (28%) of 247 as 
a yellow oil: IR (thin film) 3055, 2980, 2947, 2899, 1439, 1230, 1134, 1119, 1032, 949, 845, 
742, 696 cm-1; 1H NMR δ 7.78-7.66 (m, 4 H), 7.49-7.37 (m, 5 H), 4.09-3.99 (m, 2 H), 1.31 (t, 3 
H, J = 7.1 Hz), 0.38 (s, 9 H); 13C NMR δ 145.84 (d, 1 C, J = 18.6 Hz), 136.18 (d, 1 C, J = 138.1 
Hz), 136.04 (d, 1 C, J = 16.8 Hz), 133.33 (d, 1 C, J = 13.4 Hz), 132.77 (d, 1 C, J = 133.0 Hz), 
131.74 (s, 1 C), 131.67 (d, 2 C, J = 10.1 Hz), 130.83 (d, 1 C, J = 3.1 Hz), 128.30 (d, 2 C, J = 12.9 
Hz), 128.18 (d, 1 C, J = 13.4 Hz), 60.79 (d, 1 C, J = 5.8 Hz), 16.39 (d, 1 C, J = 6.7 Hz), 1.35 (s, 3 
C); EIMS m/z 303 ([M-CH3]+, 100), 275 (86), 197 (29), 183 (24), 135 (22), 107 (18), 77 (21); 
HRMS (EI) m/z calcd for C16H20O2PSi [M-CH3] 303.0970, found 303.0976. 
TMS
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228  
 P-[2-(Trimethylsilyl)phenyl]-P-phenylphosphinamide (228).  A solution of 2.07 g 
(6.50 mmol) of ethyl phosphinate 247 in 50 mL of CH2Cl2 was treated with 1.72 mL (13.0 
mmol) of TMS-Br.244  The mixture was stirred at room temperature for 4 h, treated with 25 mL 
of MeOH, stirred at room temperature for 1 h, and concentrated in vacuo.  A solution of the 
residue in 15 mL of CH2Cl2 was cooled to 0 °C, and treated with 1.13 mL (13.0 mmol) of 
(COCl)2 and 3 drops of DMF.  The mixture was stirred at 0 °C for 10 min, at room temperature 
for 5 h, and concentrated in vacuo.  A solution of the residue in 50 mL of CH2Cl2 was cooled to  
-78 °C, treated with 10 mL of NH3, slowly warmed to room temperature over 5 h, filtered, and 
concentrated in vacuo.  The residue was chromatographed on SiO2 (99:1, Et2O/MeOH) to yield 
1.65 g (88%) of 228 as a yellow solid: mp 141-142 °C (MeOH/Et2O); IR (thin film) 3413, 3213, 
3065, 1571, 1436, 1243, 1197, 1117, 896, 848, 758 cm-1; 1H NMR δ 7.88 (ddd, 1 H, J = 13.1, 
7.5, 1.1 Hz), 7.82-7.74 (m, 3 H), 7.47-7.34 (m, 5 H), 3.12 (bs, 2 H), 0.36 (s, 9 H); 13C NMR δ 
146.14 (d, 1 C, J = 18.3 Hz), 138.26 (d, 1 C, J = 131.8 Hz), 136.14 (d, 1 C, J = 16.2 Hz), 134.74 
(d, 1 C, J = 125.1 Hz), 133.71 (d, 1 C, J = 13.2 Hz), 131.70 (d, 2 C, J = 9.9 Hz), 131.47 (d, 1 C, J 
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 = 2.2 Hz), 130.57 (d, 1 C, J = 2.7 Hz), 128.25 (d, 2 C, J = 12.5 Hz), 128.17 (d, 1 C, J = 12.8 Hz), 
1.72 (s, 3 C); EIMS m/z 289 (M+, 1), 288 (3), 274 (100); HRMS (EI) m/z calcd for C14H17NOPSi 
[M-CH3] 274.0817, found 274.0944. 
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229  
 N-Benzylidene-P-[2-(trimethylsilyl)phenyl]-P-phenylphosphinamide (229). 
According to the General Protocol B, 1.09 g (3.77 mmol) of phosphinamide 228, 1.97 mL (11.3 
mmol) of (i-Pr)2NEt, 570 µL (5.61 mmol) of PhCHO, and 250 µL (2.28 mmol) of TiCl4 afforded 
the crude imine, which was chromatographed on SiO2 (80:20, hexanes/EtOAc, containing 2% 
Et3N) to yield 1.23 g (87%) of 229 as a yellow glass: IR (thin film) 3057, 2945, 2895, 1703, 
1618, 1577, 1452, 1437, 1242, 1205, 1113, 1057, 852, 822, 739, 688, 663 cm-1; 1H NMR δ 9.28 
(d, 1 H, J = 31.4 Hz), 8.21 (ddd, 1 H, J = 12.0, 6.8, 2.0 Hz), 7.99 (d, 2 H, J = 6.8 Hz), 7.83-7.75 
(m, 3 H), 7.59-7.38 (m, 8 H), 0.41 (s, 9 H); ESIMS m/z 400 ([M+Na]+, 72), 378 ([M+H]+, 58), 
362 ([M-CH3]+, 100); HRMS (ESI) m/z calcd for C22H25NOPSi [M+H] 378.1443, found 
378.1452. 
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230  
 (E)-P-[2-(Trimethylsilyl)phenyl]-P-phenyl-N-(1-phenylhept-2-enyl)phosphinamide 
(230).  According to the General Protocol A, 115 mg (0.446 mmol) of Cp2ZrHCl, 56.0 µL (0.487 
mmol) of 1-hexyne, 220 µL (0.440 mmol) of Me2Zn (2.0 M solution in toluene), and 85.0 mg 
(0.225 mmol) of imine 229 afforded 73 mg (70%) of 230 as an (inseparable) 51:49 mixture of 
diastereomers: IR (thin film) 3333, 3059, 2957, 2929, 1691, 1452, 1437, 1243, 1191, 1116, 843, 
754, 695 cm-1; 1H NMR δ 7.96-7.70 (m, 4 H), 7.51-7.22 (m, 10 H), 5.75-5.46 (m, 2 H), 4.88-4.76 
(m, 1 H), 3.18-3.11 (m, 1 H), 1.99-1.95 (m, 2 H), 1.30-1.20 (m, 4 H), 0.90-0.85 (m, 3 H), 0.44 (s, 
4.5 H), 0.42 (s, 4.5 H); EIMS m/z 461 (M+, 13), 446 (56), 388 (14), 362 (18), 274 (100), 258 
(54), 188 (85), 117 (52), 91 (41); HRMS (EI) m/z calcd for C28H36NOPSi 461.2304, found 
461.2312. 
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249  
 Ethyl (2-biphenyl)phenylphosphinate (249).  According to a literature procedure,  a 
suspension of 420 mg (17.3 mmol) of Mg in 40 mL of THF was treated with 4.00 g (17.2 mmol) 
of 2-bromobiphenyl (248).  The reaction was initiated with 1 drop of (CH2Br)2, and the mixture 
was heated at reflux for 2 h, cooled to room temperature, treated with 1.80 mL (11.2 mmol) of 
ClP(OEt)2 (90% purity), heated at reflux for 2 h, cooled to room temperature, diluted with 30 mL 
of dioxane, filtered through Celite, and concentrated in vacuo.  Kugelrohr distillation (120 °C, ~1 
atm) of the residue afforded a colorless oil that was dissolved in 20 mL of THF, treated with 40 
mL of 0.1 M HCl, stirred at 50 °C for 3 h, cooled to room temperature and extracted with 
CH2Cl2 (4x).  The combined organic extracts were dried (MgSO4) and concentrated in vacuo.  A 
suspension of the residue, 75.0 mg (0.334 mmol) of Pd(OAc)2, 372 mg (0.671 mmol) of dppf, 
2.90 mL (16.6 mmol) of (i-Pr)2NEt, and 1.50 mL (13.4 mmol) of iodobenzene in 100 mL of 
MeCN was stirred at 70 °C for 16 h.  The mixture was cooled to room temperature, diluted with 
EtOAc, filtered through Celite, and concentrated in vacuo.  The residue was chromatographed on 
SiO2 (1:2, hexanes/EtOAc) to yield 2.95 g (82%) of 249 as a pink solid: mp 115-116 °C 
(EtOAc/hexanes); IR (thin film) 3461, 3055, 2977, 1437, 1221, 1033, 951, 753, 696 cm-1; 1H 
NMR δ 8.04 (dd, 1 H, J = 12.2, 7.7 Hz), 7.50 (t, 1 H, J = 7.4 Hz), 7.41 (t, 1 H, J = 7.5 Hz), 7.36-
7.28 (m, 3 H), 7.22-7.07 (m, 8 H), 3.99-3.78 (m, 2 H), 1.16 (t, 3 H, J = 7.0 Hz); 13C NMR δ 
146.46, 146.31, 140.71, 140.66, 132.95, 132.84, 131.69, 131.56, 131.37, 131.32, 131.22, 129.73, 
127.91, 127.74, 127.22, 127.11, 126.72, 126.56, 60.49, 60.42, 16.21, 16.13; EIMS m/z 322 (M+, 
64), 321 (43), 293 (41), 277 (39), 245 (100), 217 (65), 199 (60), 152 (56); HRMS (EI) m/z calcd 
for C20H19O2P 322.1123, found 322.1113. 
Ph
P
NH2
O
Ph
231  
 P-2-Biphenyl-P-phenylphosphinamide (231).  A solution of 2.50 g (7.76 mmol) of 
ethyl phosphinate 249 in 50 mL of CH2Cl2 was treated with 2.05 mL (15.5 mmol) of TMS-Br.   
The mixture was stirred at room temperature for 2 h, treated with 25 mL of MeOH, stirred at 
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 room temperature for 1 h, and concentrated in vacuo.  A solution of the residue in 15 mL of 
CH2Cl2 was cooled to 0 °C, and treated with 1.35 mL (15.5 mmol) of (COCl)2 and 3 drops of 
DMF.  The mixture was stirred at 0 °C for 1 h, at room temperature for 4 h, and concentrated in 
vacuo.  A solution of the residue in 50 mL of CH2Cl2 was cooled to -78 °C, treated with 10 mL 
of NH3, slowly warmed to room temperature over 5 h, filtered, and concentrated in vacuo.  The 
residue was chromatographed on SiO2 (95:5, Et2O/ MeOH) to yield 2.15 g (95%) of 231 as a 
colorless solid: mp 149-150 °C (MeOH/Et2O); IR (thin film) 3411, 3219, 3055, 1567, 1465, 
1437, 1188, 1134, 1117, 898, 749, 697 cm-1; 1H NMR δ 7.85 (ddd, 1 H, J = 14.0, 7.7, 1.3 Hz), 
7.59-7.19 (m, 13 H), 2.89 (bs, 2 H); 13C NMR δ 144.94 (d, 1 C, J = 9.5 Hz), 140.99 (d, 1 C, J = 
3.8 Hz), 134.05 (d, 1 C, J = 129.2 Hz), 132.61 (d, 1 C, J = 10.7 Hz), 132.58 (d, 1 C, J = 125.8 
Hz), 131.63 (d, 2 C, J = 10.1 Hz), 131.44 (d, 1 C, J = 2.4 Hz), 131.11 (d, 1 C, J = 6.0 Hz), 
131.02 (d, 1 C, J = 2.0 Hz), 129.57 (s, 2 C), 128.05 (d, 2 C, J = 12.8 Hz), 127.89 (s, 2 C), 127.67 
(s, 1 C), 126.86 (d, 1 C, J = 12.7 Hz); EIMS m/z 293 (M+, 37), 292 (43), 275 (36), 216 (100), 199 
(63), 152 (26); HRMS (EI) m/z calcd for C18H16NOP 293.0970, found 293.0983. 
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 N-Benzylidene-P-2-biphenyl-P-phenylphosphinamide (232).  According to the 
General Protocol B, 1.15 g (3.92 mmol) of phosphinamide 231, 2.05 mL (11.8 mmol) of (i-
Pr)2NEt, 600 µL (5.90 mmol) of PhCHO, and 260 µL (2.37 mmol) of TiCl4 afforded the crude 
imine, which was chromatographed on SiO2 (20:80, hexanes/EtOAc, containing 2% Et3N) to 
yield 1.23 g (82%) of 232 as a colorless solid: mp 54-57 °C (solvent); IR (thin film) 3445, 3055, 
1615, 1450, 1438, 1201, 1115, 852, 829, 752, 693 cm-1; 1H NMR δ 8.79 (d, 1 H, J = 32.6 Hz), 
7.74-7.64 (m, 5 H), 7.51-7.22 (m, 11 H), 7.12-7.09 (m, 3 H); ESIMS m/z 404 ([M+Na]+, 100), 
382 ([M+H]+, 26); HRMS (ESI) m/z calcd for C25H20NOPNa [M+Na] 404.1180, found 
404.1187. 
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233  
 (E)-P-2-Biphenyl-P-phenyl-N-(1-phenylhept-2-enyl)phosphinamide (233). According 
to the General Protocol A, 135 mg (0.523 mmol) of Cp2ZrHCl, 66.0 µL (0.574 mmol) of 1-
hexyne, 260 µL (0.520 mmol) of Me2Zn (2.0 M solution in toluene), and 100 mg (0.262 mmol) 
of imine 232 at a reaction temperature of 40 °C afforded 109 mg (89%) of 233 as an 
(inseparable) 65:35 mixture of diastereomers: mp 101-104 °C (EtOAc/hexanes); IR (thin film) 
3197, 3058, 2955, 2925, 2857, 1465, 1436, 1188, 1115, 753, 697 cm-1; 1H NMR δ 7.75-7.64 (m, 
2 H), 7.54-7.15 (m, 15 H), 7.04 (dd, 1.3 H, J = 7.5, 1.7 Hz), 6.93 (dd, 0.7 H, J = 7.2, 2.1 Hz), 
5.38-5.25 (m, 1.65 H), 5.16 (dt, 0.35 H, J = 15.3, 6.6 Hz), 4.73-4.61 (m, 1 H), 2.82-2.73 (m, 1 
H), 1.90-1.80 (m, 2 H), 1.27-1.18 (m, 4 H), 0.90-0.83 (m, 3 H); EIMS m/z 465 (M+, 21), 292 
(23), 277 (59), 199 (53), 188 (100); HRMS (EI) m/z calcd for C31H32NOP 465.2222, found 
465.2235. 
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 Ethyl [2-(1-adamantyl)phenyl]phenylphosphinate (251).  According to a literature 
procedure,  a suspension of 190 mg (7.82 mmol) of Mg in 40 mL of THF was treated with 2.29 g 
(7.86 mmol) of 1-(2-bromophenyl)adamantane (250).   The reaction was initiated with 3 drops of 
(CH2Br)2, and the mixture was heated at reflux for 6 h, cooled to 0 °C, treated with 1.05 mL 
(6.53 mmol) of ClP(OEt)2 (90% purity), heated at 40 °C for 12 h, cooled to room temperature, 
diluted with 30 mL of dioxane, filtered through Celite, and concentrated in vacuo.  Kugelrohr 
distillation (130 °C, ~1 atm) of the residue afforded a colorless oil that was dissolved in 20 mL 
of THF, treated with 40 mL of 0.1 M HCl, stirred at 50 °C for 3 h, cooled to room temperature 
and extracted with CH2Cl2 (3x).  The combined organic extracts were dried (MgSO4) and 
concentrated in vacuo.  A suspension of the residue, 45.0 mg (0.200 mmol) of Pd(OAc)2, 217 mg 
(0.391 mmol) of dppf, 1.71 mL (9.82 mmol) of (i-Pr)2NEt, and 880 µL (7.86 mmol) of 
iodobenzene in 75 mL of MeCN was stirred at 70 °C for 16 h.  The mixture was cooled to room 
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 temperature, diluted with hexanes/EtOAc (1:1), filtered through Celite, and concentrated in 
vacuo.  The residue was chromatographed on SiO2 (2:1, hexanes/EtOAc) to yield 1.20 g (48%) 
of 251 as an orange solid: mp 129-130 °C (EtOAc/hexanes); IR (thin film) 2901, 2848, 1437, 
1226, 1125, 1031, 947, 750, 725, 693 cm-1; 1H NMR δ 7.97 (ddd, 1 H, J = 14.6, 7.9, 1.5 Hz), 
7.69-7.57 (m, 3 H), 7.53-7.34 (m, 4 H), 7.29-7.23 (m, 1 H), 4.21-4.02 (m, 2 H), 2.32 (d, 3 H, J = 
12.1 Hz), 2.24 (d, 3 H, J = 12.1 Hz), 2.08 (s, 3 H), 1.85 (d, 3 H, J = 11.3 Hz), 1.71 (d, 3 H, J = 
11.9 Hz), 1.36 (t, 3 H, J = 7.1 Hz); 13C NMR δ 157.58 (d, 1 C, J = 10.6 Hz), 136.48 (d, 1 C, J = 
9.7 Hz), 135.09 (d, 1 C, J = 138.1 Hz), 132.02 (d, 1 C, J = 2.5 Hz), 131.24 (s, 1 C), 131.17 (s, 2 
C, J = 9.7 Hz), 128.78 (d, 1 C, J = 125.6 Hz), 128.16 (d, 2 C, J = 13.1 Hz), 127.19 (d, 1 C, J = 
13.3 Hz), 124.97 (d, 1 C, J = 12.8 Hz), 60.73 (d, 1 C, J = 5.8 Hz), 42.57 (s, 3 C), 39.03 (s, 1 C), 
36.46 (s, 3 C), 29.38 (s, 3 C), 16.39 (d, 1 C, J = 6.8 Hz); EIMS m/z 380 (M+, 20), 348 (29), 85 
(65), 83 (99), 71 (100); HRMS (EI) m/z calcd for C24H29O2P 380.1905, found 380.1904. 
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 P-2-(1-Adamantyl)phenyl-P-phenylphosphinamide (234).  A solution of 1.16 g (3.05 
mmol) of ethyl phosphinate 251 in 25 mL of CH2Cl2 was treated with 760 µL (5.76 mmol) of 
TMS-Br.   The mixture was stirred at room temperature for 5 h, treated with 20 mL of MeOH, 
stirred at room temperature for 30 min, and concentrated in vacuo.  A solution of the residue in 
10 mL of CH2Cl2 was cooled to 0 °C, treated with 530 µL (6.08 mmol) of (COCl)2 and 5 drops 
of DMF, stirred at 0 °C for 15 min, room temperature for 4 h, and concentrated in vacuo.  A 
solution of the residue in 40 mL of CH2Cl2 was cooled to -78 °C, treated with 10 mL of NH3, 
slowly warmed to room temperature over 6 h, filtered, and concentrated in vacuo.  The residue 
was chromatographed on SiO2 (50:50, CH2Cl2/Et2O) to yield 656 mg (61%) of 234 as a colorless 
solid: mp 216-217 °C (CH2Cl2/Et2O); IR (thin film) 2899, 2846, 1564, 1435, 1191, 1115, 890, 
749, 693 cm-1; 1H NMR δ 7.80 (dd, 2 H, J = 12.3, 7.9 Hz), 7.71 (dd, 1 H, J = 16.8, 7.8 Hz), 7.58 
(t, 1 H, J = 7.0 Hz), 7.50-7.42 (m, 4 H), 7.15 (t, 1 H, J = 7.5 Hz), 2.96 (bs, 2 H), 2.38 (s, 6 H), 
2.13 (s, 3 H), 1.90 (bd, 3 H, J = 11.3 Hz), 1.74 (bd, 3 H, J = 11.7 Hz); 13C NMR δ 157.42 (d, 1 
C, J = 9.0 Hz), 137.20 (d, 1 C, J = 134.4 Hz), 136.39 (d, 1 C, J = 13.3 Hz), 131.61 (d, 1 C, J = 
99 
 2.2 Hz), 131.14 (d, 2 C, J = 9.7 Hz), 131.08 (s, 1 C), 131.07 (d, 1 C, J = 117.1 Hz), 128.30 (d, 2 
C, J = 12.9 Hz), 127.12 (d, 1 C, J = 12.3 Hz), 124.85 (d, 1 C, J = 13.6 Hz), 42.71 (s, 3 C), 39.06 
(s, 1 C), 36.50 (s, 3 C), 29.46 (s, 3 C); ESIMS m/z 413 ([M+Na+K]2+, 27), 374 ([M+Na]+, 100), 
335 (32); HRMS (ESI) m/z calcd for C22H26NOPNa [M+Na] 374.1650, found 374.1665. 
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235  
 P-2-(1-Adamantyl)phenyl-N-benzylidene-P-phenylphosphinamide (235).  According 
to the General Protocol B, 620 mg (1.76 mmol) of phosphinamide 234, 920 µL (5.28 mmol) of 
(i-Pr)2NEt, 270 µL (2.66 mmol) of PhCHO, and 120 µL (1.09 mmol) of TiCl4 afforded the crude 
imine, which was chromatographed on SiO2 (80:20, hexanes/EtOAc, containing 2% Et3N) to 
yield 749 mg (97%) of 235 as a colorless solid: mp 172-173 °C (EtOAc/hexanes); IR (thin film) 
2899, 2848, 1617, 1578, 1452, 1206, 1113, 817, 754, 691 cm-1; 1H NMR δ 9.29 (d, 1 H, J = 30.9 
Hz), 8.42 (ddd, 1 H, J = 14.8, 7.9, 1.4 Hz), 8.00 (d, 2 H, J = 8.3 Hz), 7.74-7.35 (m, 10 H), 7.31-
7.25 (m, 1 H), 2.32 (bs, 6 H), 2.10 (s, 3 H), 1.89 (d, 3 H, J = 11.3 Hz), 1.73 (d, 3 H, J = 11.9 Hz); 
ESIMS m/z 462 ([M+Na]+, 100), 440 ([M+H]+, 72; HRMS (ESI) m/z calcd for C29H31NOP 
[M+H] 440.2143, found 440.2147. 
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236  
 (E)-P-2-(1-Adamantyl)phenyl-P-phenyl-N-(1-phenylhept-2-enyl)phosphinamide 
(236).  According to the General Protocol A, 117 mg (0.454 mmol) of Cp2ZrHCl, 60.0 µL (0.522 
mmol) of 1-hexyne, 230 µL (0.460 mmol) of Me2Zn (2.0 M solution in toluene), and 100 mg 
(0.228 mmol) of imine 235 at a reaction temperature of 40 °C afforded 103 mg (86%) of 236 as 
an (inseparable) 59:41 mixture of diastereomers: mp 138-140 °C (EtOAc/hexanes); IR (thin 
film) 2901, 2846, 1433, 1186, 1113, 755, 696 cm-1; 1H NMR δ 7.87-7.01 (m, 14 H), 5.78-5.45 
(m, 2 H), 5.06-4.91 (m, 1 H), 3.04-2.93 (m, 1 H), 2.39 (s, 2.4 H), 2.29 (s, 3.6 H), 2.12-1.67 (m, 
100 
 11 H), 1.37-1.22 (m, 4 H), 0.93-0.83 (m, 3 H); ESIMS m/z 546 ([M+Na]+, 100), 335 (15); 
HRMS (ESI) m/z calcd for C35H42NOPNa [M+Na] 546.2902, found 546.2914. 
Br
252  
 2-Bromo-4’-methylbiphenyl (252).  A solution of 4.88 g (28.5 mmol) of 4-bromo-
toluene (254) in 125 mL of THF was cooled to -78 °C and treated with 12.0 mL (30.0 mmol) of 
n-BuLi (2.5 M solution in hexanes).  The mixture was stirred at -78 °C for 30 min, treated with 
6.70 mL (58.7 mmol) of B(OMe)3, slowly warmed to room temperature over 16 h, quenched 
with saturated NH4Cl, diluted with Et2O, washed with 1 N HCl and brine, dried (MgSO4), and 
concentrated in vacuo.  According to a literature procedure,245 a solution of the residue in 50 mL 
of DME and 100 mL of H2O was treated with 3.50 mL (29.0 mmol) of 1,2-dibromobenzene 
(255), 11.8 g (85.4 mmol) of K2CO3, and 1.65 g (1.43 mmol) of Pd(PPh3)4.  The mixture was 
heated at reflux for 12 h, cooled to room temperature and extracted with CH2Cl2 (3x).  The 
combined organic extracts were washed with H2O and brine, dried (MgSO4), and concentrated in 
vacuo.  The residue was chromatographed on SiO2 (99:1, hexanes/Et2O) to yield 4.86 g (69%) of 
252 as a colorless oil: IR (neat) 3053, 3027, 2918, 1464, 1434, 1027, 1005, 818, 753 cm-1; 1H 
NMR δ 7.71 (d, 1 H, J = 7.6 Hz), 7.40-7.35 (m, 4 H), 7.29 (d, 2 H, J = 7.9 Hz), 7.25-7.20 (m, 1 
H), 2.46 (s, 3 H); 13C NMR δ 142.57, 138.23, 137.28, 133.04, 131.27, 129.20 (2 C), 128.64 (2 
C), 128.45, 127.27, 122.72, 21.20; EIMS m/z 248 (81Br-M+, 92), 246 (79Br-M+, 100), 167 (42), 
165 (83), 152 (35); HRMS (EI) m/z calcd for C13H1179Br 246.0044, found 246.0043. 
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253  
 Ethyl [2-(4’-methylbiphenyl)]phenylphosphinate (253).  According to a literature 
procedure,  a suspension of 410 mg (16.9 mmol) of Mg in 50 mL of THF was treated with 4.20 g 
(17.0 mmol) of aryl bromide 252.  The reaction was initiated with 2 drops of (CH2Br)2, and the 
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 mixture was heated at reflux for 3 h, cooled to 0 °C, treated with 1.82 mL (11.3 mmol) of 
ClP(OEt)2 (90% purity), heated at reflux at 4 h, cooled to room temperature, diluted with 100 mL 
of dioxane, filtered through Celite, and concentrated in vacuo.  Kugelrohr distillation (120 °C, ~1 
atm) of the residue afforded a colorless oil that was dissolved in 20 mL of THF, treated with 40 
mL of 0.1 M HCl, stirred at 50 °C for 2 h, cooled to room temperature and extracted with 
CH2Cl2 (3x).  The combined organic extracts were dried (MgSO4) and concentrated in vacuo.  A 
suspension of the residue, 76.0 mg (0.339 mmol) of Pd(OAc)2, 377 mg (0.608 mmol) of dppf, 
2.40 mL (17.2 mmol) of (i-Pr)2NEt, and 1.52 mL (13.6 mmol) of iodobenzene in 100 mL of 
MeCN was stirred at 70 °C for 16 h.  The mixture was cooled to room temperature, diluted with 
hexanes/EtOAc (1:1), filtered through Celite, and concentrated in vacuo.  The residue was 
chromatographed on SiO2 (1:2, hexanes/EtOAc) to yield 2.04 g (54%) of 253 as a yellow oil: IR 
(thin film) 3463, 3053, 2980, 1466, 1436, 1223, 1134, 1119, 1033, 948, 817, 763, 750, 693 cm-1; 
1H NMR δ 8.06 (ddd, 1 H, J = 12.9, 7.6, 1.3 Hz), 7.54-7.18 (m, 8 H), 6.99 (s, 4 H), 4.01-3.84 (m, 
2 H), 2.34 (s, 3 H), 1.21 (t, 3 H, J = 7.1 Hz); 13C NMR δ 146.41 (d, 1 C, J = 11.4 Hz), 137.73 (d, 
1 C, J = 4.3 Hz), 136.73 (s, 1 C), 132.85 (d, 1 C, J = 9.0 Hz), 132.23 (d, 1 C, J = 116.3 Hz), 
131.57 (d, 2 C, J = 10.3 Hz), 131.57 (d, 1 C, J = 2.8 Hz), 131.33 (d, 1 C, J = 8.1 Hz), 131.23 (s, 1 
C), 129.54 (s, 2 C), 128.73 (d, 1 C, J = 137.3 Hz), 127.86 (s, 2 C), 127.69 (d, 2 C, J = 13.2 Hz), 
126.46 (d, 1 C, J = 12.4 Hz), 60.39 (d, 1 C, J = 5.6 Hz), 21.10 (s, 1 C), 16.16 (d, 1 C, J = 6.8 
Hz); ESIMS m/z 359 ([M+Na]+, 100), 337 ([M+H]+, 13); HRMS (ESI) m/z calcd for 
C21H21O2Pna [M+Na] 359.1177, found 359.1168. 
P
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237  
 P-2-(4’-Methylbiphenyl)-P-phenylphosphinamide (237).  A solution of 2.02 g (6.01 
mmol) of ethyl phosphinate 253 in 50 mL of CH2Cl2 was treated with 1.59 mL (12.0 mmol) of 
TMS-Br.   The mixture was stirred at room temperature for 2 h, treated with 25 mL of MeOH, 
stirred at room temperature for 1 h, and concentrated in vacuo.  A solution of the residue in 15 
mL of CH2Cl2 was cooled to 0 °C, treated with 1.05 mL (12.0 mmol) of (COCl)2 and 3 drops of 
DMF, stirred at 0 °C for 1 h, at room temperature for 4 h, and concentrated in vacuo.  A solution 
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 of the residue in 20 mL of CH2Cl2 was cooled to -78 °C and treated with 10 mL of NH3, slowly 
warmed to room temperature over 12 h, filtered, and concentrated in vacuo.  The residue was 
chromatographed on SiO2 (95:5, Et2O/MeOH) to yield 1.60 g (87%) of 237 as a colorless solid: 
mp 93-97 °C (MeOH/Et2O); IR (thin film) 3420, 3225, 3046, 1591, 1563, 1464, 1437, 1191, 
1134, 1119, 899, 819, 763, 694   cm-1; 1H NMR δ 7.77 (ddd, 1 H, J = 14.2, 7.7, 1.2 Hz), 7.63 
(ddt, 2 H, J = 12.5, 6.9, 1.3 Hz), 7.52-7.44 (m, 2 H), 7.40-7.32 (m, 3 H), 7.26 (ddd, 1 H, J = 7.5, 
4.6, 1.1 Hz), 7.17 (d, 2 H, J = 8.0 Hz), 7.12 (d, 2 H, J = 8.2 Hz), 2.65 (bs, 2 H), 2.38 (s, 3 H); 13C 
NMR δ 144.76 (d, 1 C, J = 8.9 Hz), 138.10 (d, 1 C, J = 3.8 Hz), 137.60 (s, 1 C), 134.05 (d, 1 C, J 
= 129.3 Hz), 132.65 (d, 1 C, J = 132.6 Hz), 132.52 (d, 1 C, J = 11.2 Hz), 131.77 (d, 2 C, J = 9.9 
Hz), 131.54 (d, 1 C, J = 3.0 Hz), 131.14 (d, 1 C, J = 11.5 Hz), 131.02 (d, 1 C, J = 2.4 Hz), 
129.41 (s, 2 C), 128.73 (s, 2 C), 128.08 (d, 2 C, J = 12.9 Hz), 126.72 (d, 1 C, J = 12.8 Hz), 21.18 
(s, 1 C); ESIMS m/z 346 ([M+K]+, 6), 330 ([M+Na]+, 100), 291 (12); HRMS (ESI) m/z calcd for 
C19H18NOPNa [M+Na] 330.1024, found 330.1009. 
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238  
 N-Benzylidene-P-2-(4’-methylbiphenyl)-P-phenylphosphinamide (238).  According to 
the General Protocol B, 1.01 g (3.29 mmol) of phosphinamide 237, 400 µL (3.94 mmol) of 
PhCHO, 1.70 mL (9.76 mmol) of (i-Pr)2NEt, and 210 µL (1.91 mmol) of TiCl4 afforded the 
crude imine, which was chromatographed on SiO2 (40:60, hexanes/EtOAc, containing 2% Et3N) 
to yield 1.15 g (88%) of 238 as a colorless solid: mp 145-146 °C (EtOAc/hexanes); IR (thin film) 
3439, 3055, 1612, 1575, 1467, 1452, 1436, 1201, 1132, 1114, 851, 828, 760, 693 cm-1; 1H NMR 
δ 8.73 (d, 1 H, J = 32.8 Hz), 7.81-7.26 (m, 14 H), 7.19 (d, 2 H, J = 8.1 Hz), 6.91 (d, 2 H, J = 7.7 
Hz), 2.18 (s, 3 H); ESIMS m/z 813 ([2M+Na]+, 100), 418 ([M+Na]+, 88), 396 ([M+H]+, 20); 
HRMS (ESI) m/z calcd for C26H22NOPNa 418.1337, found 418.1337. 
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239  
 (E)-P-2-(4’-Methylbiphenyl)-P-phenyl-N-(1-phenylhept-2-enyl)phosphinamide 
(239).  According to the General Protocol B, 98.0 mg (0.380 mmol) of Cp2ZrHCl, 52.0 µL 
(0.453 mmol) of 1-hexyne, 130 µL (0.260 mmol) of Me2Zn (2.0 M solution in toluene), and 100 
mg (0.253 mmol) of imine 238 at a reaction temperature of 45 °C afforded 105 mg (87%) of 239 
as an (inseparable) 63:37 mixture of diastereomers: IR (thin film) 3059, 2957, 2927, 2871, 1691, 
1453, 1435, 1184, 1110, 817, 762, 696 cm-1; 1H NMR δ 7.77-7.12 (m, 15 H), 7.07-7.01 (m, 2 H), 
6.93-6.89 (m, 1 H), 5.38-5.13 (m, 2 H), 4.68-4.60 (m, 1 H), 2.86-2.76 (m, 1 H), 2.41 (s, 1.2 H), 
2.32 (s, 1.8 H), 1.92-1.81 (m, 2 H), 1.29-1.13 (m, 4 H), 0.89-0.83 (m, 3 H); ESIMS m/z 518 
([M+K]+, 11), 502 ([M+Na]+, 100), 291 (15); HRMS (ESI) m/z calcd for C32H34NOPNa [M+Na] 
502.2276, found 502.2299. 
NHP(O)Ph2
Ph C4H9
257  
 N-{(R*)-[(1R*,2R*)-2-Butylcyclopropyl](phenyl)methyl}-P,P-diphenylphosphin-
amide (257).  A suspension of 389 mg (1.51 mmol) of Cp2ZrHCl in 2.5 mL of CH2Cl2 was 
treated with 200 µL (1.74 mmol) of 1-hexyne.  After 5 min, the yellow solution was cooled to     
-78 °C, treated with 750 µL (1.50 mmol) of Me2Zn (2.0 M solution in toluene), warmed to room 
temperature over a period of 5 min, treated with a solution of 155 mg (0.508 mmol) of imine 104 
in 1.5 mL of CH2Cl2, heated at reflux for 16 h, quenched with saturated NaHCO3, diluted with 
EtOAc, filtered through Celite, washed with H2O and brine, dried (MgSO4), filtered through a 
pad of Florisil, and concentrated in vacuo.  The residue was chromatographed on deactivated 
SiO2 (1:3, hexanes/EtOAc containing 1% Et3N) to yield 119 mg (58%) of 257 as a colorless 
solid and 21 mg (11%) of 146 as a colorless solid.  257: mp 150-151 °C (EtOAc/hexane); IR 
(KBr) 3185, 3059, 2957, 2923, 2856, 1456, 1437, 1183, 1123, 1110, 1086, 1065, 724, 698 cm-1; 
1H NMR δ 7.97-7.90 (m, 2 H), 7.80-7.73 (m, 2 H), 7.53-7.40 (m, 4 H), 7.36-7.22 (m, 7 H), 3.80 
(q, 1 H, J = 8.9 Hz), 3.33 (t, 1 H, J = 6.6 Hz), 1.36-1.29 (m, 5 H), 1.10-0.98 (m, 2 H), 0.89 (t, 3 
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 H, J = 7.0 Hz), 0.78-0.72 (m, 1 H), 0.41 (dt, 1 H, J = 8.6, 4.8 Hz), 0.26 (dt, 1 H, J = 8.3, 5.0 Hz); 
13C NMR δ 143.37, 143.30, 134.30, 133.15, 132.60, 132.42, 132.29, 131.96, 131.84, 131.71, 
131.67, 131.57, 131.54, 131.43, 128.42, 128.29, 128.23, 128.09, 127.74, 127.62, 126.96, 126.77, 
58.84, 33.22, 31.69, 26.85, 26.79, 22.52, 18.92, 14.10, 10.61; EIMS m/z 403 (M+, 7), 360 (3), 
319 (17), 306 (81), 256 (27), 201 (100), 91 (36), 77 (37); HRMS (EI) m/z calcd for C26H30NOP 
403.2065, found 403.2066. 
 Preparation of 257 in the presence of Diiodomethane. General Protocol C. 
A suspension of 390 mg (1.51 mmol) of Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 190 µL 
(1.65 mmol) of 1-hexyne.  After 5 min, the yellow solution was cooled to -78 °C, treated with 
750 µL (1.50 mmol) of Me2Zn (2.0 M solution in toluene), warmed to room temperature over a 
period of 5 min, treated with a solution of 153 mg (0.501 mmol) of imine 104 in 2 mL of 
CH2Cl2, and heated at reflux for 1 h.  The mixture was cooled to room temperature, treated with 
200 µL (2.48 mmol) of CH2I2, heated at reflux for a further 2 h, quenched with saturated NH4Cl, 
diluted with EtOAc, washed with 1N HCl and brine, dried (MgSO4), and concentrated in vacuo.  
The residue was chromatographed on deactivated SiO2 (1:9, hexanes/EtOAc containing 1% 
Et3N) to yield 149 mg (74%) of 257 [dr = 97:3 (HPLC)] as a colorless solid. 
 Preparation of 257 in the presence of Diiodomethane and Benzyl Alcohol. 
A suspension of 390 mg (1.51 mmol) of Cp2ZrHCl in 2 mL of CH2Cl2 was treated with 200 µL 
(1.74 mmol) of 1-hexyne.  After 5 min, the yellow solution was cooled to -78 °C, treated with 
1.00 mL (2.00 mmol) of Me2Zn (2.0 M solution in toluene), warmed to room temperature over a 
period of 5 min, treated with a solution of 153 mg (0.501 mmol) of imine 104 and 55.0 mg 
(0.509 mmol) of PhCH2OH in 2 mL of CH2Cl2, and heated at reflux for 90 min.  The mixture 
was cooled to room temperature, treated with 200 µL (2.48 mmol) of CH2I2, heated at reflux for 
a further 3 h, quenched with saturated NaHCO3, diluted with EtOAc, filtered through Celite, 
washed with H2O and brine, dried (MgSO4), filtered through a pad of Florisil, and concentrated 
in vacuo.  The residue was chromatographed on deactivated SiO2 (1:9, hexanes/EtOAc 
containing 1% Et3N) to yield 183 mg (91%) of 257 as a colorless solid. 
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 N-{(R*)-[(1R*,2R*)-2-Butyl-3,3-bisdeuterocyclopropyl](phenyl)methyl}-P,P-
diphenylphosphinamide (258).  A suspension of 192 mg (0.745 mmol) of Cp2ZrHCl in 1.2 mL 
of CD2Cl2 was treated at room temperature with 95.0 µL (0.827 mmol) of 1-hexyne.  After 5 
min, the yellow solution was cooled to -78 °C, treated with 380 µL (0.760 mmol) of Me2Zn (2.0 
M solution in toluene), warmed to room temperature over a period of 5 min, treated with a 
solution of 78.0 mg (0.255 mmol) of imine 104 in 2 mL of CD2Cl2, and heated at reflux for 16 h, 
cooled to room temperature, quenched with saturated NH4Cl, diluted with EtOAc, washed with 1 
N HCl and brine, dried (MgSO4), and concentrated in vacuo.  The residue was chromatographed 
on deactivated SiO2 (1:4, hexanes/EtOAc containing 1% Et3N) to yield 35 mg (34%) of 258 as a 
colorless solid: mp 151-152 °C (EtOAc/hexane); IR (KBr) 3176, 2954, 2922, 2851, 1437, 1185, 
1124, 1110, 1083, 1062 cm-1; 1H NMR δ 7.93-7.86 (m, 2 H), 7.76-7.69 (m, 2 H), 7.51-7.36 (m, 4 
H), 7.32-7.18 (m, 7 H), 3.76 (q, 1 H, J = 8.9 Hz), 3.37 (dd, 1 H, J = 8.4, 6.0 Hz), 1.32-1.20 (m, 5 
H), 1.06-0.95 (m, 2 H), 0.85 (t, 3 H, J = 7.0 Hz), 0.79-0.66 (m, 1 H); 13C NMR δ 143.34, 143.28, 
134.20, 133.07, 132.51, 132.38, 132.25, 131.93, 131.80, 131.69, 131.65, 131.55, 131.52, 131.35, 
128.43, 128.26, 128.23, 128.20, 128.06, 126.93, 126.73, 58.76, 33.12, 31.68, 26.62, 26.56, 22.49, 
18.67, 14.08, 9.94; 2H NMR (77 MHz) δ 0.35, 0.20; EIMS m/z 405 (M+, 9), 319 (28), 306 (85), 
258 (45), 204 (45), 201 (100), 106 (21), 77 (37); HRMS (EI) m/z calcd for C26H38D2NOP 
405.2191, found 405.2179. 
NHP(O)Ph2
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 N-{(R*)-[(1S*,2R*)-2-{2-[(tert-Butyldiphenylsilyl)oxy]ethyl}cyclopropyl](phenyl)-
methyl}-P,P-diphenylphosphinamide (259).  According to the General Protocol C, 390 mg 
(1.51 mmol) of Cp2ZrHCl, 531 mg (1.72 mmol) of alkyne 148, 750 µL (1.50 mmol) of Me2Zn 
(2.0 M solution in toluene), 153 mg (0.501 mmol) of imine 104 (2 h reaction time), and 200 µL 
(2.48 mmol) of CH2I2 (12 h reaction time) afforded 216 mg (68%) of 259 [dr = 98:2 (HPLC)] as 
a colorless oil: IR (neat) 3189, 3070, 2930, 2857, 1456, 1437, 1428, 1390, 1191, 1123, 1068, 
1028, 823, 722, 694 cm-1; 1H NMR δ 7.95-7.87 (m, 2 H), 7.81-7.66 (m, 6 H), 7.49-7.37 (m, 10 
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 H), 7.34-7.26 (m, 7 H), 3.87-3.70 (m, 3 H), 3.43 (dd, 1 H, J = 8.7, 5.7 Hz), 1.59 (dq, 1 H, J = 
13.5, 6.8 Hz), 1.39 (dq, 1 H, J = 13.7, 6.8 Hz), 1.08 (s, 9 H), 1.08-1.01 (m, 1 H), 0.87-0.76 (m, 1 
H), 0.44 (dt, 1 H, J = 8.6, 4.9 Hz), 0.30 (dt, 1 H, J = 8.4, 5.1 Hz); 13C NMR δ 143.22, 143.15, 
135.50, 135.47, 134.11, 133.93, 133.89, 133.05, 132.38, 132.25, 131.88, 131.75, 131.65, 131.62, 
131.52, 131.49, 131.33, 129.45, 128.40, 128.20, 128.04, 127.53, 127.50, 126.94, 126.70, 63.98, 
58.54, 36.40, 26.83, 26.57, 26.51, 19.07, 15.53, 10.20; EIMS m/z 629 (M+, 3), 573 (100), 398 
(28), 319 (17), 306 (92), 256 (17), 218 (18), 201 (94), 183 (20); HRMS (EI) m/z calcd for 
C40H44NO2PSi 629.2879, found 629.2887. 
NHP(O)Ph2
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 O-Triisopropylsilyl-4-[(1R*,2R*)-2-{(R*)-[(diphenylphosphinyl)amino](phenyl)-
methyl}cyclopropyl]propanoate (260).  According to the General Protocol C, 390 mg (1.51 
mmol) of Cp2ZrHCl, 426 mg (1.65 mmol) of alkyne 150, 750 µL (1.50 mmol) of Me2Zn (2.0 M 
solution in toluene), 153 mg (0.501 mmol) of imine 104 (4 h reaction time), and 200 µL (2.48 
mmol) of CH2I2 (16 h reaction time) afforded 205 mg (71%) of 260 as a colorless oil: IR (neat) 
3183, 2947, 2866, 1716, 1462, 1437, 1186, 1125, 1111 cm-1; 1H NMR δ 7.94-7.87 (m, 2 H), 
7.76-7.69 (m, 2 H), 7.52-7.37 (m, 4 H), 7.32-7.19 (m, 7 H), 3.79 (q, 1 H, J = 9.0 Hz), 3.50 (dd, 1 
H, J = 8.8, 6.1 Hz), 2.46-2.31 (m, 2 H), 1.59 (dq, 1 H, J = 14.5, 7.1 Hz), 1.48-1.17 (m, 5 H), 1.06 
(d, 18 H, J = 7.2 Hz), 0.87-0.75 (m, 1 H), 0.44 (dt, 1 H, J = 8.6, 4.9 Hz), 0.30 (dt, 1 H, J = 8.4, 
5.1 Hz); 13C NMR δ 173.61, 143.12, 134.35, 133.19, 132.44, 132.31, 131.91, 131.79, 128.47, 
128.29, 128.10, 127.04, 126.73, 58.59, 35.74, 29.12, 26.91, 18.27, 17.75, 11.88, 10.57; EIMS 
m/z 575 (M+, 1), 532 (21), 330 (32), 319 (20), 306 (50), 256 (19), 218 (27), 201 (100), 143 (20), 
115 (21), 103 (23), 91 (23); HRMS (EI) m/z calcd for C34H46NO3PSi 575.2985, found 575.2979. 
NHP(O)Ph2
Ph
261
N(Ts)CO2Et
 
 O-Ethyl-N-{2-[(1S*,2R*)-2-{(R*)-[(diphenylphosphinyl)amino](phenyl)methyl}-
cyclopropyl]ethyl}-N-[(4-methylphenyl)sulfonyl]carbamate (261).  According to the General 
Protocol C, 390 mg (1.51 mmol) of Cp2ZrHCl, 495 mg (1.68 mmol) of alkyne 152, 750 µL (1.50 
mmol) of Me2Zn (2.0 M solution in toluene), 153 mg (0.501 mmol) of imine 104 (2 h reaction 
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 time), and 200 µL (2.48 mmol) of CH2I2 (12 h reaction time) afforded 138 mg (45%) of 261 as a 
colorless oil: IR (neat) 3344, 3187, 3060, 2990, 1731, 1438, 1370, 1353, 1274, 1187, 1170, 1123, 
1089, 728, 700, 675 cm-1; 1H NMR δ 7.98-7.91 (m, 2 H), 7.83-7.74 (m, 4 H), 7.53-7.42 (m, 4 H), 
7.38-7.25 (m, 9 H), 4.11 (q, 2 H, J = 7.1 Hz), 3.90 (t, 2 H, J = 7.7 Hz), 3.85-3.72 (m, 1 H), 3.51 
(dd, 1 H, J = 8.5, 6.3 Hz), 2.46 (s, 3 H), 1.77 (dq, 1 H, J = 13.7, 6.9 Hz), 1.53 (dq, 1 H, J = 13.7, 
7.7 Hz), 1.20-1.11 (m, 1 H), 1.17 (t, 3 H, J = 7.1 Hz), 0.82-0.71 (m, 1 H), 0.47 (dt, 1 H, J = 8.6, 
5.2 Hz), 0.39 (dt, 1 H, J = 8.4, 5.1 Hz); 13C NMR δ 152.22, 144.31, 143.05, 142.98, 136.75, 
134.18, 133.01, 132.39, 132.27, 131.93, 131.80, 131.63, 131.60, 131.29, 129.21, 128.51, 128.32, 
128.22, 128.15, 127.97, 127.46, 127.09, 126.75, 63.15, 58.61, 46.96, 34.06, 26.53, 26.47, 21.58, 
16.11, 13.96, 10.39; EIMS m/z 616 (M+, 2), 461 (8), 415 (10), 360 (9), 319 (17), 306 (100), 256 
(15), 243 (24), 216 (23), 201 (89), 155 (39), 91 (52), 77 (28); HRMS (EI) m/z calcd for 
C34H37N2O5PS 616.2161, found 616.2154.  Approximately 2.5 mg of racemic 261 was separated 
by HPLC on a Chiracel OD analytical column (solvent system: 7.5% i-PrOH in hexanes; flow 
rate: 1 mL/min).  Enantiomer 1: RT 11.2 min; >99% ee (HPLC chiracel OD analytical column, 
7.5% i-PrOH in hexanes, 1.0 mL/min); αD -10.9 (CHCl3, c = 0.1).  Enantiomer 2: RT 16.8 min; 
>99% ee (HPLC chiracel OD analytical column, 7.5% i-PrOH in hexanes, 1.0 mL/min); αD 
+11.1 (CHCl3, c = 0.1). 
NHP(O)Ph2
C4H9
262
Ph
 
 N-{1-(R*)-[(1R*,2R*)-2-Butylcyclopropyl]-3-phenylprop-2-ynyl}-P,P-diphenyl-phos-
phinamide (262).  According to the General Protocol C, 395 mg (1.53 mmol) of Cp2ZrHCl, 195 
µL (1.70 mmol) of 1-hexyne, 750 µL (1.50 mmol) of Me2Zn (2.0 M solution in toluene), 168 mg 
(0.510 mmol) of imine 164 (3 h reaction time), and 200 µL (2.48 mmol) of CH2I2 (4 h reaction 
time) afforded 131 mg (60%) of 262 as a colorless oil: IR (neat) 3166, 3058, 2955, 2924, 2855, 
1490, 1438, 1189, 1124, 1110, 1070, 755, 723, 692 cm-1; 1H NMR (600 MHz) δ 8.04-8.00 (m, 2 
H), 7.91-7.87 (m, 2 H), 7.52-7.41 (m, 6 H), 7.34-7.28 (m, 5 H), 4.24 (td, 1 H, J = 9.4, 5.6 Hz), 
3.30 (t, 1 H, J = 8.8 Hz), 1.33-1.18 (m, 6 H), 1.11 (dq, 1 H, J = 9.9, 5.0 Hz), 0.90-0.84 (m, 1 H), 
0.85 (t, 3 H, J = 7.1 Hz), 0.69 (dt, 1 H, J = 9.0, 4.6 Hz), 0.31 (dt, 1 H, J = 8.2, 4.9 Hz); 13C NMR 
(151 MHz) δ 133.38, 132.77, 132.71, 132.54, 132.38, 131.91, 131.78, 131.72, 131.65, 131.50, 
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 128.52, 128.44, 128.19, 122.78, 87.91, 87.86, 83.84, 46.40, 32.94, 31.64, 24.97, 22.48, 17.58, 
14.08, 8.79; EIMS m/z 427 (M+, 2), 370 (9), 330 (16), 201 (100); HRMS (EI) m/z calcd for 
C28H30NOP 427.2065, found 427.2063. 
 Conversion of 262 to 264.  A solution of 50.0 mg (0.117 mmol) of cyclopropane 262 in 
5 mL of EtOH was treated with 8.0 mg of 10% Pd on activated charcoal, stirred under an H2 
atmosphere (1 atm) for 16 h, diluted with Et2O, filtered through Celite and concentrated in 
vacuo.  A solution of the residue in 5 mL of a 1 N solution of HCl(g) in MeOH was stirred at 
room temperature for 4 h, basified with 5% NaOH, and extracted with CH2Cl2.  The organic 
extract was dried (MgSO4), concentrated in vacuo, dissolved in 2 mL of CH2Cl2, and treated with 
65.0 mg (0.341 mmol) of TsCl, 10.0 mg (0.0819 mmol) of DMAP, and 60.0 µL (0.619 mmol) of 
Et3N.  The mixture was stirred at room temperature for 16 h, diluted with Et2O, washed with 
H2O and brine, dried (MgSO4), and concentrated in vacuo.  The residue was chromatographed on 
SiO2 (9:1, hexanes/EtOAc) to yield 31 mg (68%) of 264 as a colorless oil. 
Ph C4H9
263
NHTs
 
 N-{(R*)-[(1R*,2R*)-2-Butylcyclopropyl]phenylmethyl}-S-(4-methylphenyl)sulfon-
amide (263).  According to the General Protocol C, 193 mg (0.748 mmol) of Cp2ZrHCl, 95.0 µL 
(0.827 mmol) of 1-hexyne, 380 µL (0.760 mmol) of Me2Zn (2.0 M solution in toluene), 64.0 mg 
(0.247 mmol) of imine 90 (1 h reaction time), and 100 µL (1.24 mmol) of CH2I2 (12 h reaction 
time) afforded 58 mg (66%) of 263 [dr = 96:4 (1H NMR)] as a colorless oil: IR (neat) 3277, 
2956, 2925, 2856, 1455, 1435, 1326, 1161, 1095, 1056, 1022, 813, 700, 668 cm-1; 1H NMR δ 
7.58-7.54 (m, 2 H), 7.17-7.08 (m, 7 H), 5.23 (d, 1 H, J = 6.3 Hz), 3.71 (dd, 1 H, J = 8.6, 6.3 Hz), 
2.35 (s, 3 H), 1.25-1.13 (m, 5 H), 1.07-0.97 (m, 1 H), 0.88-0.77 (m, 1 H), 0.86 (t, 3 H, J = 7.1 
Hz), 0.57-0.46 (m, 1 H), 0.39 (dt, 1 H, J = 8.6, 4.8 Hz), 0.23 (dt, 1 H, J = 8.4, 5.0 Hz); 13C NMR 
δ 142.87, 140.62, 137.76, 129.22, 128.16, 127.16, 127.02, 126.73, 62.07, 33.05, 31.52, 25.36, 
22.42, 21.39, 18.53, 14.02, 10.95; CIMS m/z 358 ([M+H]+, 37), 273 (15), 260 (50), 187 (100), 
173 (39), 117 (37), 105 (24), 91 (39); HRMS (CI) m/z calcd for C21H28NO2S [M+H] 358.1841, 
found 358.1856. 
 Conversion of 257 to 263.  A solution of 88.0 mg (0.218 mmol) of cyclopropane 257 in 
5 mL of a 1 N solution of HCl(g) in MeOH (prepared by treating 4.5 mL of MeOH with 0.5 mL 
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 of AcCl at 0 °C and stirring at room temperature for 30 min) was stirred at room temperature for 
4 h, basified with 5% NaOH, and extracted with CH2Cl2.  The extract was dried (MgSO4) and 
concentrated in vacuo.  The residue was dissolved in 2 mL of CH2Cl2, and treated with 166 mg 
(0.871 mmol) of TsCl, 10.0 mg (0.0819 mmol) of DMAP, and 130 µL (1.34 mmol) of Et3N.  The 
mixture was stirred at room temperature for 16 h, diluted with Et2O, washed with H2O and brine, 
dried (MgSO4), filtered through a pad of Florisil, and concentrated in vacuo.  The residue was 
chromatographed on SiO2 (4:1, hexanes/EtOAc) to yield 56 mg (72%) of 263 as a colorless oil. 
C4H9
264
NHTs
Ph
 
 N-{1-(S*)-[(1R*,2R*)-2-Butylcyclopropyl]-3-phenylpropyl}-S-(4-methylphenyl)-
sulfonamide (264).  According to the General Protocol C, 392 mg (1.52 mmol) of Cp2ZrHCl, 
190 µL (1.65 mmol) of 1-hexyne, 750 µL (1.50 mmol) of Me2Zn (2.0 M solution in toluene), 
144 mg (0.501 mmol) of imine 166 (1.5 h reaction time), and 400 µL (4.96 mmol) of CH2I2 (17 h 
reaction time) afforded 130 mg (67%) of 264 [dr = 87:13 (1H NMR)] as a colorless oil: IR (neat) 
3278, 2954, 2925, 2857, 1454, 1325, 1160, 1095, 814, 700, 665 cm-1; 1H NMR δ 7.76-7.74 (m, 2 
H), 7.28-7.15 (m, 5 H), 7.09-7.06 (m, 2 H), 4.84 (d, 1 H, J = 7.3 Hz), 2.66-2.60 (m, 3 H), 2.41 (s, 
3 H), 1.86-1.76 (m, 2 H), 1.23-1.01 (m, 5 H), 0.94-0.78 (m, 1 H), 0.84 (t, 3 H, J = 6.9 Hz), 0.55-
0.46 (m, 1 H), 0.30-0.16 (m, 3 H); 13C NMR δ 143.04, 141.65, 138.38, 129.53, 128.26 (2 C), 
127.00, 125.73, 58.25, 37.55, 33.18, 31.56, 31.50, 23.64, 22.41, 21.43, 17.41, 14.03, 11.29; 
CIMS m/z 386 ([M+H]+, 76), 288 (61), 280 (32), 215 (74), 172 (81), 131 (67), 119 (48), 117 
(100), 105 (36), 91 (82); HRMS (CI) m/z calcd for C23H32NO2S [M+H] 386.2154, found 
386.2161. 
C4H9
265
NHTs
 
 N-[(2-Butylcyclopropyl)cyclohexylmethyl]-S-(4-methylphenyl)sulfonamide (265).  A 
suspension of 195 mg (0.756 mmol) of Cp2ZrHCl in 2 mL of CH2Cl2 was treated at room 
temperature with 100 µL (0.870 mmol) of 1-hexyne.  After 10 min, the yellow solution was 
cooled to -78 °C, treated with 380 µL (0.760 mmol) of Me2Zn (2.0 M solution in toluene), 
warmed to room temperature and cannulated into a solution of 66.0 mg (0.249 mmol) of imine 
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 170 in 1 mL of CH2Cl2.  The mixture was heated at reflux for 2 h, cooled to 0 °C, treated with 
200 µL (2.48 mmol) of CH2I2 and 380 µL (0.760 mmol) of Me2Zn (2.0 M solution in toluene), 
heated at reflux for 12 h, cooled to room temperature, quenched with saturated NaHCO3, diltued 
with EtOAc, filtered through Celite, washed with H2O and brine, dried (MgSO4), filtered through 
a pad of Florisil and concentrated in vacuo.  The residue was purified on SiO2 (80:20, 
hexanes/EtOAc) to yield 66 mg of a 85:15 mixture of 265 (major isomer: 37%, minor isomer: 
25%) to 171 (11%).  265 (major isomer, colorless oil): IR (neat) 3281, 2924, 2843, 1445, 1327, 
1161, 1088, 1015 cm-1; 1H NMR δ 7.73 (d, 2 H, J = 8.3 Hz), 7.25 (d, 2 H, J = 8.0 Hz), 4.88 (d, 1 
H, J = 7.6 Hz), 2.43-2.36 (m, 1 H), 2.40 (s, 3 H), 1.69-1.37 (m, 6 H), 1.23-0.92 (m, 11 H), 0.82 
(t, 3 H, J = 6.7 Hz), 0.51-0.40 (m, 2 H), -0.08 (dt, 1 H, J = 7.7, 5.2 Hz), -0.16 (dt, 1 H, J = 8.4, 
4.9 Hz); 13C NMR δ 142.79, 138.77, 129.32, 127.01, 63.54, 43.39, 33.29, 31.34, 28.93, 28.70, 
26.42, 26.37, 26.22, 22.44, 21.45, 21.20, 18.77, 13.99, 10.27; CIMS m/z 364 ([M+H]+, 22), 266 
(100), 193 (27); HRMS (CI) m/z calcd for C21H34NO2S [M+H] 364.2310, found 364.2321. 
NHP(O)Ph2
Ph Et
Et
266  
 N-{(R*)-[(1R*,2R*)-1,2-Diethylcyclopropyl](phenyl)methyl}-P,P-diphenylphosphin-
amide (266).  According to the General Protocol C, 390 mg (1.51 mmol) of Cp2ZrHCl, 190 µL 
(1.67 mmol) of 3-hexyne, 750 µL (1.50 mmol) of Me2Zn (2.0 M solution in toluene), 153 mg 
(0.501 mmol) of imine 104 (3 h reaction time), and 200 µL (2.48 mmol) CH2I2 (12 h reaction 
time) afforded 93 mg (46%) of 266 [dr = 96:4 (HPLC)] as a colorless solid: mp 136-137 °C 
(EtOAc/hexane); IR (KBr) 3188, 3058, 2961, 2930, 2870, 1453, 1426, 1185, 1123, 1109, 1094, 
1063, 752, 720, 699 cm-1; 1H NMR δ 7.91-7.84 (m, 2 H), 7.76-7.68 (m, 2 H), 7.55-7.40 (m, 4 H), 
7.34-7.21 (m, 5 H), 7.19-7.16 (m, 2 H), 4.24 (t, 1 H, J = 10.7 Hz), 3.23 (dd, 1 H, J = 10.0, 7.0 
Hz), 1.69 (dq, 1 H, J = 14.8, 7.4 Hz), 1.50 (dq, 1 H, J = 13.9, 6.9 Hz), 1.31-1.16 (m, 2 H), 0.97-
0.84 (m, 1 H), 0.94 (t, 3 H, J = 7.3 Hz), 0.87 (t, 3 H, J = 7.3 Hz), 0.66 (tt, 1 H, J = 8.5, 6.1 Hz), -
0.03 (dd, 1 H, J = 5.5, 4.8 Hz); 13C NMR δ 142.31, 142.25, 134.18, 132.79, 132.60, 132.47, 
131.92, 131.79, 131.72, 131.69, 131.57, 131.53, 131.06, 128.47, 128.31, 128.15, 127.99, 127.20, 
126.81, 58.08, 30.69, 30.62, 23.69, 22.92, 21.95, 14.36, 14.07, 11.57; EIMS m/z 403 (M+, 7), 306 
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 (46), 284 (59), 218 (45), 201 (100), 157 (17), 146 (15), 129 (19), 91 (10), 77 (16); HRMS (EI) 
m/z calcd for C26H30NOP 403.2065, found 403.2075. 
NHP(O)Ph2
Ph C4H9
267
CH3
H
 
 N-(R*)-{[(1R*,2R*,3R*)-2-Butyl-3-methylcyclopropyl]phenylmethyl}-P,P-diphenyl-
phosphinamide (267).  A suspension of 195 mg (0.756 mmol) of Cp2ZrHCl in 2 mL of THF 
was treated at room temperature with 100 µL (0.870 mmol) of 1-hexyne, stirred for 10 min and 
concentrated in vacuo.  A solution of the resulting yellow solid in 2 mL of (CH2Cl)2 was cooled 
to -78 °C, treated with 380 µL (0.760 mmol) of Me2Zn (2.0 M solution in toluene), warmed to 
room temperature and cannulated into a suspension of 76.0 mg (0.249 mmol) of imine 104 in 1 
mL of (CH2Cl)2.  The mixture was stirred for 2 h at 40 °C, cooled to -78 °C, treated with 680 µL 
(0.748 mmol) of Et2Zn (1.1 M solution in toluene) and 130 µL (1.29 mmol) of CH3CHI2, stirred 
for 16 h at 40 °C, cooled to room temperature, treated with a cold (0 °C) solution of 680 µL 
(0.748 mmol) of Et2Zn (1.1 M solution in toluene), 130 µL (1.29 mmol) of CH3CHI2, and 80.0 
µL (0.770 mmol) of DME in 1 mL of ClCH2CH2Cl, and stirred for 24 h at 40 °C, quenched with 
saturated NaHCO3, diluted with EtOAc, filtered through Celite, washed with H2O and brine, 
dried (MgSO4), filtered through a pad of Florisil, and concentrated in vacuo.  The residue was 
chromatographed on deactivated SiO2 (1:4, hexanes/EtOAc containing 1% Et3N) to yield 20 mg 
(21%) of 146 and 54 mg (52%) of 267 as colorless solids. 267: mp 152-153 °C (Et2O/hexane); 
IR (KBr) 3200, 2955, 2923, 2861, 1435, 1185, 1123, 1107, 1067, 749, 726, 698 cm-1; 1H NMR δ 
7.92-7.85 (m, 2 H), 7.77-7.70 (m, 2 H), 7.49-7.40 (m, 4 H), 7.38-7.22 (m, 9 H), 3.76 (q, 1 H, J = 
8.9 Hz), 3.25 (bt, 1 H, J = 7.1 Hz), 1.31-1.18 (m, 6 H), 0.92-0.84 (m, 6 H), 0.70-0.67 (m, 2 H), 
0.61 (dt, 1 H, J = 8.0, 4.7 Hz); 13C NMR δ 143.76, 143.70, 133.18, 132.58, 132.45, 132.33, 
132.03, 131.90, 131.73, 131.69, 131.60, 131.57, 128.47, 128.30, 128.23, 128.12, 126.87, 126.74, 
58.92, 34.06, 33.99, 32.32, 27.49, 23.13, 22.73, 15.95, 14.17, 12.33; EIMS m/z 417 (M+, 2), 306 
(100), 201 (56), 106 (19); HRMS (EI) m/z calcd for C27H32NOP 417.2222, found 417.2237. 
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 NHCOPh
Ph C4H9
268  
 N-{(R*)-[(1R*,2R*)-2-Butylcyclopropyl](phenyl)methyl}benzamide (268).  A solution 
of 91.0 mg (0.226 mmol) of 257 in 5 mL of a 1 N solution of HCl(g) in MeOH was stirred at 
room temperature for 3 h, basified with 5% NaOH, and extracted with CH2Cl2.  The organic 
layer was dried (MgSO4), concentrated in vacuo, dissolved in 3 mL of CH2Cl2, and treated with 
205 mg (0.906 mmol) of (PhCO)2O, 10.0 mg (0.0819 mmol) of DMAP, and 240 µL (1.38 mmol) 
of (i-Pr)2NEt.  The mixture was stirred at room temperature for 1 h, poured into EtOAc, washed 
with H2O and brine, dried (MgSO4), and concentrated in vacuo.  The residue was chromato-
graphed on SiO2 (80:20, hexanes/EtOAc) to yield 69 mg (99%) of 268 as a colorless solid: mp 
115-116 °C (hexane); IR (KBr) 3354, 2955, 2921, 2954, 1632, 1524, 1490, 701 cm-1; 1H NMR δ 
7.85-7.81 (m, 2 H), 7.57-7.28 (m, 8 H), 6.54 (d, 1 H, J = 7.9 Hz), 4.72 (t, 1 H, J = 8.3 Hz), 1.44-
1.32 (m, 5 H), 1.25-1.20 (m, 1 H), 1.05-0.98 (m, 2 H), 0.88 (t, 3 H, J = 7.1 Hz), 0.65 (dt, 1 H, J = 
8.2, 4.9 Hz), 0.49 (dt, 1 H, J = 8.0, 5.3 Hz); 13C NMR δ 166.60, 141.99, 134.67, 131.41, 128.54, 
128.47, 127.24, 126.88, 126.67, 57.15, 33.42, 31.86, 24.31, 22.42, 17.87, 14.05, 11.38; EIMS 
m/z 307 (M+, 19), 292 (4), 264 (6) 250 (14), 236 (16), 222 (31), 210 (40), 160 (15), 152 (22), 105 
(100), 77 (53); HRMS (EI) m/z calcd for C21H25NO 307.1936, found 307.1935. 
OH
Ph C4H9
syn-271
OH
Ph C4H9
anti-271
+
 
 1-(R*)-[(1R*,2R*)-2-Butylcyclopropyl]-3-phenylpropan-1-ol (syn-271) and 1-(S*)-
[(1R*,2R*)-2-butylcyclopropyl]-3-phenylpropan-1-ol (anti-271).  A solution of 361 mg (1.65 
mmol) of 1-phenylnon-4-en-3-ol (270) in 15 mL of CH2Cl2 was treated at room temperature 
with 530 µL (6.58 mmol) of CH2I2, cooled to 0 °C, treated with 3.40 mL (3.40 mmol) of Et2Zn 
(1.0 M solution in hexanes), stirred at room temperature for 12 h, quenched with saturated 
NH4Cl, diluted with EtOAc and saturated NaHCO3, filtered through Celite, washed with H2O 
and brine, dried (MgSO4), filtered through a pad of Florisil, and concentrated in vacuo.  The 
residue was chromatographed on SiO2 (4:1, hexanes/EtOAc) to yield 47 mg (12%) of anti-271 
and 300 mg (78%) of syn-271 as colorless oils.  anti-271: IR (neat) 3394, 3062, 3026, 2992, 
2855, 1716, 1602, 1496, 1454, 1046 cm-1; 1H NMR δ 7.47-7.30 (m, 5 H), 3.10 (q, 1 H, J = 6.8 
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 Hz), 3.02-2.82 (m, 2 H), 2.08-2.01 (m, 2 H), 1.68 (s, 1 H), 1.58-1.31 (m, 6 H), 1.05 (t, 3 H, J = 
7.0 Hz), 0.88-0.76 (m, 2 H), 0.54-0.44 (m, 2 H); 13C NMR δ 142.28, 128.36, 128.30, 125.68, 
75.57, 38.54, 33.37, 32.03, 31.92, 25.57, 22.50, 16.81, 14.07, 9.92; EIMS m/z 232 (M+, 7), 215 
(7), 148 (15), 130 (51), 109 (28), 105 (29), 91 (100); HRMS (EI) m/z calcd for C16H24O 
232.1827, found 232.1824.  syn-271: IR (neat) 3391 3026, 2919, 2855, 1496, 1454, 1031 cm-1; 
1H NMR δ 7.47-7.31 (m, 5 H), 3.10-2.82 (m, 3 H), 2.11-2.04 (m, 2 H), 1.71 (s, 1 H), 1.53-1.35 
(m, 6 H), 1.05 (t, 3 H, J = 7.0 Hz), 0.88-0.80 (m, 1 H), 0.78-0.69 (m, 1 H), 0.58 (dt, 1 H, J = 8.8, 
4.4 Hz), 0.45 (dt, 1 H, J = 8.0, 4.7 Hz); 13C NMR δ 142.27, 128.36, 128.33, 125.71, 75.67, 38.75, 
33.32, 32.01, 31.66, 25.76, 2250, 17.01, 14.05, 9.97; EIMS m/z 232 (M+, 2), 214 (6), 130 (25), 
109 (20), 109 (20), 91 (86); HRMS (EI) m/z calcd for C16H24O 232.1827, found 232.1827. 
N3
Ph C4H9
syn-272
N3
Ph C4H9
anti-272
+
 
 3-(S*)-Azido-3-[(1R*,2R*)-2-butylcyclopropyl]propylbenzene (anti-272) and 3-(S*)-
Azido-3-[(1R*,2R*)-2-butylcyclopropyl]propylbenzene (syn-272).  According to a literature 
procedure,  a solution of 68.0 mg (0.293 mmol) of syn-271 in 3 mL of THF was treated with 55.0 
µL (0.349 mmol) of DEAD, 76.0 µL (0.352 mmol) of diphenylphosphoryl azide and 92.0 mg 
(0.351 mmol) of PPh3, stirred at room temperature for 16 h, diluted with Et2O, filtered through a 
pad of Florisil, and concentrated in vacuo.  The residue was chromatographed on SiO2 (9:1, 
hexanes/EtOAc) to yield 64 mg (85%) of 272 as an (inseparable) 78:22 (anti: syn) mixture of 
diastereomers: IR (neat) 3027, 2998, 2922, 2856, 2097, 1496, 1454, 1248, 1031 cm-1; 1H NMR δ 
7.34-7.28 (m, 2 H), 7.23-7.19 (m, 3 H), 2.86-2.63 (m, 3 H), 1.96-1.85 (m, 2 H), 1.49-1.19 (m, 6 
H), 0.93 (t, 3 H, J = 7.1 Hz), 0.87-0.73 (m, 1.78 H), 0.64-0.54 (m, 0.44 H), 0.54-0.43 (m, 0.22 
H), 0.41-0.32 (m, 1.56 H); 13C NMR (major isomer) δ 141.39, 128.39, 128.33, 125.91, 66.54, 
36.42, 33.36, 32.28, 31.30, 22.70, 22.46, 17.80, 13.99, 10.04; EIMS m/z 230 ([M-N2+H]+, 56), 
215 (100), 186 (23), 172 (50), 158 (47), 144 (48), 131 (42), 117 (86), 106 (38); HRMS (EI) m/z 
calcd for C16H23N [M-N2] 229.1831, found 229.1834. 
 According to a literature procedure,  a solution of 76.0 mg (0.327 mmol) of anti-271 in 3 
mL of THF was treated with 62.0 µL (0.394 mmol) of DEAD, 85.0 µL (0.422 mmol) of 
diphenylphosphoryl azide and 103 mg (0.393 mmol) of PPh3, stirred at room temperature for 16 
h, diluted with Et2O, filtered through a pad of SiO2, and concentrated in vacuo.  The residue was 
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 chromatographed on SiO2 (50:1, hexanes/EtOAc) to yield 49 mg (58%) of 272 as an 
(inseparable) 15:85 (anti:syn) mixture of diastereomers. 
 Conversion of anti-272 into 264.  A solution of 77.0 mg (0.299 mmol) of a 78:22 (anti: 
syn) mixture of 272 in 2 mL of THF was treated with 12.0 mg of 10% Pd on activated charcoal, 
stirred under an H2 atmosphere (1 atm) for 12 h, filtered through Celite, and concentrated in 
vacuo.  A solution of the residue in 3 mL of CH2Cl2 was treated with 228 mg (1.20 mmol) of 
TsCl 10.0 mg (0.0819 mmol) of DMAP, and 170 µL (1.75 mmol) of Et3N, stirred at room 
temperature for 16 h, diluted with Et2O, washed with H2O and brine, dried (MgSO4), and 
concentrated in vacuo.  The residue was chromatographed on SiO2 (4:1, hexanes/ EtOAc) to 
yield 76 mg (66%) of 264 as a colorless oil. 
NHP(O)Ph2
Ph C4H9
syn-257  
 Preparation of 257 by Simmons-Smith Cyclopropanation of Allylic Amide 146. N-
{(S*)-[(1R*,2R*)-2-Butylcyclopropyl](phenyl)methyl}-P,P-diphenylphosphinamide (syn-
257).  A solution of 1.50 mL (1.50 mmol) of Et2Zn (1.0 M solution in hexanes) in 4 mL of 
CH2Cl2 was cooled to 0 °C and treated with 250 µL (310 mmol) of CH2I2 and a solution of 289 
mg (0.742 mmol) of phosphinamide 146 in 4 mL of CH2Cl2, stirred at room temperature for 16 
h, quenched with saturated NH4Cl, diluted with EtOAc and saturated NaHCO3, filtered through 
Celite, washed with brine, dried (MgSO4), filtered through a pad of Florisil, and concentrated in 
vacuo.  The residue was chromatographed on deactivated SiO2 (1:4, hexanes/EtOAc, containing 
1% Et3N) to yield 242 mg (81%) of 257 as a 71:29 (anti:syn) mixture of diastereoisomers.  syn-
257 (colorless solid): mp 142-143 °C (EtOAc/hexanes); IR (thin film) 3179, 2959, 2918, 2850, 
1437, 1183, 1124, 725, 696 cm-1; 1H NMR δ 7.96-7.90 (m, 2 H), 7.78-7.72 (m, 2 H), 7.53-7.39 
(m, 4 H), 7.34-7.22 (m, 7 H), 3.65 (t, 1 H, J = 9.2 Hz), 3.31 (bs, 1 H), 1.10-0.97 (m, 6 H), 0.96-
0.88 (m, 1 H), 0.73 (t, 3 H, J = 6.6 Hz), 0.60-0.53 (m, 2 H), 0.32-0.27 (m, 1 H); 13C NMR δ 
132.42, 132.29, 132.10, 131.98, 131.71, 131.56, 128.44, 128.28, 128.13, 127.01, 126.69, 59.67, 
33.15, 31.38, 27.16, 22.18, 18.14, 13.87, 12.64; ESIMS m/z 426 ([M+Na]+, 100), 404 ([M+H]+, 
45); HRMS (ESI) m/z calcd for C26H30NOPNa 426.1963, found 426.1947. 
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 Ph C4H9
syn-263
NHTs
 
 Preparation of 263 by Simmons-Smith Cyclopropanation of Allylic Amide 91. N-
{(S*)-[(1R*,2R*)-2-Butylcyclopropyl]phenylmethyl}-S-(4-methylphenyl)sulfonamide (syn-
263).  A solution of 1.50 mL (1.50 mmol) of Et2Zn (1.0 M solution in hexanes) in 4 mL of 
CH2Cl2 was cooled to 0 °C and treated with 250 µL (310 mmol) of CH2I2 and a solution of 238 
mg (0.693 mmol) of sulfonamide 91 in 4 mL of CH2Cl2, stirred at room temperature for 16 h, 
quenched with saturated NH4Cl, diluted with EtOAc and saturated NaHCO3, filtered through 
Celite, washed with brine, dried (MgSO4), filtered through a pad of Florisil, and concentrated in 
vacuo.  The residue was chromatographed on SiO2 (4:1, hexanes/ EtOAc) to yield 231 mg (93%) 
of 263 as a 81:19 (anti:syn) mixture of diastereoisomers.  syn-263: IR (thin film) 3277, 2957, 
2920, 2852, 1432, 1324, 1160, 1050, 812, 699, 666 cm-1; 1H NMR δ 7.56-7.51 (m, 2 H), 7.17-
7.07 (m, 7 H), 5.06 (d, 1 H, J = 5.6 Hz), 3.66 (dd, 1 H, J = 8.8, 5.7 Hz), 2.35 (s, 3 H), 1.13-0.97 
(m, 6 H), 0.80-0.73 (m, 1 H), 0.70 (t, 3 H, J = 6.9 Hz), 0.63-0.60 (m, 1 H), 0.35 (dt, 1 H, J = 8.6, 
4.9 Hz), 0.26 (dt, 1 H, J = 8.0, 5.1 Hz); 13C NMR δ 142.91, 140.73, 137.66, 129.20, 128.17, 
127.21, 127.11, 126.67, 62.33, 32.95, 31.24, 25.74, 22.12, 21.44, 18.01, 13.92, 11.65; EIMS m/z 
357 (M+, 1), 273 (53), 260 (38), 160 (49), 155 (46), 129 (22), 118 (63), 104 (37), 91 (100); 
HRMS (EI) m/z calcd for C21H27NO2S 357.1763, found 357.1751. 
OH
Ph C4H9
33  
 Attempted preparation of (2-butylcyclopropyl)phenylmethanol. (E)-1-Phenylhept-2-
en-1-ol (33).  A suspension of 390 mg (1.51 mmol) of Cp2ZrHCl in 3 mL of CH2Cl2 was treated 
at room temperature with 190 µL (1.65 mmol) of 1-hexyne.  After 5 min, the yellow solution 
was cooled to -78 °C, treated with 750 µL (1.50 mmol) of Me2Zn (2.0 M solution in toluene), 
warmed to room temperature over a period of 5 min, treated with 50.0 µL (0.492 mmol) of 
PhCHO, heated at reflux for 48 h, quenched with saturated NH4Cl, diluted with EtOAc, filtered 
through Celite, washed with H2O and brine, dried (MgSO4), filtered through a pad of Florisil and 
concentrated in vacuo.  The residue was chromatographed on SiO2 (4:1, hexanes/EtOAc) to yield 
84 mg (90%) of 33 as a colorless oil: 1H NMR δ 7.37-7.25 (m, 5 H), 5.77 (dt, 1 H, J = 15.4, 6.4 
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 Hz), 5.65 (dd, 1 H, J = 15.4, 6.4 Hz), 5.14 (d, 1 H, J = 6.3 Hz), 2.15 (s, 1 H), 2.09-2.03 (m, 2 H), 
1.43-1.29 (m, 4 H), 0.90 (t, 3 H, J = 7.0 Hz).   
 Attempted preparation of 266 using a B-Zn transmetalation.  A solution of 190 µL 
(1.67 mmol) of 3-hexyne in 2.5 mL of CH2Cl2 was cooled to 0 °C, and treated with 500 µL 
(0.500 mmol) of borane (1.0 M solution in THF).  The mixture was stirred at 0 °C for 1 h, treated 
with 750 µL (1.50 mmol) of Me2Zn (2.0 M solution in toluene), warmed to room temperature, 
treated with a solution of 152 mg (0.498 mmol) of imine 104 in 1 mL of CH2Cl2, heated at reflux 
for 16 h, quenched with saturated NH4Cl, diluted with EtOAc, filtered through Celite, washed 
with H2O, saturated NaHCO3 and brine, dried (MgSO4), filtered through a pad of Florisil and 
concentrated in vacuo.  The residue was chromatographed on deactivated SiO2 (1:4, hexanes/ 
EtOAc containing 1% Et3N) to yield 96 mg (50%) of 147. 
Ph2(O)PNH
Ph C4H9
276  
 Attempted preparation of 278 using an Al-Zn transmetalation. (E)-N-(3-Methyl-1-
phenylhept-2-enyl)-P,P-diphenylphosphinamide (276).  A suspension of 15.0 mg (0.0513 
mmol) of Cp2ZrCl2 in 5 mL of CH2Cl2 was treated at 0 °C with 208 mg (2.89 mmol) of Me3Al, 
27.0 µL (1.50 mmol) of H2O, and 175 µL (1.52 mmol) of 1-hexyne.  The mixture was stirred at 0 
°C for 30 min, cooled to -78 °C, treated with 750 µL (1.50 mmol) of Me2Zn, warmed to room 
temperature, treated with a solution of 153 mg (0.501 mmol) of imine 104 in 1 mL of CH2Cl2, 
heated at reflux for 12 h, cooled to room temperature, quenched with saturated NaHCO3, diluted 
with EtOAc, filtered through Celite, washed with 2 N HCl, H2O and brine, dried (MgSO4), 
filtered through Florisil, and concentrated in vacuo.  The residue was chromatographed on 
deactivated SiO2 (1:4, hexanes/EtOAc, containing 1% Et3N) to yield 109 mg (54%) of 276 as a 
colorless oil: IR (thin film) 3057, 2957, 2927, 1669, 1437, 1185, 1126, 753, 724, 696 cm-1; 1H 
NMR δ 7.98-7.91 (m, 2 H), 7.88-7.81 (m, 2 H), 7.50-7.17 (m, 11 H), 5.34 (dd, 1 H, J = 9.3, 1.2 
Hz), 5.05 (q, 1 H, J = 9.0 Hz), 3.25 (t, 1 H, J = 7.2 Hz), 1.91 (t, 2 H, J = 7.0 Hz), 1.37 (d, 3 H, J 
= 1.3 Hz), 1.35-1.21 (m, 4 H), 0.88 (t, 3 H, J = 7.0 Hz); 13C NMR δ 143.72, 143.65, 137.41, 
133.81, 133.65, 132.55, 132.42, 132.11, 131.92, 131.79, 131.58, 128.43, 128.30, 128.22, 128.13, 
126.94, 126.74, 126.21, 126.15, 52.81, 39.12, 30.47, 29.74, 22.40, 16.22, 13.94; EIMS m/z 403 
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 (M+, 1), 346 (1), 306 (2), 216 (82), 201 (35), 199 (66), 140 (46), 124 (58), 105 (46), 77 (100); 
HRMS (EI) m/z calcd for C26H30NOP 403.2065, found 403.2067. 
 Preparation of 276 using the General Protocol A.  A suspension of 15.0 mg (0.0513 
mmol) of Cp2ZrCl2 in 5 mL of toluene was treated at 0 °C with 210 mg (2.91 mmol) of Me3Al, 
27.0 µL (1.50 mmol) of H2O, and 175 µL (1.52 mmol) of 1-hexyne.  The mixture was stirred at 0 
°C for 30 min, treated with 750 µL (1.50 mmol) of Me2Zn, warmed to room temperature, 
cannulated into a suspension of 153 mg (0.501 mmol) of imine 104 in 1 mL of toluene, stirred at 
room temperature for 6 h, quenched with saturated NaHCO3, diluted with EtOAc, filtered 
through Celite, washed with H2O and brine, dried (MgSO4), filtered through Florisil, and 
concentrated in vacuo.  The residue was chromatographed on deactivated SiO2 (1:4, hexanes/ 
EtOAc, containing 1% Et3N) to yield 147 mg (73%) of 276 as a colorless oil. 
Ph2(O)PNH
Ph C4H9
278  
 N-{(S*)-[(1R*,2R*)-2-Butyl-2-methyl-cyclopropyl](phenyl)methyl}-P,P-diphenyl-
phosphinamide (278).  A suspension of 15.0 mg (0.0513 mmol) of Cp2ZrCl2 in 5 mL of CH2Cl2 
was treated at 0 °C with 208 mg (2.89 mmol) of Me3Al, 27.0 µL (1.50 mmol) of H2O, and 175 
µL (1.52 mmol) of 1-hexyne.  The mixture was stirred at 0 °C for 30 min, cooled to -78 °C, 
treated with 750 µL (1.50 mmol) of Me2Zn, warmed to room temperature, treated with a solution 
of 153 mg (0.501 mmol) of imine 104 in 1 mL of CH2Cl2, heated at reflux for 4 h, cooled to 
room temperature, treated with 200 µL (2.48 mmol) of CH2I2, heated at reflux for 12 h, cooled to 
room temperature, quenched with saturated NaHCO3, diluted with EtOAc, filtered through 
Celite, washed with H2O and brine, dried (MgSO4), filtered through Florisil, and concentrated in 
vacuo.  The residue was chromatographed on deactivated SiO2 (1:4, hexanes/EtOAc, containing 
1% Et3N) to yield 59 mg (28%) of 278 as an 88:12 (syn:anti) mixture of diastereomers, and 94 
mg (46%) of 276 as a colorless oil.  278 (colorless solid): mp 116-118 °C (EtOAc/hexanes); IR 
(KBr) 3189, 3059, 2953, 2923, 2871, 1435, 1186, 1124, 1107, 1065, 931, 749, 723, 698 cm-1; 1H 
NMR δ 7.93-7.86 (m, 2 H), 7.77-7.69 (m, 2 H), 7.47-7.34 (m, 5 H), 7.31-7.14 (m, 6 H), 3.81 (q, 
1 H, J = 9.3 Hz), 3.35 (t, 1 H, J = 7.8 Hz), 1.25-0.95 (m, 7 H), 0.81 (s, 3 H), 0.73 (t, 3 H, J = 6.8 
Hz), 0.47 (dd, 1 H, J = 8.4, 4.8 Hz), 0.31 (t, 1 H, J = 5.1 Hz); 13C NMR δ 144.57, 144.50, 
134.35, 133.38, 132.65, 132.24, 132.13, 132.02, 131.56, 131.44, 128.26, 128.13, 128.04, 126.86, 
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 126.70, 56.76, 40.63, 32.10, 28.39, 22.61, 21.79, 19.68, 17.81, 13.94; EIMS m/z 417 (M+, 6), 374 
(7), 319 (31), 306 (64), 218 (45), 201 (100), 129 (31), 106 (34), 91 (44), 77 (65); HRMS (EI) m/z 
calcd for C27H32NOP 417.2222, found 417.2222. 
 Preparation of 278 using a modified General Protocol C (no Al-Zn transmetalation). 
A suspension of 15.0 mg (0.0513 mmol) of Cp2ZrCl2 in 5 mL of toluene was treated at 0 °C with 
210 mg (2.91 mmol) of Me3Al, 27.0 µL (1.50 mmol) of H2O, and 175 µL (1.52 mmol) of 1-
hexyne.  The mixture was stirred at 0 °C for 30 min, warmed to room temperature, cannulated 
into a suspension of 153 mg (0.501 mmol) of imine 104 in 1 mL of toluene, stirred at room 
temperature for 7 h, and treated with 320 µL (4.05 mmol) of CH2I2, stirred at room temperature 
for 12 h, quenched with saturated NaHCO3, diluted with EtOAc, filtered through Celite, washed 
with H2O and brine, dried (MgSO4), filtered through Florisil, and concentrated in vacuo.  The 
residue was chromatographed on deactivated SiO2 (1:4, hexanes/EtOAc, containing 1% Et3N) to 
yield 99 mg (47%) of 278 as an 90:10 (syn:anti) mixture of diastereomers, and 64 mg (32%) of 
276 as a colorless oil. 
 Preparation of 278 by Simmons-Smith Cyclopropanation of Allylic Amide 276.  A 
solution of 147 mg (0.364 mmol) of phosphinamide 276 in 4 mL of CH2Cl2 was cooled to 0 °C 
and treated with 180 µL (2.23 mmol) of CH2I2 and 1.00 mL (1.10 mmol) of Et2Zn (1.1 M 
solution in toluene), stirred at room temperature for 16 h, quenched with saturated NaHCO3, 
diluted with EtOAc, filtered through Celite, washed with H2O and brine, dried (MgSO4), filtered 
through Florisil, and concentrated in vacuo.  The residue was chromatographed on SiO2 (3:7, 
hexanes/EtOAc) to yield 86 mg (57%) of 278 as a colorless solid, and 21 mg (14%) of phosphin-
amide 276 was recovered. 
Ph
NHP(O)Ph2
C4H9
syn-279
Ph
NHP(O)Ph2
C4H9
anti-279
+
 
 N-[(1S*,2R*)-2-Butyl-1-phenylbut-3-enyl]-P,P-diphenylphosphinamide (syn-279) 
and N-[(1S*,2S*)-2-butyl-1-phenylbut-3-enyl]-P,P-diphenylphosphinamide (anti-279).  
General Protocol D.  A suspension of 195 mg (0.756 mmol) of Cp2ZrHCl in 2 mL of CH2Cl2 
was treated at room temperature with 95.0 µL (0.827 mmol) of 1-hexyne.  After 5 min, the 
yellow solution was cooled to -78 °C, treated with 560 µL (1.12 mmol) of Me2Zn (2.0 M 
solution in toluene), and warmed to room temperature over a period of 5 min.  The mixture was 
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 treated with 60.0 µL (0.745 mmol) of CH2I2, stirred for 2 min, treated with a solution of 76.0 mg 
(0.249 mmol) of imine 104 in 1 mL of CH2Cl2, stirred at room temperature for 12 h, quenched 
with saturated NH4Cl, diluted with EtOAc and saturated NaHCO3, filtered through Celite, 
washed with H2O and brine, dried (MgSO4), filtered through a pad of Florisil and concentrated in 
vacuo.  The residue was chromatographed on deactivated SiO2 (1:9, hexanes/EtOAc containing 
1% Et3N) to yield 71 mg (71%) of 279 as an 85:15 mixture of diastereomers.  syn-279 (colorless 
solid): mp 158-159 °C (EtOAc/hexane); IR (KBr) 3221, 3059, 2951, 2914, 2858, 1436, 1185, 
1123, 1108, 1068, 919, 723, 702, 692 cm-1; 1H NMR δ 7.90-7.83 (m, 2 H), 7.73-7.65 (m, 2 H), 
7.54-7.38 (m, 4 H), 7.32-7.24 (m, 5 H), 7.07-7.04 (m, 2 H), 5.43 (dt, 1 H, J = 17.2, 9.7 Hz), 5.25 
(dd, 1 H, J = 17.5, 2.2 Hz), 5.21 (dd, 1 H, J = 9.8, 2.4 Hz), 4.23 (td, 1 H, J = 11.2, 4.6 Hz), 3.75 
(dd, 1 H, J = 10.8, 6.5 Hz), 2.59 (tt, 1 H, J = 10.0, 4.2 Hz), 1.47-1.38 (m, 1 H), 1.33-1.13 (m, 4 
H), 1.02-0.86 (m, 1 H), 0.83 (t, 3 H, J = 6.7 Hz); 13C NMR δ 140.89, 140.82, 137.80, 134.13, 
132.68, 132.61, 132.55, 132.45, 131.76, 131.72, 131.66, 131.57, 131.53, 130.86, 128.51, 128.35, 
128.16, 128.00, 127.71, 127.61, 126.85, 119.07, 57.72, 52.11, 52.07, 31.65, 29.57, 22.53, 13.98; 
EIMS m/z 403 (M+, 1), 306 (100), 201 (98), 77 (22); HRMS (EI) m/z calcd for C26H30NOP 
403.2065, found 403.2068.  anti-279 (colorless solid): mp 160-161 °C (EtOAc/ hexane); IR 
(KBr) 3181, 2953, 2928, 2852, 1435, 1180, 1126, 1109, 915, 745, 726, 696 cm-1; 1H NMR δ 
7.87-7.80 (m, 2 H), 7.70-7.62 (m, 2 H), 7.54-7.34 (m, 4 H), 7.30-7.19 (m, 5 H), 7.13-7.09 (m, 2 
H), 5.72 (ddd, 1 H, J = 17.2, 10.3, 8.8 Hz), 5.25 (dd, 1 H, J = 10.3, 1.9 Hz), 5.11 (ddd, 1 H, J = 
17.2, 1.8, 0.7 Hz), 4.14 (dt, 1 H, J = 10.1, 7.4 Hz), 3.45 (t, 1 H, J = 6.1 Hz), 2.40-2.31 (m, 1 H), 
1.35-1.09 (m, 6 H), 0.81 (t, 3 H, J = 6.6 Hz); 13C NMR δ 142.78, 142.74, 139.25, 132.72, 132.57, 
132.44, 132.34, 131.78, 131.73, 131.70, 131.66, 131.42, 131.39, 130.98, 128.48, 128.32, 128.04, 
128.00, 127.87, 127.74, 127.65, 127.28, 126.86, 118.09, 58.13, 51.86, 51.79, 30.31, 29.39, 22.45, 
13.97; EIMS m/z 404 ([M+H]+, 3), 306 (100), 201 (96), 77 (67); HRMS (EI) m/z calcd for 
C26H31NOP [M+H] 404.2143, found 404.2142. 
Ph
Et
syn-280
EtPh2(O)PNH
Ph
Et
anti-280
EtPh2(O)PNH
+
 
 N-[(1S*,2R*)-2,3-Diethyl-1-phenylbut-3-enyl]-P,P-diphenylphosphinamide (syn-280) 
and N-[(1S*,2S*)-2,3-diethyl-1-phenylbut-3-enyl]-P,P-diphenylphosphinamide (anti-280).  
According to the General Protocol D, 387 mg (1.50 mmol) of Cp2ZrHCl, 190 µL (1.65 mmol) of 
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 3-hexyne, 1.25 mL (2.50 mmol) of Me2Zn (2.0 M solution in toluene), 120 µL (1.49 mmol) of 
CH2I2, and 153 mg (0.501 mmol) of imine 104 (24 h reaction time) afforded 99 mg (49%) of 280 
as a 75:25 mixture of diastereomers.  syn-280 (colorless solid): mp 166-167 °C (EtOAc/hexane); 
IR (KBr) 3121, 2962, 2920, 2872, 2846, 1435, 1183, 1123, 1110, 1061, 897, 749, 726, 694 cm-1; 
1H NMR δ 7.84-7.77 (m, 2 H), 7.67-7.61 (m, 2 H), 7.51-7.37 (m, 4 H), 7.29-7.17 (m, 5 H), 7.02-
6.99 (m, 2 H), 4.79 (s, 1 H), 4.72 (s, 1 H), 4.12 (q, 1 H, J = 9.6 Hz), 3.39 (t, 1 H, J = 8.8 Hz), 
2.34 (ddd, 1 H, J = 11.3, 7.9, 3.5 Hz), 2.00 (dqd, 1 H, J = 14.7, 7.4, 3.6 Hz), 1.65 (dq, 1 H, J = 
14.8, 7.4 Hz), 1.57-1.42 (m, 2 H), 0.84 (t, 3 H, J = 7.3 Hz), 0.80 (t, 3 H, J = 7.3 Hz); 13C NMR δ 
149.63, 142.89, 142.84, 133.98, 132.74, 132.61, 132.29, 131.80, 131.77, 131.74, 131.68, 131.58, 
131.54, 130.95, 128.49, 128.32, 128.15, 127.98, 127.78, 127.10, 126.68, 111.66, 58.61, 56.82, 
56.76, 26.35, 23.12, 12.10, 11.54; EIMS m/z 404 ([M+H]+, 1), 306 (100), 201 (93), 77 (86); 
HRMS (EI) m/z calcd for C26H30NOP 403.2065, found 403.2052.  anti-280 (colorless solid): mp 
164-165 °C (EtOAc/hexane); IR (KBr) 3197, 2961, 2932, 2873, 1436, 1185, 1124, 1109, 747, 
725, 695 cm-1; 1H NMR δ 7.77-7.69 (m, 2 H), 7.60-7.53 (m, 2 H), 7.51-7.27 (m, 4 H), 7.20-7.04 
(m, 7 H), 5.04 (s, 1 H), 4.96 (s, 1 H), 4.14 (td, 1 H, J = 9.2, 6.2 Hz), 3.60-3.50 (m, 1 H), 2.29 
(ddd, 1 H, J = 10.7, 8.8, 4.2 Hz), 2.05 (dq, 1 H, J = 14.7, 7.4 Hz), 1.84 (dq, 1 H, J = 14.6, 7.3 
Hz), 1.32 (ddq, 1 H, J = 14.0, 10.8, 7.3 Hz), 1.16 (dqd, 1 H, J = 14.2, 7.4, 4.4 Hz), 1.07 (t, 3 H, J 
= 7.3 Hz), 0.69 (t, 3 H, J = 7.4 Hz); 13C NMR δ 150.73, 143.11, 134.08, 132.58, 132.45, 131.68, 
131.65, 131.50, 131.37, 131.23, 130.79, 128.46, 128.29, 127.93, 127.89, 127.72, 127.46, 126.84, 
112.49, 57.69, 57.60, 56.88, 24.31, 22.98, 12.09, 11.64; EIMS m/z 403 (M+, 1), 306 (100), 201 
(62), 91 (12), 77 (19); HRMS (EI) m/z calcd for C26H30NOP 403.2065, found 403.2076. 
Ph
NHP(O)Ph2
OBDPS
syn-281  
 N-{(1S*,2R*)-2-[2-(tert-Butyldiphenylsilyl)oxyethyl]-1-phenylbut-3-enyl}-P,P-
diphenylphosphinamide (syn-281).  According to the General Protocol D, 387 mg (1.50 mmol) 
of Cp2ZrHCl, 510 mg (1.65 mmol) of alkyne 148, 1.25 mL (2.50 mmol) of Me2Zn (2.0 M 
solution in toluene), 120 µL (1.49 mmol) of CH2I2, and 153 mg (0.501 mmol) of imine 104 (12 h 
reaction time) afforded 227 mg (72%) of 281 as an 85:15 mixture of diastereomers.  syn-281 
(colorless oil): IR (neat) 3196, 3070, 2930, 2857, 1438, 1428, 1191, 1110, 726, 700 cm-1; 1H 
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 NMR δ 7.96-7.88 (m, 2 H), 7.80-7.72 (m, 2 H), 7.72-7.67 (m, 4 H), 7.57-7.30 (m, 14 H), 7.12-
7.09 (m, 2 H), 5.47 (dt, 1 H, J = 17.2, 9.7 Hz), 5.22 (dd, 1 H, J = 17.3, 2.2 Hz), 5.20 (dd, 1 H, J = 
9.8, 2.2 Hz), 4.26 (td, 1 H, J = 10.8, 5.1 Hz), 3.75 (dd, 1 H, J = 10.7, 6.9 Hz), 3.70-3.63 (m, 2 H), 
2.89-2.80 (m, 1 H), 1.92 (dtd, 1 H, J = 13.4, 7.9, 3.3 Hz), 1.34-1.15 (m, 1 H), 1.10 (s, 9 H); 13C 
NMR δ 141.02, 140.96, 137.22, 135.49, 135.46, 133.94, 133.76, 133.71, 132.78, 132.54, 132.41, 
132.24, 131.75, 131.62, 131.57, 131.05, 129.45, 128.50, 128.34, 128.19, 128.02, 127.80, 127.52, 
126.89, 119.12, 61.73, 57.91, 48.28, 48.22, 34.54, 26.80, 19.08; EIMS m/z 628 ([M-H]+, 1), 572 
(48), 306 (100), 201 (75); HRMS (EI) m/z calcd for C36H35NO2PSi [M-C4H9] 572.2175, found 
572.2174. 
Ph
NHP(O)Ph2
CO2TIPS
syn-282
Ph
NHP(O)Ph2
CO2TIPS
anti-282
+
 
 (4R*)-O-Triisopropylsilyl-4-{(S*)-[(diphenylphosphinyl)amino](phenyl)methyl}hex-
5-enoate (syn-282) and (4S*)-O-triisopropylsilyl-4-{(S*)-[(diphenylphosphinyl)amino]-
(phenyl)methyl}hex-5-enoate (anti-282).  A solution of 324 mg (3.30 mmol) of 4-pentynoic 
acid in 6 mL of CH2Cl2 was treated with 710 µL (3.32 mmol) of TIPS-Cl and 225 mg (3.30 
mmol) of imidazole, stirred at room temperature for 1 h, washed with H2O and brine, dried 
(MgSO4) and concentrated in vacuo.  The residue was dissolved in 1 mL of CH2Cl2, transferred 
into a suspension of 780 mg (3.02 mmol) of Cp2ZrHCl in 2 mL of CH2Cl2, strirred for 5 min and 
concentrated in vacuo.  A solution of the residue in 3 mL of toluene was cooled to -78 °C, treated 
with 1.50 mL (3.00 mmol) of Me2Zn (2.0 M solution in toluene), warmed to room temperature 
over a period of 5 min, treated with 400 µL (4.97 mmol) of CH2I2, stirred for 2 min, cannulated 
into a suspension of 305 mg (1.00 mmol) of imine 104 in 1 mL of toluene, stirred at room 
temperature for 6 h, quenched with saturated NH4Cl, diluted with EtOAc and saturated NaHCO3, 
filtered through Celite, washed with H2O and brine, dried (MgSO4), filtered through a pad of 
Florisil and concentrated in vacuo.  The residue was chromatographed on deactivated SiO2 (1:4, 
hexanes/EtOAc containing 1% Et3N) to yield 278 mg (48%) of 282 as a 62:38 mixture of 
diastereomers.  syn-282 (colorless oil): IR (neat) 3187, 2945, 2867, 1716, 1456, 1438, 1189, 
1124, 1110, 1070, 918, 884, 751, 726, 700 cm-1; 1H NMR δ 7.85-7.78 (m, 2 H), 7.69-7.62 (m, 2 
H), 7.50-7.39 (m, 4 H), 7.36-7.22 (m, 5 H), 7.03-7.00 (m, 2 H), 5.39 (dt, 1 H, J = 17.3, 9.6 Hz), 
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 5.24-5.17 (m, 2 H), 4.18 (td, 1 H, J = 11.0, 5.1 Hz), 3.76 (dd, 1 H, J = 10.8, 6.4 Hz), 2.63-2.52 
(m, 1 H), 2.30-2.24 (m, 2 H), 1.93-1.87 (m, 1 H), 1.29-1.14 (m, 4 H), 1.02 (d, 18 H, J = 7.3 Hz); 
13C NMR δ 173.37, 140.50, 136.67, 133.92, 132.64, 132.51, 132.23, 131.72, 131.59, 131.46, 
130.70, 128.49, 128.32, 128.17, 128.00, 127.85, 127.42, 126.99, 120.03, 57.97, 51.63, 33.56, 
27.25, 17.67, 11.75; EIMS m/z 575 (M+, 1), 532 (46), 306 (100), 201 (91); HRMS (EI) m/z calcd 
for C34H46NO3PSi 575.2985, found 575.2999.  anti-282 (colorless oil): IR (neat) 2924, 2863, 
1712, 1439, 1416, 1185, 1161, 1124, 1109, 1069, 997, 920, 883, 753, 724, 698 cm-1; 1H NMR δ 
7.92-7.85 (m, 2 H), 7.75-7.68 (m, 2 H), 7.57-7.42 (m, 4 H), 7.35-7.24 (m, 5 H), 7.18-7.15 (m, 2 
H), 5.73 (ddd, 1 H, J = 17.1, 10.2, 9.0 Hz), 5.34 (dd, 1 H, J = 10.3, 1.7 Hz), 5.19 (dd, 1 H, J = 
17.2, 1.1 Hz), 4.21 (dt, 1 H, J = 10.1, 7.9 Hz), 3.53 (dd, 1 H, J = 8.4, 6.0 Hz), 2.52-2.22 (m, 3 H), 
1.79-1.75 (m, 1 H), 1.65-1.59 (m, 1 H), 1.37-1.25 (m, 3 H), 1.09 (d, 18 H, J = 7.3 Hz); 13C NMR 
δ 173.33, 142.08, 142.04, 138.24, 133.93, 132.68, 132.55, 132.42, 132.24, 131.75, 131.62, 
131.47, 130.95, 128.50, 128.33, 128.10, 127.91, 127.23, 127.03, 118.97, 58.30, 51.25, 51.17, 
33.44, 25.98, 17.72, 11.81; EIMS m/z 575 (M+, 1), 532 (12), 306 (100), 201 (78); HRMS (EI) 
m/z calcd for C34H46NO3PSi 575.2985, found 575.2995. 
NHP(O)Ph2
OBDPS
MeO2C
syn-283  
 Methyl 4-[(1S*,2R*)-2-[2-(tert-butyldiphenylsilyl)oxyethyl]-1-(diphenylphosphinyl-
amino)-but-3-enyl]benzoate (syn-283).  According to the General Protocol D, 195 mg (0.756 
mmol) of Cp2ZrHCl, 255 mg (0.827 mmol) of alkyne 148, 500 µL (1.00 mmol) of Me2Zn (2.0 M 
solution in toluene), 100 µL (1.24 mmol) of CH2I2, and 91.0 mg (0.250 mmol) of imine 156 (12 
h reaction time) afforded 118 mg (69%) of 283 as an 85:15 mixture of diastereomers.  syn-283 
(colorless oil): IR (neat) 3191, 3071, 2952, 2931, 2857, 1721, 1437, 1282, 1190, 1110, 911, 728, 
702 cm-1; 1H NMR δ 8.00 (d, 2 H, J = 8.3 Hz), 7.94-7.87 (m, 2 H), 7.77-7.65 (m, 6 H), 7.62-7.31 
(m, 12 H), 7.17 (d, 2 H, J = 8.3 Hz), 5.40 (dt, 1 H, J = 17.9, 9.3 Hz), 5.21-5.15 (m, 2 H), 4.31 (td, 
1 H, J = 10.6, 5.4 Hz), 4.01 (s, 3 H), 3.76 (dd, 1 H, J = 10.6, 6.9 Hz), 3.71-3.61 (m, 2 H), 2.89-
2.79 (m, 1 H), 1.92 (dtd, 1 H, J = 13.3, 8.0, 3.2 Hz), 1.30-1.18 (m, 1 H), 1.09 (s, 9 H); 13C NMR 
δ 167.06, 146.68, 146.62, 136.96, 135.66, 135.63, 133.84, 133.78, 133.75, 132.76, 132.61, 
132.48, 132.05, 131.91, 131.79, 131.03, 129.69, 129.33, 128.96, 128.76, 128.60, 128.44, 128.27, 
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 127.73, 119.70, 61.74, 57.87, 52.23, 48.34, 48.28, 34.62, 26.97, 19.24; EIMS m/z 688 ([M+H]+, 
1), 630 (80), 398 (19), 364 (100), 201 (99), 183 (33), 135 (46), 77 (70); HRMS (EI) m/z calcd for 
C42H45NO4PSi [M-H] 686.2856, found 686.2840. 
NHP(O)Ph2
C4H9
syn-284
MeO
 
 N-[(1S*,2R*)-2-Butyl-1-(4-methoxyphenyl)but-3-enyl]-P,P-diphenylphosphinamide 
(syn-284).  According to the General Protocol D, 390 mg (1.51 mmol) of Cp2ZrHCl, 190 µL 
(1.65 mmol) of 1-hexyne, 1.00 mL (2.00 mmol) of Me2Zn (2.0 M solution in toluene), 200 µL 
(2.48 mmol) of CH2I2, and 168 mg (0.501 mmol) of imine 158 (12 h reaction time) afforded 169 
mg (79%) of 284 as an 83:17 mixture of diastereomers.  syn-284 (colorless solid): mp 155-156 
°C (Et2O/hexane); IR (KBr) 3218, 2956, 2916, 2857, 1516, 1436, 1252, 1183, 1123, 1108, 1072, 
909, 825, 748, 724, 694 cm-1; 1H NMR δ 7.94-7.86 (m, 2 H), 7.79-7.72 (m, 2 H), 7.56-7.44 (m, 4 
H), 7.38-7.31 (m, 2 H), 7.03 (d, 2 H, J = 8.7 Hz), 6.87 (d, 2 H, J = 8.7 Hz), 5.48 (dt, 1 H, J = 
17.3, 9.7 Hz), 5.29 (dd, 1 H, J = 17.2, 2.5 Hz), 5.25 (dd, 1 H, J = 9.7, 2.5 Hz), 4.23 (td, 1 H, J = 
11.1, 4.5 Hz), 3.88 (s, 3 H), 3.74 (dd, 1 H, J = 10.8, 6.4 Hz), 2.61 (tt, 1 H, J = 9.9, 4.2 Hz), 1.51-
1.40 (m, 1 H), 1.32-1.18 (m, 4 H), 1.07-0.96 (m, 1 H), 0.88 (t, 3 H, J = 6.7 Hz); 13C NMR δ 
158.38, 137.92, 134.19, 133.09, 133.02, 132.77, 132.65, 132.52, 131.68, 131.65, 131.52, 131.49, 
131.02, 128.59, 128.47, 128.31, 128.15, 127.98, 118.94, 113.05, 57.17, 55.14, 52.19, 52.15, 
31.69, 29.53, 22.53, 13.96; FABMS m/z 456 ([M+Na]+, 5), 434 ([M+H]+, 28), 336 (20), 202 
(17), 122 (100); HRMS (CI) m/z calcd for C27H33NO2P [M+H] 434.2249, found 434.2227. 
Ph
NHTs
OBDPS
syn-285
Ph
NHTs
OBDPS
anti-285
+
 
 N-{(1S*,2R*)-2-[2-(tert-Butyldiphenylsilyl)oxyethyl]-1-phenylbut-3-enyl}-S-(4-
methylphenyl)sulfonamide (syn-285) and N-{(1S*,2S*)-2-[2-(tert-butyldiphenylsilyl)oxy-
ethyl]-1-phenylbut-3-enyl}-S-(4-methylphenyl)sulfonamide (anti-285).  According to the 
General Protocol D, 390 mg (1.51 mmol) of Cp2ZrHCl, 510 mg (1.65 mmol) of alkyne 148, 750 
µL (1.50 mmol) of Me2Zn (2.0 M solution in toluene), 200 µL (2.48 mmol) of CH2I2, and 130 
mg (0.501 mmol) of imine 90 (2 h reaction time) afforded 238 mg (81%) of 285 as an 
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 (inseparable) 60:40 mixture of diastereomers: IR (neat) 3280, 3070, 2930, 2857, 1428, 1326, 
1162, 1111, 1093, 736, 702, 667 cm-1; 1H NMR δ 7.72-7.35 (m, 12 H), 7.25-7.11 (m, 6 H), 7.01-
6.98 (m, 1 H), 5.56-5.07 (m, 4 H), 4.46 (dd, 0.6 H, J = 8.6, 5.5 Hz), 4.22 (dd, 0.4 H, J = 8.3, 5.3 
Hz), 3.70-3.55 (m, 2 H), 2.75-2.64 (m, 1 H), 2.41 (s, 1.2 H), 2.39 (s, 1.8 H), 1.90-1.80 (m, 0.6 
H), 1.57-1.47 (m, 0.4 H), 1.44-1.19 (m, 1 H), 1.11 (s, 5.4 H), 1.07 (s, 3.6 H); 13C NMR δ 142.74, 
139.30, 138.03, 137.71, 137.61, 137.40, 136.52, 135.49, 135.42, 133.62, 129.57, 129.50, 129.14, 
129.02, 128.07, 127.80, 127.61, 127.58, 127.54, 127.23, 127.08, 127.04, 126.88, 119.67, 119.18, 
61.19, 60.78, 60.71, 60.57, 46.77, 46.33, 33.90, 33.25, 26.81, 26.75, 21.38, 19.10; EIMS m/z 526 
([M-C4H9]+, 42), 352 (83), 260 (96), 199 (68), 155 (68), 135 (46), 91 (100); HRMS (EI) m/z 
calcd for C31H32NO3SSi [M-C4H9] 526.1872, found 526.1869. 
NHTs
OBDPS
Ph
syn-286  
 N-{(1S*,2R*)-2-[2-(tert-Butyldiphenylsilyl)oxyethyl]-1-phenethylbut-3-enyl}-S-(4-
methylphenyl)sulfonamide (syn-286).  According to the General Protocol D, 195 mg (0.756 
mmol) of Cp2ZrHCl, 255 mg (0.827 mmol) of alkyne 148, 500 µL (1.00 mmol) of Me2Zn (2.0 M 
solution in toluene), 100 µL (1.24 mmol) of CH2I2, and 72.0 mg (0.251 mmol) of imine 166 (4 h 
reaction time) afforded 134 mg (87%) of syn-286 as a colorless oil: IR (thin film) 3280, 2930, 
2857, 1428, 1327, 1160, 1111, 1094, 912, 816, 737, 702, 665 cm-1; 1H NMR δ 7.84 (d, 2 H, J = 
8.3 Hz), 7.80-7.70 (m, 5 H), 7.54-7.45 (m, 6 H), 7.39-7.25 (m, 4 H), 7.20-7.15 (m, 2 H), 5.50 (dt, 
1 H, J = 17.0, 9.9 Hz), 5.15 (dd, 1 H, J = 10.1, 1.9 Hz), 4.95 (dd, 1 H, J = 17.0, 1.8 Hz), 4.72 (d, 
1 H, J = 9.7 Hz), 3.67-3.38 (m, 3 H), 2.84-2.71 (m, 1 H), 2.60-2.49 (m, 1 H), 2.44 (s, 3 H), 2.28-
2.20 (m, 1 H), 1.92-1.81 (m, 1 H), 1.73-1.64 (m, 1 H), 1.61-1.32 (m, 2 H), 1.13 (s, 9 H); 13C 
NMR δ 143.17, 141.63, 138.51, 136.86, 135.48, 135.46, 133.64, 129.60, 128.35, 128.31, 127.60, 
126.93, 125.84, 119.03, 61.65, 56.96, 44.89, 33.95, 32.88, 32.01, 26.80, 21.45, 19.08; EIMS m/z 
554 ([M-C4H9]+, 66), 352 (46), 288 (70), 199 (67), 155 (31), 135 (37), 117 (69), 91 (100); 
HRMS (EI) m/z calcd for C27H32NO2P [M-C4H9] 554.2185, found 554.2188. 
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O Ph
anti-287  
 (5R*,6S*)-6-Phenyl-5-vinylpiperidin-2-one (anti-287).  A solution of 92.0 mg (0.160 
mmol) of syn-282 in 5 mL of a 1 N solution of HCl(g) in MeOH was stirred at room temperature 
for 12 h and concentrated in vacuo.  The residue was dissolved in 3 mL of CH2Cl2, treated with 
220 µL (1.58 mmol) of Et3N and 75.0 µL (0.494 mmol) of diethyl cyanophosphonate, stirred for 
16 h, filtered through a pad of Florisil and concentrated in vacuo.  The residue was purified by 
preparative TLC (EtOAc) to yield 18 mg (56%) of anti-287 as a colorless solid: mp 131-132 °C 
(Et2O/hexane); IR (KBr) 3171, 3070, 2883, 1647, 1400, 1004, 917, 760, 702 cm-1; 1H NMR δ 
7.38-7.22 (m, 5 H), 5.72 (bs, 1 H), 5.62 (ddd, 1 H, J = 17.3, 10.4, 7.1 Hz), 4.99 (d, 1 H, J = 10.4 
Hz), 4.91 (d, 1 H, J = 17.2 Hz), 4.22 (d, 1 H, J = 9.3 Hz), 2.57-2.38 (m, 3 H), 2.03-1.95 (m, 1 H), 
1.90-1.79 (m, 1 H); 13C NMR δ 171.61, 140.73, 137.32, 128.61, 128.22, 127.21, 116.86, 62.69, 
45.40, 30.55, 26.14; EIMS m/z 201 (M+, 26), 173 (9), 147 (12), 118 (13), 106 (100); HRMS (EI) 
m/z calcd for C13H15NO 201.1154, found 201.1158. 
N
H
O Ph
syn-287  
 (5S*,6S*)-6-Phenyl-5-vinylpiperidin-2-one (syn-287).  A solution of 25.0 mg (0.0434 
mmol) of anti-282 in 5 mL of a 1 N solution of HCl(g) in MeOH was stirred at room temperature 
for 12 h and concentrated in vacuo.  The residue was dissolved in 3 mL of CH2Cl2, treated with 
60.0 µL (0.430 mmol) of Et3N and 20.0 µL (0.132 mmol) of diethyl cyanophosphonate, stirred 
for 16 h, filtered through a pad of Florisil and concentrated in vacuo.  The residue was purified 
by preparative TLC (EtOAc) to yield 6.0 mg (69%) of syn-287 as a colorless solid: mp 108-109 
°C (Et2O/hexane); IR (thin film) 3200, 3061, 2933, 1660, 1404, 1353, 998, 915, 763, 700 cm-1; 
1H NMR δ 7.37-7.26 (m, 3 H), 7.19-7.16 (m, 2 H), 5.89 (bs, 1 H), 5.46 (ddd, 1 H, J = 17.3, 10.1, 
8.3 Hz), 5.01 (d, 1 H, J = 16.9 Hz), 4.99 (d, 1 H, J = 11.1 Hz), 4.68 (dd, 1 H, J = 4.9, 2.5 Hz), 
2.82 (tt, 1 H, J = 8.7, 4.4 Hz), 2.67-2.44 (m, 2 H), 1.94-1.77 (m, 2 H); 13C NMR δ 172.03, 
138.90, 136.63, 128.23, 127.87, 127.52, 117.12, 60.38, 42.65, 29.66, 23.33; EIMS m/z 201 (M+, 
6), 173 (2), 147 (3), 119 (4), 106 (37), 84 (100); HRMS (EI) m/z calcd for C13H15NO 201.1154, 
found 201.1156. 
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  Attempted preparation of 2-butyl-1-phenylbut-3-en-1-ol using the General Protocol 
D.  A suspension of 97.0 mg (0.376 mmol) of Cp2ZrHCl in 2 mL of CH2Cl2 was treated at room 
temperature with 45.0 µL (0.392 mmol) of 1-hexyne.  After 5 min, the yellow solution was 
cooled to -78 °C, treated with 190 µL (0.380 mmol) of Me2Zn (2.0 M solution in toluene), 
warmed to 0 °C over a period of 5 min, treated with 90.0 µL (1.12 mmol) of CH2I2, stirred for 2 
min, treated with 25.0 µL (0.246 mmol) of PhCHO, stirred at 0 °C for 30 min, quenched with 
saturated NH4Cl, diluted with EtOAc, filtered through Celite, washed with H2O and brine, dried 
(MgSO4), filtered through a pad of Florisil and concentrated in vacuo.  The residue was 
chromatographed on SiO2 (4:1, hexanes/EtOAc) to yield 41 mg (88%) of 33. 
 Attempted preparation of 280 using a B-Zn transmetalation.  A solution of 190 µL 
(1.67 mmol) of 3-hexyne in 2 mL of CH2Cl2 was cooled to 0 °C, treated with 500 µL (0.500 
mmol) of borane (1.0 M solution in THF), and stirred at 0 °C for 1 h.  The mixture was treated 
with 750 µL (1.50 mmol) of Me2Zn (2.0 M solution in toluene), stirred for 2 min, treated with 
200 µL (2.48 mmol) of CH2I2, warmed to room temperature, treated with a solution of 153 mg 
(0.501 mmol) of imine 104 in 2 mL of CH2Cl2, stirred at room temperature for 16 h, quenched 
with saturated NH4Cl, diluted with EtOAc, filtered through Celite, washed with H2O, saturated 
NaHCO3 and brine, dried (MgSO4), filtered through a pad of Florisil and concentrated in vacuo.  
The residue was chromatographed on deactivated SiO2 (1:9, hexanes/EtOAc contain-ing 1% 
Et3N) to yield 97 mg (50%) of 147. 
NHP(O)Ph2
Ph
NHP(O)Ph2
Ph+
293 294  
 (E)-N-(2,2-Dimethyl-1-phenylpent-3-enyl)-P,P-diphenylphosphinamide (293) and N-
(2-methyl-1-phenylallyl)-P,P-diphenylphosphinamide (294).  A solution of 876 mg (3.00 
mmol) of Cp2ZrCl2 in 10 mL of THF was cooled to -78 °C, treated with 3.80 mL (6.08 mmol) of 
n-BuLi (1.6 M solution in hexanes), stirred at -78 °C for 1 h, treated with 300 µL (3.38 mmol) of 
2-bromopropene, warmed to room temperature over 5 min, stirred for 1 h and concentrated in 
vacuo.  The residue was suspended in 2 mL of toluene, cooled to -78 °C, treated with 1.50 mL 
(3.00 mmol) of Me2Zn (2.0 M solution in toluene), warmed to room temperature over 5 min, 
stirred for 2 h, treated with a solution of 153 mg (0.501 mmol) of imine 104 in 0.5 mL of THF 
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 and 2 mL of toluene, stirred at room temperature for 12 h, quenched with saturated NH4Cl, 
diluted with EtOAc and saturated NaHCO3, filtered through Celite, washed with H2O and brine, 
dried (MgSO4), filtered through a pad of Florisil and concentrated in vacuo.  The residue was 
chromatographed on deactivated SiO2 (1:4, hexanes/EtOAc containing 1% Et3N) to yield 88 mg 
(45%) of 293 and 27 mg (16%) of 294 as colorless solids.  293: Rf 0.61 (1:4, hexanes/EtOAc); 
mp 134-135 °C (Et2O/hexane); IR (KBr) 3323, 3059, 3017, 2967, 2937, 2875, 1434, 1182, 1125, 
1068, 754, 724, 707, 692 cm-1; 1H NMR δ 7.80-7.73 (m, 2 H), 7.59-7.52 (m, 2 H), 7.49-7.27 (m, 
5 H), 7.21-7.15 (m, 4 H), 6.99-6.96 (m, 2 H), 5.53-5.36 (m, 2 H), 3.83 (t, 1 H, J = 10.6 Hz), 3.45 
(t, 1 H, J = 8.7 Hz), 1.70 (d, 3 H, J = 5.1 Hz), 1.22 (s, 3 H), 0.81 (s, 3 H); 13C NMR δ 141.68, 
141.64, 136.15, 134.37, 132.84, 132.80, 132.67, 131.91, 131.78, 131.53, 131.50, 131.10, 128.61, 
128.45, 128.10, 127.94, 127.49, 126.84, 125.48, 63.77, 40.87, 40.81, 26.06, 25.92, 18.45; EIMS 
m/z 390 ([M+H]+, 1), 306 (100), 201 (93); HRMS (EI) m/z calcd for C25H29NOP [M+H] 
390.1987, found 390.1971.  294: Rf 0.53 (1:4, hexanes/EtOAc); mp 135-136 °C (Et2O/hexane); 
IR (KBr) 3192, 1438, 1184, 1123, 1109, 725, 701 cm-1; 1H NMR δ 8.04-7.89 (m, 4 H), 7.61-7.31 
(m, 11 H), 5.22 (s, 1 H), 5.13 (s, 1 H), 4.77 (t, 1 H, J = 10.6 Hz), 3.43 (dd, 1 H, J = 10.6, 6.6 Hz), 
1.70 (s, 3 H); 13C NMR δ 145.72, 145.66, 141.69, 141.63, 133.50, 133.11, 132.39, 132.27, 
132.20, 132.07, 131.89, 131.85, 131.82, 131.79, 131.40, 128.55, 128.51, 128.45, 128.34, 128.29, 
127.31, 127.01, 126.68, 112.54, 60.21, 19.79; EIMS m/z 347 (M+, 19), 306 (26), 201 (72), 193 
(43), 146 (95), 99 (100), 77 (59); HRMS (EI) m/z calcd for C22H22NOP 347.1439, found 
347.1431. 
NHP(O)Ph2
Ph
295  
 N-[(1-Methylcyclopropyl)phenylmethyl]-P,P-diphenylphosphinamide (295). 
A solution of 438 mg (1.50 mmol) of Cp2ZrCl2 in 5 mL of THF was cooled to -78 °C, treated 
with 1.88 mL (3.01 mmol) of n-BuLi (1.6 M solution in hexanes), stirred at -78 °C for 1 h, 
treated with 140 µL (1.57 mmol) of 2-bromopropene, warmed to room temperature over 5 min, 
stirred for 1 h and concentrated in vacuo.  The residue was dissolved in 3 mL of CH2Cl2, cooled 
to -78 °C, treated with 750 µL (3.00 mmol) of Me2Zn (2.0 M solution in toluene), warmed to 
room temperature over 5 min and treated with a solution of 153 mg (0.501 mmol) of imine 104 
in 1 mL of CH2Cl2.  The mixture was heated at reflux for 1 h, treated with 200 µL (2.48 mmol) 
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 of CH2I2, heated at reflux for 12 h, quenched with saturated NH4Cl, diluted with EtOAc and 
saturated NaHCO3, filtered through Celite, washed with H2O and brine, dried (MgSO4), filtered 
through a pad of Florisil and concentrated in vacuo.  The residue was chromatographed on 
deactivated SiO2 (1:4, hexanes/EtOAc containing 1% Et3N) to yield 81 mg (42%) of 293 and 25 
mg (14%) of 295 as a colorless oil. 295: IR (thin film) 3199, 3056, 2957, 2869, 1452, 1439, 
1186, 1123, 1108, 1063, 751, 723, 698 cm-1; 1H NMR δ 7.93-7.86 (m, 2 H), 7.74-7.68 (m, 2 H), 
7.52-7.36 (m, 4 H), 7.31-7.19 (m, 7 H), 3.77 (t, 1 H, J = 10.5 Hz), 3.42 (dd, 1 H, J = 9.5, 6.0 Hz), 
1.01 (s, 3 H), 0.68-0.64 (m, 1 H), 0.60-0.54 (m, 1 H), 0.40-0.30 (m, 2 H); 13C NMR δ 142.44, 
142.37, 132.67, 132.55, 132.19, 132.07, 131.93, 131.81, 128.65, 128.49, 128.42, 128.25, 128.18, 
127.16, 127.02, 61.57, 21.57, 21.51, 19.89, 12.94, 12.40; EIMS m/z 361 (M+, 7), 306 (100), 201 
(91), 160 (53), 91 (25), 77 (26); HRMS (EI) m/z calcd for C23H24NOP 361.1596, found 
361.1592. 
NHP(O)Ph2
Ph
296
D
D
 
 (E)-N-(4-Deutero-2-(deuteromethyl)-2-methyl-1-phenylpent-3-enyl)-P,P-diphenyl-
phosphinamide (296).  A solution of 590 mg (2.02 mmol) of Cp2ZrCl2 in 6 mL of THF was 
cooled to -78 °C, treated with 2.50 mL (4.00 mmol) of n-BuLi (1.6 M solution in hexanes), 
stirred at -78 °C for 1 h, treated with 270 µL (3.04 mmol) of 2-bromopropene, warmed to room 
temperature over 5 min, stirred for 1 h and concentrated in vacuo.  The residue was suspended in 
3 mL of toluene, cooled to -78 °C, treated with 1.00 mL (2.00 mmol) of Me2Zn (2.0 M solution 
in toluene), warmed to room temperature over 5 min, and cannulated into a suspension of 153 
mg (0.501 mmol) of imine 104 in 1 mL of toluene.  The mixture was stirred at room temperature 
for 12 h, quenched with saturated NH4Cl, diluted with EtOAc and saturated NaHCO3, filtered 
through Celite, washed with H2O and brine, dried (MgSO4), filtered through a pad of Florisil and 
concentrated in vacuo.  The residue was chromatographed on deactivated SiO2 (1:4, hexanes/ 
EtOAc containing 1% Et3N) to yield 90 mg (46%) of 296 and 46 mg (6%) of 294 as a colorless 
solid. 296: mp 133-134 °C (Et2O/hexane); IR (thin film) 3207, 3055, 2958, 2929, 1454, 1436, 
1183, 1125, 1107, 1068, 908, 749, 726, 696 cm-1; 1H NMR δ 7.82-7.75 (m, 2 H), 7.61-7.48 (m, 2 
H), 7.47-7.32 (m, 4 H), 7.24-7.17 (m, 5 H), 7.01-6.98 (m, 2 H), 5.41 (bs, 1 H), 3.85 (t, 1 H, J = 
129 
 10.6 Hz), 3.47 (dd, 1 H, J = 9.7, 7.7 Hz), 1.71 (d, 3 H, J = 0.8 Hz), 1.22 (s, 2 H), 0.83 (s, 3 H); 
13C NMR δ 141.57, 141.53, 135.87, 134.26, 132.68, 132.55, 131.78, 131.66, 131.40, 131.36, 
130.96, 128.48, 128.32, 127.97, 127.80, 127.35, 126.69, 125.09 (t, 1 C, J = 22.7 Hz), 63.61, 
40.66, 40.59, 25.93, 25.48 (t, 1 C, J = 19.5 Hz), 18.19; 2H NMR (77 MHz) δ 5.51, 1.18; EIMS 
m/z 392 ([M+H]+, 1), 306 (100), 201 (77), 77 (24); HRMS (EI) m/z calcd for C25H27D2NOP 
[M+H] 392.2112 found 392.2104. 
Ph2(O)PNH
Ph
304  
 N-(3-Methyl-1-phenylbut-3-enyl)-P,P-diphenylphosphinamide (304).  A solution of 
584 mg (2.00 mmol) of Cp2ZrCl2 in 6 mL of THF was cooled to -78 °C, treated with 2.50 mL 
(4.00 mmol) of n-BuLi (1.6 M solution in hexanes), stirred at -78 °C for 1 h, treated with 200 µL 
(2.25 mmol) of 2-bromopropene, warmed to room temperature over 5 min, stirred for 1 h and 
concentrated in vacuo.  The residue was suspended in 2 mL of toluene, cooled to -78 °C, treated 
with 1.00 mL (2.00 mmol) of Me2Zn (2.0 M solution in toluene), warmed to room temperature 
over 5 min, treated with 200 µL (2.48 mmol) of CH2I2, stirred for 2 min, treated with a solution 
of 153 mg (0.501 mmol) of imine 104 in 0.5 mL of CH2Cl2 and 1.5 mL of toluene, stirred at 
room temperature for 4 h, quenched with saturated NH4Cl, diluted with EtOAc and saturated 
NaHCO3, filtered through Celite, washed with H2O and brine, dried (MgSO4), filtered through a 
pad of Florisil and concentrated in vacuo.  The residue was chromatographed on deactivated 
SiO2 (1:9, hexanes/EtOAc containing 1% Et3N) to yield 136 mg (75%) of 304 as a colorless 
solid: mp 165-166 °C (Et2O/hexane); IR (thin film) 3182, 3058, 2910, 1437, 1186, 1123, 1109, 
724, 696 cm-1; 1H NMR δ 7.87-7.79 (m, 2 H), 7.76-7.67 (m, 2 H), 7.51-7.33 (m, 4 H), 7.31-7.14 
(m, 7 H), 4.77 (s, 1 H), 4.68 (s, 1 H), 4.36 (qn, 1 H, J = 6.3 Hz), 3.28 (dd, 1 H, J = 7.9, 6.0 Hz), 
2.61 (dd, 1 H, J = 13.6, 7.3 Hz), 2.52 (dd, 1 H, J = 13.7, 7.0 Hz), 1.57 (s, 3 H); 13C NMR δ 
143.49, 142.00, 133.88, 132.86, 132.51, 132.38, 132.19, 131.83, 131.71, 131.62, 131.13, 128.52, 
128.35, 128.30, 128.26, 128.09, 127.06, 126.56, 114.40, 53.39, 48.20, 48.13, 22.26; EIMS m/z 
361 (M+, 1), 306 (74), 201 (100); HRMS (EI) m/z calcd for C23H24NOP 361.1596, found 
361.1593. 
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 Appendix A 
X-ray Structure and Data of Binaphthyl-Phenyl Phosphinimine 219 
 
Appendix A, Table 1. Crystal data and structure refinement. 
Identification ck1203s  code 
Empirical formula C H NOP 33 24
Formula weig 481.50 ht 
Temperature 100(2) K 
Wavelength 0.71073 Å 
Crystal system Triclinic 
= 106.997(3)° 
= 97.186(3)° 
114.688(3)° 
F(000) 504 
Crystal size 0.27 x 0.18 x 0.18 mm3
Theta range for data collection 1.67 to 32.48° 
Index ranges -15 ≤ h ≤ 15, -16 ≤ k ≤ 15, -19 ≤ l ≤ 19 
Reflections collected 16001 
Independent reflections 8473 [R(int) = 0.0551] 
Completeness to theta = 32.48° 92.9% 
Absorption correction None 
Max. and min. transmission 0.9760 and 0.9643 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 8473 / 0 / 421 
Goodness-of-fit on F2 1.011 
Final R indices [I>2sigma(I)] R1 = 0.0736, wR2 = 0.1766 
R indices (all data) R1 = 0.1153, wR2 = 0.1996 
Largest diff. peak and hole 0.862 and -0.484 e.Å-3
Space group P-1 
Unit cell dimensions a = 10.5978(16) Å α 
) Å β 
 
 b = 10.7312(16
 c = 13.330(2) Å γ = 
3Volume 1262.9(3) Å
Z 2 
3Density (calculated) 1.266 Mg/m
Absorption coefficient 0.136 mm-1
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 Appendix A, Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement para-
meters (Å2 x 103) for ck1203s. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 
 x y z U(eq) 
P 2297(1) 5153(1) 1897(1) 16(1) 
O 2456(2) 4133(2) 961(1) 19(1) 
N 3572(2) 5987(2) 3101(1) 17(1) 
C(1) 3382(2) 7871(2) 1630(2) 16(1) 
C(2) 2169(2) 6667(2) 1637(2) 16(1) 
C(3) 783(2) 6561(2) 1372(2) 20(1) 
C(4) 605(2) 7651(2) 1148(2) 22(1) 
C(5) 1819(2) 8914(2) 1166(2) 20(1) 
C(6) 1669(3) 10071(2) 944(2) 24(1) 
C(7) 2839(3) 11246(2) 902(2) 29(1) 
C(8) 4200(3) 11303(3) 1068(2) 28(1) 
C(9) 4390(3) 10220(2) 1299(2) 23(1) 
C(10) 3210(2) 9002(2) 1372(2) 17(1) 
C(11) 4844(2) 7967(2) 1848(2) 17(1) 
C(12) 5155(2) 7086(2) 1053(2) 19(1) 
C(13) 6518(2) 7126(2) 1219(2) 24(1) 
C(14) 7555(2) 8046(2) 2201(2) 25(1) 
C(15) 7289(2) 8982(2) 3048(2) 20(1) 
C(16) 8358(2) 9933(3) 4067(2) 25(1) 
C(17) 8088(3) 10818(3) 4882(2) 26(1) 
C(18) 6746(2) 10813(2) 4713(2) 22(1) 
C(19) 5687(2) 9904(2) 3732(2) 18(1) 
C(20) 5925(2) 8960(2) 2872(2) 17(1) 
C(21) 4631(2) 5705(2) 3202(2) 19(1) 
C(22) 5739(2) 6366(2) 4250(2) 19(1) 
C(23) 5576(3) 7172(3) 5201(2) 25(1) 
C(24) 6645(3) 7828(3) 6187(2) 30(1) 
C(25) 7883(3) 7678(3) 6217(2) 33(1) 
C(26) 8060(3) 6872(3) 5278(2) 34(1) 
C(27) 6977(3) 6202(3) 4290(2) 28(1) 
C(28) 705(2) 4212(2) 2290(2) 17(1) 
C(29) 396(2) 4913(2) 3212(2) 22(1) 
C(30) -829(2) 4123(3) 3485(2) 25(1) 
C(31) -1745(3) 2622(3) 2853(2) 28(1) 
C(32) -1440(3) 1921(3) 1944(2) 28(1) 
C(33) -214(2) 2708(2) 1663(2) 21(1) 
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 Appendix A, Table 3. Bond lengths [Å] and angles [°] for ck1203s. 
 
P-O 1.4800(15) O-P-N 118.46(9) C(14)-C(13)-C(12) 119.6(2) 
P-N 1.6764(18) O-P-C(28) 112.25(9) C(13)-C(14)-C(15) 120.9(2) 
P-C(28) 1.802(2) N-P-C(28) 100.60(9) C(16)-C(15)-C(14) 121.1(2) 
P-C(2) 1.8114(19) O-P-C(2) 113.64(9) C(16)-C(15)-C(20) 119.49(19) 
N-C(21) 1.280(3) N-P-C(2) 104.07(9) C(14)-C(15)-C(20) 119.46(19) 
C(1)-C(2) 1.394(3) C(28)-P-C(2) 106.38(9) C(17)-C(16)-C(15) 120.7(2) 
C(1)-C(10) 1.427(3) C(21)-N-P 119.98(15) C(16)-C(17)-C(18) 120.2(2) 
C(1)-C(11) 1.494(3) C(2)-C(1)-C(10) 119.27(18) C(19)-C(18)-C(17) 120.5(2) 
C(2)-C(3) 1.415(3) C(2)-C(1)-C(11) 121.10(17) C(18)-C(19)-C(20) 120.7(2) 
C(3)-C(4) 1.367(3) C(10)-C(1)-C(11) 119.60(17) C(19)-C(20)-C(15) 118.37(18) 
C(4)-C(5) 1.418(3) C(1)-C(2)-C(3) 120.11(18) C(19)-C(20)-C(11) 122.79(18) 
C(5)-C(6) 1.423(3) C(1)-C(2)-P 121.53(15) C(15)-C(20)-C(11) 118.82(18) 
C(5)-C(10) 1.423(3) C(3)-C(2)-P 118.26(15) N-C(21)-C(22) 121.77(19) 
C(6)-C(7) 1.372(4) C(4)-C(3)-C(2) 121.3(2) C(23)-C(22)-C(27) 119.5(2) 
C(7)-C(8) 1.405(4) C(3)-C(4)-C(5) 120.1(2) C(23)-C(22)-C(21) 120.65(19) 
C(8)-C(9) 1.368(3) C(4)-C(5)-C(6) 121.3(2) C(27)-C(22)-C(21) 119.8(2) 
C(9)-C(10) 1.421(3) C(4)-C(5)-C(10) 119.39(18) C(22)-C(23)-C(24) 120.5(2) 
C(11)-C(12) 1.374(3) C(6)-C(5)-C(10) 119.2(2) C(25)-C(24)-C(23) 119.6(2) 
C(11)-C(20) 1.432(3) C(7)-C(6)-C(5) 120.8(2) C(26)-C(25)-C(24) 120.7(2) 
C(12)-C(13) 1.414(3) C(6)-C(7)-C(8) 119.7(2) C(25)-C(26)-C(27) 119.6(2) 
C(13)-C(14) 1.369(3) C(9)-C(8)-C(7) 121.1(2) C(22)-C(27)-C(26) 120.1(2) 
C(14)-C(15) 1.420(3) C(8)-C(9)-C(10) 120.8(2) C(29)-C(28)-C(33) 119.49(19) 
C(15)-C(16) 1.416(3) C(9)-C(10)-C(5) 118.27(18) C(29)-C(28)-P 122.66(15) 
C(15)-C(20) 1.425(3) C(9)-C(10)-C(1) 122.05(19) C(33)-C(28)-P 117.81(16) 
C(16)-C(17) 1.366(3) C(5)-C(10)-C(1) 119.68(18) C(30)-C(29)-C(28) 119.98(19) 
C(17)-C(18) 1.410(3) C(12)-C(11)-C(20) 119.48(19) C(29)-C(30)-C(31) 120.2(2) 
C(18)-C(19) 1.376(3) C(12)-C(11)-C(1) 119.42(18) C(32)-C(31)-C(30) 120.0(2) 
C(19)-C(20) 1.417(3) C(20)-C(11)-C(1) 121.10(17) C(31)-C(32)-C(33) 120.1(2) 
C(21)-C(22) 1.465(3) C(11)-C(12)-C(13) 121.8(2) C(32)-C(33)-C(28) 120.2(2) 
C(22)-C(23) 1.388(3)     
C(22)-C(27) 1.391(3)     
C(23)-C(24) 1.388(3)     
C(24)-C(25) 1.385(4)     
C(25)-C(26) 1.382(4)     
C(26)-C(27) 1.396(3)     
C(28)-C(29) 1.395(3)     
C(28)-C(33) 1.396(3)     
C(29)-C(30) 1.385(3)     
C(30)-C(31) 1.393(3)     
C(31)-C(32) 1.381(3)     
C(32)-C(33) 1.391(3)     
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 Appendix A, Table 4. Anisotropic displacement parameters (Å2 x 103) for ck1203s. The aniso-
tropic displacement factor exponent takes the form: -2π2[h2(a*)2U11 + ... + 2hk(a*)(b*)U12]. 
 
 U11 U22 U33 U23 U13 U12
P 17(1) 11(1) 18(1) 6(1) 3(1) 6(1) 
O 21(1) 14(1) 22(1) 5(1) 5(1) 9(1) 
N 16(1) 13(1) 20(1) 8(1) 2(1) 5(1) 
C(1) 19(1) 13(1) 17(1) 6(1) 4(1) 8(1) 
C(2) 19(1) 13(1) 17(1) 6(1) 3(1) 8(1) 
C(3) 18(1) 18(1) 22(1) 8(1) 2(1) 8(1) 
C(4) 23(1) 22(1) 21(1) 7(1) 3(1) 14(1) 
C(5) 29(1) 17(1) 17(1) 6(1) 3(1) 15(1) 
C(6) 35(1) 21(1) 19(1) 6(1) 0(1) 18(1) 
C(7) 51(2) 18(1) 22(1) 8(1) 3(1) 21(1) 
C(8) 40(1) 19(1) 28(1) 13(1) 6(1) 14(1) 
C(9) 28(1) 15(1) 25(1) 10(1) 6(1) 9(1) 
C(10) 22(1) 12(1) 18(1) 6(1) 3(1) 9(1) 
C(11) 19(1) 12(1) 21(1) 8(1) 6(1) 9(1) 
C(12) 23(1) 14(1) 21(1) 7(1) 7(1) 9(1) 
C(13) 25(1) 23(1) 29(1) 11(1) 14(1) 14(1) 
C(14) 22(1) 24(1) 34(1) 12(1) 10(1) 14(1) 
C(15) 18(1) 18(1) 26(1) 11(1) 8(1) 9(1) 
C(16) 20(1) 24(1) 30(1) 10(1) 4(1) 10(1) 
C(17) 21(1) 22(1) 26(1) 7(1) 0(1) 6(1) 
C(18) 23(1) 18(1) 24(1) 8(1) 6(1) 8(1) 
C(19) 19(1) 15(1) 21(1) 8(1) 6(1) 8(1) 
C(20) 18(1) 13(1) 22(1) 9(1) 7(1) 7(1) 
C(21) 19(1) 15(1) 22(1) 8(1) 2(1) 8(1) 
C(22) 19(1) 15(1) 24(1) 10(1) 2(1) 8(1) 
C(23) 27(1) 24(1) 25(1) 9(1) 3(1) 13(1) 
C(24) 36(1) 29(1) 23(1) 7(1) 0(1) 17(1) 
C(25) 34(1) 29(1) 31(1) 9(1) -8(1) 15(1) 
C(26) 26(1) 31(1) 42(2) 12(1) -2(1) 16(1) 
C(27) 26(1) 29(1) 30(1) 9(1) 3(1) 16(1) 
C(28) 18(1) 12(1) 19(1) 6(1) 2(1) 6(1) 
C(29) 23(1) 17(1) 24(1) 5(1) 4(1) 8(1) 
C(30) 25(1) 25(1) 24(1) 9(1) 7(1) 11(1) 
C(31) 23(1) 26(1) 28(1) 14(1) 7(1) 4(1) 
C(32) 25(1) 17(1) 29(1) 7(1) 4(1) 2(1) 
C(33) 23(1) 15(1) 22(1) 6(1) 6(1) 7(1) 
134 
 Appendix A, Table 5. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2 
x 103) for ck1203s. 
 
 x y z U(eq) 
H(3) -70(30) 5680(30) 1340(20) 24(6) 
H(4) -390(30) 7500(30) 900(20) 32(7) 
H(6) 700(30) 10010(30) 870(20) 26(7) 
H(7) 2670(30) 12010(30) 780(20) 27(7) 
H(8) 5030(30) 12130(30) 1030(20) 27(7) 
H(9) 5320(30) 10270(30) 1380(20) 32(7) 
H(12) 4460(30) 6400(30) 360(20) 22(6) 
H(13) 6750(30) 6530(30) 640(20) 35(8) 
H(14) 8490(30) 8090(30) 2350(20) 33(7) 
H(16) 9310(30) 9960(30) 4190(20) 28(7) 
H(17) 8830(30) 11490(30) 5560(20) 31(7) 
H(18) 6580(30) 11450(30) 5310(20) 37(8) 
H(19) 4710(30) 9890(30) 3610(20) 33(7) 
H(21) 4790(30) 5110(30) 2570(20) 34(7) 
H(23) 4720(30) 7220(30) 5190(20) 37(8) 
H(24) 6490(30) 8260(30) 6840(20) 39(8) 
H(25) 8680(30) 8110(30) 6910(30) 44(8) 
H(26) 8980(30) 6820(30) 5280(30) 48(9) 
H(27) 7080(30) 5670(30) 3590(20) 41(8) 
H(29) 1030(30) 5980(30) 3670(20) 30(7) 
H(30) -1030(30) 4650(30) 4140(20) 22(6) 
H(31) -2590(30) 2090(30) 3070(20) 45(8) 
H(32) -2120(30) 850(30) 1510(20) 40(8) 
H(33) 50(30) 2280(30) 1070(20) 21(6) 
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 Appendix B 
X-ray Structure and Data of Benzamide 268. 
 
Appendix B, Table 1. Crystal data and structure refinement for ck102s. 
Identification code  ck102s 
Empirical formula  C21H25NO 
Formula weight  307.42 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.3218(6) Å α = 82.892(2)° 
 b = 9.5102(10) Å β = 82.762(2)° 
 c = 17.900(2) Å γ = 87.377(3)° 
Volume 891.38(17) Å3
Z 2 
Density (calculated) 1.145 Mg/m3
Absorption coefficient 0.069 mm-1
F(000) 332 
Crystal size 0.27 x 0.03 x 0.03 mm3
Theta range for data collection 2.16 to 32.52° 
Index ranges -8 ≤ h ≤ 8, -13 ≤ k ≤ 13, -26 ≤ l ≤ 25 
Reflections collected 11657 
Independent reflections 6038 [R(int) = 0.1076] 
Completeness to theta = 32.52° 93.6% 
Absorption correction None 
Max. and min. transmission 0.9979 and 0.9815 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 6038 / 0 / 212 
Goodness-of-fit on F2 0.987 
Final R indices [I>2sigma(I)] R1 = 0.1098, wR2 = 0.1907 
R indices (all data) R1 = 0.2921, wR2 = 0.2549 
Largest diff. peak and hole 0.582 and -0.362 e.Å-3
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 Appendix B, Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement para-
meters (Å2 x 103) for ck102s.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 
 x y z U(eq) 
O 8439(4) 451(2) 3148(1) 35(1) 
N 4293(5) 714(3) 2976(2) 30(1) 
C(1) 3226(6) -916(3) 4470(2) 29(1) 
C(2) 2738(6) -1919(4) 5099(2) 34(1) 
C(3) 4500(6) -2986(4) 5266(2) 35(1) 
C(4) 6784(7) -3048(4) 4791(2) 37(1) 
C(5) 7294(6) -2053(3) 4174(2) 32(1) 
C(6) 5516(6) -981(3) 4004(2) 25(1) 
C(7) 6202(6) 116(3) 3341(2) 28(1) 
C(8) 4648(6) 1887(3) 2367(2) 29(1) 
C(9) 3028(6) 1691(4) 1754(2) 34(1) 
C(10) 3768(9) 2398(5) 967(2) 66(1) 
C(11) 3993(7) 824(5) 1138(2) 52(1) 
C(12) 2266(8) -152(5) 854(2) 69(2) 
C(13) 2236(11) -1598(5) 1265(5) 128(3) 
C(14) 554(13) -2589(7) 926(6) 177(4) 
C(15) 1253(14) -3911(8) 932(5) 154(3) 
C(16) 4131(6) 3307(3) 2662(2) 28(1) 
C(17) 5892(6) 4370(4) 2498(2) 39(1) 
C(18) 5424(7) 5657(4) 2777(2) 49(1) 
C(19) 3178(7) 5912(4) 3230(2) 51(1) 
C(20) 1429(6) 4871(4) 3390(2) 40(1) 
C(21) 1874(6) 3584(4) 3112(2) 34(1) 
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 Appendix B, Table 3. Bond lengths [Å] and angles [°] for ck102s. 
 
O-C(7) 1.242(3) C(7)-N-C(8) 122.8(3) 
N-C(7) 1.343(4) C(2)-C(1)-C(6) 119.8(3) 
N-C(8) 1.462(4) C(3)-C(2)-C(1) 120.7(3) 
C(1)-C(2) 1.389(4) C(2)-C(3)-C(4) 119.0(3) 
C(1)-C(6) 1.391(4) C(5)-C(4)-C(3) 120.7(3) 
C(2)-C(3) 1.381(4) C(4)-C(5)-C(6) 120.3(3) 
C(3)-C(4) 1.397(5) C(5)-C(6)-C(1) 119.5(3) 
C(4)-C(5) 1.370(4) C(5)-C(6)-C(7) 118.3(3) 
C(5)-C(6) 1.391(4) C(1)-C(6)-C(7) 122.1(3) 
C(6)-C(7) 1.499(4) O-C(7)-N 122.3(3) 
C(8)-C(16) 1.511(4) O-C(7)-C(6) 120.8(3) 
C(8)-C(9) 1.512(4) N-C(7)-C(6) 116.9(3) 
C(9)-C(11) 1.485(5) N-C(8)-C(16) 111.7(3) 
C(9)-C(10) 1.498(5) N-C(8)-C(9) 109.7(3) 
C(10)-C(11) 1.493(6) C(16)-C(8)-C(9) 112.1(3) 
C(11)-C(12) 1.509(5) C(11)-C(9)-C(10) 60.1(2) 
C(12)-C(13) 1.476(7) C(11)-C(9)-C(8) 120.4(3) 
C(13)-C(14) 1.553(8) C(10)-C(9)-C(8) 118.8(3) 
C(14)-C(15) 1.293(8) C(11)-C(10)-C(9) 59.5(2) 
C(16)-C(17) 1.389(4) C(9)-C(11)-C(10) 60.4(2) 
C(16)-C(21) 1.394(4) C(9)-C(11)-C(12) 120.6(3) 
C(17)-C(18) 1.379(5) C(10)-C(11)-C(12) 122.1(4) 
C(18)-C(19) 1.386(5) C(13)-C(12)-C(11) 113.7(4) 
C(19)-C(20) 1.369(5) C(12)-C(13)-C(14) 112.0(6) 
C(20)-C(21) 1.377(4) C(15)-C(14)-C(13) 118.1(7) 
  C(17)-C(16)-C(21) 118.0(3) 
  C(17)-C(16)-C(8) 121.2(3) 
  C(21)-C(16)-C(8) 120.8(3) 
  C(18)-C(17)-C(16) 120.9(3) 
  C(17)-C(18)-C(19) 120.4(3) 
  C(20)-C(19)-C(18) 119.0(4) 
  C(19)-C(20)-C(21) 121.1(3) 
  C(20)-C(21)-C(16) 120.6(3) 
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 Appendix B, Table 4. Anisotropic displacement parameters  (Å2 x 103) for ck102s. The aniso-
tropic displacement factor exponent takes the form: -2π2[h2(a*)2U11 + ... + 2hk(a*)(b*)U12]. 
 
 U11 U22 U33 U23 U13 U12
O 18(1) 44(1) 41(1) -2(1) -4(1) -4(1) 
N 17(1) 33(2) 39(2) -3(1) -5(1) -2(1) 
C(1) 23(2) 31(2) 32(2) -4(2) -4(1) 4(1) 
C(2) 26(2) 44(2) 33(2) -9(2) -1(2) -2(2) 
C(3) 36(2) 34(2) 34(2) 3(2) -10(2) -5(2) 
C(4) 34(2) 34(2) 45(2) -4(2) -12(2) 6(2) 
C(5) 21(2) 33(2) 42(2) -6(2) -6(2) 1(1) 
C(6) 19(2) 28(2) 29(2) -10(2) -4(1) -2(1) 
C(7) 21(2) 29(2) 35(2) -14(2) -4(1) -1(1) 
C(8) 20(2) 36(2) 29(2) -1(2) -2(1) 0(1) 
C(9) 27(2) 45(2) 30(2) -7(2) -1(2) 1(2) 
C(10) 76(3) 77(3) 47(3) 3(2) -13(2) -30(3) 
C(11) 38(2) 78(3) 43(2) -31(2) 3(2) -8(2) 
C(12) 51(3) 106(4) 60(3) -52(3) 8(2) -21(3) 
C(13) 79(4) 59(4) 266(9) -45(5) -77(5) -3(3) 
C(14) 103(6) 81(5) 367(14) -89(7) -41(7) -5(4) 
C(15) 144(7) 134(7) 196(8) -59(6) -24(6) -18(6) 
C(16) 20(2) 33(2) 32(2) -5(2) -6(1) 3(1) 
C(17) 22(2) 44(2) 52(2) -4(2) -9(2) -2(2) 
C(18) 34(2) 37(2) 78(3) -8(2) -15(2) -8(2) 
C(19) 36(2) 39(2) 83(3) -23(2) -19(2) 7(2) 
C(20) 26(2) 49(2) 52(2) -21(2) -12(2) 4(2) 
C(21) 24(2) 37(2) 41(2) -7(2) -7(2) -1(2) 
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 Appendix B, Table 5. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2 
x 103) for ck102s. 
 
 x y z U(eq) 
H(1N) 2790(70) 270(30) 3136(19) 50(11) 
H(1A) 2000 -188 4358 35 
H(2A) 1175 -1870 5417 41 
H(3A) 4163 -3668 5699 42 
H(4A) 7996 -3788 4896 45 
H(5A) 8871 -2095 3861 38 
H(8A) 6461 1851 2139 35 
H(9A) 1164 1651 1920 41 
H(10A) 2396 2797 671 80 
H(10B) 5350 2935 870 80 
H(11A) 5769 443 1159 62 
H(12A) 521 263 902 83 
H(12B) 2810 -212 309 83 
H(13A) 1590 -1550 1805 153 
H(13B) 3989 -2000 1241 153 
H(14A) -1171 -2545 1206 213 
H(14B) 424 -2195 394 213 
H(15A) 78 -4399 679 231 
H(15B) 1243 -4350 1457 231 
H(15C) 2967 -3984 663 231 
H(17A) 7440 4208 2189 47 
H(18A) 6648 6372 2659 59 
H(19A) 2857 6795 3426 61 
H(20A) -117 5040 3697 48 
H(21A) 630 2879 3229 40 
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 Appendix C 
X-ray Structure and Data of a Derivative of Cyclopropane 267. 
 
Appendix C, Table 1. Crystal data and structure refinement for ck502s. 
Identification code  ck502s 
Empirical form Cula  
 
Å 
 
 α = 98.396(2)° 
 96.477(2)° 
γ = 94.354(2)° 
Density (calculated) 1.154 Mg/m3
Absorption coefficient 0.070 mm-1
F(000) 348 
Crystal size 0.29 x 0.03 x 0.03 mm3
Theta range for data collection 2.02 to 25.00° 
Index ranges -6 ≤ h ≤ 6, -12 ≤ k ≤ 12, -20 ≤ l ≤ 20 
Reflections collected 7446 
Independent reflections 3268 [R(int) = 0.0545] 
Completeness to theta = 25.00° 100.0% 
Absorption correction Sadabs 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3268 / 0 / 325 
Goodness-of-fit on F2 1.036 
Final R indices [I>2sigma(I)] R1 = 0.0743, wR2 = 0.1549 
R indices (all data) R1 = 0.1263, wR2 = 0.1713 
Largest diff. peak and hole 0.280 and -0.167 e.Å-3
22H27NO 
Formula weight  321.45
Temperature  150(2) K 
Wavelength  0.71073 
Crystal system  Triclinic
Space group  P-1 
Unit cell dimensions a = 5.3816(6) Å
 b = 10.2141(11) Å β =
 c = 17.2013(19) Å 
Volume 925.31(18) Å3
Z 2 
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 Appendix C, Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement para-
meters (Å2 x 103) for ck502s. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 
 x y z U(eq) 
O 3321(4) 5849(2) 1936(1) 38(1) 
N 7560(5) 6105(3) 2092(2) 32(1) 
C(1) 12461(13) 1826(6) 3554(4) 92(2) 
C(2) 13152(9) 3254(5) 3954(3) 69(1) 
C(3) 11184(8) 4172(4) 3713(3) 59(1) 
C(4) 11701(7) 5569(4) 4179(2) 48(1) 
C(5) 9688(7) 6423(3) 3939(2) 41(1) 
C(6) 9965(7) 7915(4) 4142(2) 44(1) 
C(7) 9965(6) 7261(3) 3309(2) 32(1) 
C(8) 7811(6) 7311(3) 2681(2) 34(1) 
C(9) 8037(5) 8546(3) 2288(2) 33(1) 
C(10) 6417(6) 9519(3) 2398(2) 42(1) 
C(11) 6623(7) 10634(4) 2029(2) 51(1) 
C(12) 8443(6) 10776(4) 1539(2) 47(1) 
C(13) 10084(7) 9814(3) 1432(2) 44(1) 
C(14) 9897(6) 8707(3) 1800(2) 36(1) 
C(15) 5326(5) 5481(3) 1745(2) 30(1) 
C(16) 5411(5) 4349(3) 1101(2) 29(1) 
C(17) 3435(6) 3339(3) 961(2) 33(1) 
C(18) 3328(6) 2323(3) 337(2) 39(1) 
C(19) 5169(6) 2284(3) -156(2) 36(1) 
C(20) 7137(6) 3264(3) -22(2) 36(1) 
C(21) 7267(6) 4274(3) 601(2) 34(1) 
C(22) 12291(8) 8665(5) 4628(3) 62(1) 
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 Appendix C, Table 3. Bond lengths [Å] and angles [°] for ck502s. 
 
O-C(15) 1.233(3) C(15)-N-C(8) 123.4(3) N-C(8)-H(8) 105.3(15) 
N-C(15) 1.349(4) C(15)-N-H(1N) 117(2) C(7)-C(8)-H(8) 110.9(16) 
N-C(8) 1.462(4) C(8)-N-H(1N) 120(2) C(9)-C(8)-H(8) 106.5(16) 
N-H(1N) 0.84(3) C(2)-C(1)-H(1A) 104(2) C(10)-C(9)-C(14) 118.6(3) 
C(1)-C(2) 1.519(7) C(2)-C(1)-H(1B) 86(4) C(10)-C(9)-C(8) 121.3(3) 
C(1)-H(1A) 1.09(5) H(1A)-C(1)-H(1B) 114(5) C(14)-C(9)-C(8) 120.0(3) 
C(1)-H(1B) 1.09(8) C(2)-C(1)-H(1C) 100(3) C(9)-C(10)-C(11) 120.8(4) 
C(1)-H(1C) 1.09(6) H(1A)-C(1)-H(1C) 119(4) C(9)-C(10)-H(10) 122.7(19) 
C(2)-C(3) 1.529(6) H(1B)-C(1)-H(1C) 123(5) C(11)-C(10)-H(10) 116.5(19) 
C(2)-H(2A) 1.13(8) C(1)-C(2)-C(3) 112.1(4) C(12)-C(11)-C(10) 120.2(4) 
C(2)-H(2B) 1.15(7) C(1)-C(2)-H(2A) 108(4) C(12)-C(11)-H(11) 123(2) 
C(3)-C(4) 1.519(5) C(3)-C(2)-H(2A) 109(4) C(10)-C(11)-H(11) 117(2) 
C(3)-H(3A) 1.00(3) C(1)-C(2)-H(2B) 107(3) C(11)-C(12)-C(13) 119.4(4) 
C(3)-H(3B) 1.08(5) C(3)-C(2)-H(2B) 100(3) C(11)-C(12)-H(12) 118(2) 
C(4)-C(5) 1.501(5) H(2A)-C(2)-H(2B) 121(5) C(13)-C(12)-H(12) 123(2) 
C(4)-H(4A) 0.98(3) C(4)-C(3)-C(2) 112.6(3) C(14)-C(13)-C(12) 120.8(4) 
C(4)-H(4B) 1.08(4) C(4)-C(3)-H(3A) 114.3(17) C(14)-C(13)-H(13) 120(2) 
C(5)-C(7) 1.490(5) C(2)-C(3)-H(3A) 108.8(18) C(12)-C(13)-H(13) 119(2) 
C(5)-C(6) 1.505(5) C(4)-C(3)-H(3B) 120(3) C(13)-C(14)-C(9) 120.2(3) 
C(5)-H(5) 0.96(3) C(2)-C(3)-H(3B) 104(3) C(13)-C(14)-H(14) 120.9(19) 
C(6)-C(7) 1.490(5) H(3A)-C(3)-H(3B) 96(3) C(9)-C(14)-H(14) 118.8(19) 
C(6)-C(22) 1.511(5) C(5)-C(4)-C(3) 110.7(3) O-C(15)-N 121.9(3) 
C(6)-H(6) 0.94(3) C(5)-C(4)-H(4A) 110(2) O-C(15)-C(16) 121.8(3) 
C(7)-C(8) 1.502(4) C(3)-C(4)-H(4A) 109(2) N-C(15)-C(16) 116.3(3) 
C(7)-H(7) 0.92(3) C(5)-C(4)-H(4B) 104.6(19) C(21)-C(16)-C(17) 118.1(3) 
C(8)-C(9) 1.518(4) C(3)-C(4)-H(4B) 112.1(19) C(21)-C(16)-C(15) 123.7(3) 
C(8)-H(8) 0.96(3) H(4A)-C(4)-H(4B) 111(3) C(17)-C(16)-C(15) 118.1(3) 
C(9)-C(10) 1.378(4) C(7)-C(5)-C(4) 121.2(3) C(18)-C(17)-C(16) 120.5(3) 
C(9)-C(14) 1.393(4) C(7)-C(5)-C(6) 59.7(2) C(18)-C(17)-H(17) 124.7(17) 
C(10)-C(11) 1.386(5) C(4)-C(5)-C(6) 123.2(3) C(16)-C(17)-H(17) 114.8(17) 
C(10)-H(10) 0.94(3) C(7)-C(5)-H(5) 111(2) C(17)-C(18)-C(19) 120.3(3) 
C(11)-C(12) 1.374(5) C(4)-C(5)-H(5) 114(2) C(17)-C(18)-H(18) 120(2) 
C(11)-H(11) 0.95(4) C(6)-C(5)-H(5) 116(2) C(19)-C(18)-H(18) 120(2) 
C(12)-C(13) 1.377(5) C(7)-C(6)-C(5) 59.7(2) C(18)-C(19)-C(20) 119.9(3) 
C(12)-H(12) 0.93(4) C(7)-C(6)-C(22) 122.3(3) C(18)-C(19)-H(19) 119.2(16) 
C(13)-C(14) 1.376(5) C(5)-C(6)-C(22) 121.9(3) C(20)-C(19)-H(19) 120.8(17) 
C(13)-H(13) 0.91(4) C(7)-C(6)-H(6) 113.3(19) C(21)-C(20)-C(19) 120.1(3) 
C(14)-H(14) 0.95(3) C(5)-C(6)-H(6) 116.9(18) C(21)-C(20)-H(20) 121.1(18) 
C(15)-C(16) 1.487(4) C(22)-C(6)-H(6) 112.9(18) C(19)-C(20)-H(20) 118.7(18) 
C(16)-C(21) 1.389(4) C(5)-C(7)-C(6) 60.7(2) C(20)-C(21)-C(16) 121.1(3) 
C(16)-C(17) 1.399(4) C(5)-C(7)-C(8) 120.5(3) C(20)-C(21)-H(21) 118.4(17) 
C(17)-C(18) 1.373(5) C(6)-C(7)-C(8) 121.6(3) C(16)-C(21)-H(21) 120.5(17) 
C(17)-H(17) 0.98(3) C(5)-C(7)-H(7) 113.0(17) C(6)-C(22)-H(22A) 105.8(19) 
C(18)-C(19) 1.375(5) C(6)-C(7)-H(7) 114.8(16) C(6)-C(22)-H(22B) 112(3) 
C(18)-H(18) 0.96(3) C(8)-C(7)-H(7) 115.2(17) H(22A)-C(22)-H(22B) 113(3) 
C(19)-C(20) 1.375(4) N-C(8)-C(7) 109.8(3) C(6)-C(22)-H(22C) 111(3) 
C(19)-H(19) 0.92(3) N-C(8)-C(9) 110.9(3) H(22A)-C(22)-H(22C) 107(3) 
C(20)-C(21) 1.367(4) C(7)-C(8)-C(9) 113.1(3) H(22B)-C(22)-H(22C) 107(4) 
C(20)-H(20) 0.93(3)     
C(21)-H(21) 0.94(3)     
C(22)-H(22A) 1.02(3)     
C(22)-H(22B) 1.05(5)     
C(22)-H(22C) 1.09(5)     
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 Appendix C, Table 4. Anisotropic displacement parameters (Å2 x 103) for ck502s. The aniso-
tropic displacement factor exponent takes the form: -2π2[h2(a*)2U11 + ... + 2hk(a*)(b*)U12]. 
 
 U11 U22 U33 U23 U13 U12
O 20(1) 41(1) 52(1) 3(1) 5(1) 0(1) 
N 18(1) 33(2) 44(2) 3(1) 3(1) 0(1) 
C(1) 94(4) 70(4) 105(5) -4(3) 0(4) 24(3) 
C(2) 63(3) 63(3) 78(3) 4(3) -8(3) 17(2) 
C(3) 56(3) 59(3) 60(3) 9(2) -3(2) 15(2) 
C(4) 43(2) 49(2) 52(3) 16(2) 5(2) 0(2) 
C(5) 30(2) 43(2) 50(2) 12(2) 2(2) -1(2) 
C(6) 35(2) 45(2) 50(2) 3(2) 5(2) 4(2) 
C(7) 21(2) 37(2) 39(2) 7(2) 7(2) 0(1) 
C(8) 25(2) 36(2) 40(2) 3(2) 4(2) -1(1) 
C(9) 20(2) 36(2) 39(2) 0(2) -4(1) -2(1) 
C(10) 26(2) 45(2) 55(2) 3(2) 6(2) 1(2) 
C(11) 31(2) 42(2) 80(3) 16(2) 0(2) 7(2) 
C(12) 33(2) 43(2) 63(3) 17(2) -11(2) -10(2) 
C(13) 29(2) 48(2) 53(2) 15(2) -1(2) -8(2) 
C(14) 24(2) 36(2) 47(2) 6(2) 2(2) 3(2) 
C(15) 23(2) 29(2) 39(2) 14(2) 3(1) -3(1) 
C(16) 22(2) 28(2) 34(2) 7(1) -6(1) -2(1) 
C(17) 24(2) 37(2) 39(2) 11(2) 0(2) -2(1) 
C(18) 28(2) 37(2) 48(2) 8(2) -1(2) -8(2) 
C(19) 32(2) 37(2) 37(2) 2(2) -6(2) 2(2) 
C(20) 28(2) 42(2) 38(2) 5(2) 5(2) 2(2) 
C(21) 20(2) 34(2) 46(2) 9(2) 2(2) -6(1) 
C(22) 53(3) 62(3) 60(3) -6(2) -11(2) -1(2) 
144 
 Appendix C, Table 5. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2 
x 103) for ck502s. 
 
 x y z U(eq) 
H(1N) 8850(60) 5770(30) 1960(17) 29(9) 
H(1A) 14070(100) 1320(50) 3750(30) 107(16) 
H(1B) 12600(130) 2210(70) 3000(50) 190(30) 
H(1C) 10680(130) 1620(60) 3780(40) 160(30) 
H(2A) 13290(130) 3270(70) 4610(50) 200(30) 
H(2B) 14820(120) 3660(60) 3670(40) 170(30) 
H(3A) 11020(50) 4130(30) 3120(20) 38(9) 
H(3B) 9410(100) 3610(50) 3720(30) 130(19) 
H(4A) 13330(70) 5950(30) 4080(20) 55(11) 
H(4B) 11650(60) 5580(30) 4800(20) 63(11) 
H(5) 8010(60) 6000(30) 3886(19) 50(10) 
H(6) 8500(60) 8330(30) 4224(18) 35(9) 
H(7) 11530(50) 7260(20) 3135(15) 22(7) 
H(8) 6250(50) 7310(20) 2901(16) 22(7) 
H(10) 5180(60) 9490(30) 2741(19) 38(9) 
H(11) 5530(70) 11300(40) 2150(20) 76(13) 
H(12) 8460(70) 11510(40) 1280(20) 62(12) 
H(13) 11320(70) 9920(30) 1120(20) 54(11) 
H(14) 10980(60) 8020(30) 1710(18) 41(9) 
H(17) 2180(60) 3440(30) 1328(18) 40(9) 
H(18) 1940(60) 1640(30) 240(20) 53(10) 
H(19) 5020(50) 1620(30) -590(16) 20(7) 
H(20) 8380(60) 3210(30) -359(18) 32(8) 
H(21) 8630(50) 4920(30) 681(16) 24(7) 
H(22A) 13770(70) 8250(30) 4410(20) 51(10) 
H(22B) 12290(80) 8640(40) 5240(30) 99(16) 
H(22C) 12450(90) 9710(50) 4550(30) 126(19) 
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 Appendix D 
X-ray Structure and Data of Lactam anti-287 
 
Appendix D, Table 1. Crystal data and structure refinement for chris601. 
Identification code  chris601 
Empirical formula  C13H15NO 
Formula weight  201.26 
Temperature  210(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 12.024(2) Å α = 90° 
 b = 6.1680(12) Å β = 96.28(3)° 
 c = 15.437(3) Å γ = 90° 
Volume 1138.0(4) Å3
Z 4 
Density (calculated) 1.175 Mg/m3
Absorption coefficient 0.074 mm-1
F(000) 432 
Crystal size 0.35 x 0.14 x 0.04 mm3
Theta range for data collection 2.65 to 25.03° 
Index ranges 0 ≤ h ≤ 14, 0 ≤ k ≤ 7, -18 ≤ l ≤ 18 
Reflections collected 2119 
Independent reflections 2016 [R(int) = 0.0341] 
Completeness to theta = 25.03° 100.0% 
Absorption correction Sadabs 
Max. and min. transmission 0.9970 and 0.9745 
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 2016 / 0 / 197 
Goodness-of-fit on F2 1.055 
Final R indices [I>2sigma(I)] R1 = 0.0500, wR2 = 0.0886 
R indices (all data) R1 = 0.1103, wR2 = 0.1077 
Extinction coefficient 0.017(3) 
Largest diff. peak and hole 0.111 and -0.118 e.Å-3
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 Appendix D, Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement para-
meters (Å2 x 103) for chris601. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 
 x y z U(eq) 
O 10119(2) 84(3) 11145(1) 66(1) 
N 9090(2) 2373(3) 10251(1) 45(1) 
C(1) 9491(2) 1678(4) 11045(1) 47(1) 
C(2) 9136(3) 2849(5) 11820(2) 58(1) 
C(3) 8558(3) 4990(5) 11625(2) 56(1) 
C(4) 7729(2) 4854(4) 10802(1) 45(1) 
C(5) 8389(2) 4283(4) 10038(1) 41(1) 
C(6) 7111(3) 6958(5) 10638(2) 61(1) 
C(7) 6028(4) 7211(9) 10602(2) 92(1) 
C(8) 7645(2) 3901(4) 9195(1) 40(1) 
C(9) 7470(2) 5552(5) 8586(2) 55(1) 
C(10) 6756(3) 5232(6) 7824(2) 70(1) 
C(11) 6234(2) 3296(6) 7667(2) 71(1) 
C(12) 6404(2) 1640(6) 8256(2) 69(1) 
C(13) 7110(2) 1955(4) 9018(2) 55(1) 
 
Appendix D, Table 3. Bond lengths [Å] and angles [°] for chris601. 
 
O-C(1) 1.239(3) C(1)-N-C(5) 127.2(2) N-C(5)-H(5) 110.2(11) 
N-C(1) 1.338(3) C(1)-N-H(1N) 113.7(16) C(8)-C(5)-H(5) 106.7(12) 
N-C(5) 1.465(3) C(5)-N-H(1N) 119.0(16) C(4)-C(5)-H(5) 106.8(12) 
N-H(1N) 0.90(3) O-C(1)-N 121.5(2) C(7)-C(6)-C(4) 125.6(4) 
C(1)-C(2) 1.498(3) O-C(1)-C(2) 120.4(2) C(7)-C(6)-H(6) 121.0(18) 
C(2)-C(3) 1.507(4) N-C(1)-C(2) 118.1(2) C(4)-C(6)-H(6) 113.3(18) 
C(2)-H(2A) 0.92(3) C(1)-C(2)-C(3) 115.4(2) C(6)-C(7)-H(7A) 123(2) 
C(2)-H(2B) 1.00(3) C(1)-C(2)-H(2A) 104.5(18) C(6)-C(7)-H(7B) 113.7(19) 
C(3)-C(4) 1.528(3) C(3)-C(2)-H(2A) 111.5(18) H(7A)-C(7)-H(7B) 123(3) 
C(3)-H(3A) 0.96(2) C(1)-C(2)-H(2B) 107.9(16) C(13)-C(8)-C(9) 118.3(2) 
C(3)-H(3B) 0.96(3) C(3)-C(2)-H(2B) 111.0(16) C(13)-C(8)-C(5) 121.7(2) 
C(4)-C(6) 1.504(3) H(2A)-C(2)-H(2B) 106(2) C(9)-C(8)-C(5) 120.0(2) 
C(4)-C(5) 1.534(3) C(2)-C(3)-C(4) 111.2(2) C(8)-C(9)-C(10) 120.2(3) 
C(4)-H(4) 1.00(2) C(2)-C(3)-H(3A) 113.0(14) C(8)-C(9)-H(9) 120.5(15) 
C(5)-C(8) 1.514(3) C(4)-C(3)-H(3A) 107.0(14) C(10)-C(9)-H(9) 119.3(15) 
C(5)-H(5) 1.01(2) C(2)-C(3)-H(3B) 109.4(15) C(11)-C(10)-C(9) 120.3(3) 
C(6)-C(7) 1.306(4) C(4)-C(3)-H(3B) 110.5(14) C(11)-C(10)-H(10) 121.7(17) 
C(6)-H(6) 0.97(3) H(3A)-C(3)-H(3B) 106(2) C(9)-C(10)-H(10) 117.9(18) 
C(7)-H(7A) 0.97(3) C(6)-C(4)-C(3) 111.0(2) C(10)-C(11)-C(12) 120.3(3) 
C(7)-H(7B) 1.01(3) C(6)-C(4)-C(5) 110.9(2) C(10)-C(11)-H(11) 122.1(18) 
C(8)-C(13) 1.375(3) C(3)-C(4)-C(5) 107.9(2) C(12)-C(11)-H(11) 117.6(18) 
C(8)-C(9) 1.386(3) C(6)-C(4)-H(4) 109.3(11) C(11)-C(12)-C(13) 119.5(3) 
C(9)-C(10) 1.393(4) C(3)-C(4)-H(4) 110.2(12) C(11)-C(12)-H(12) 122.6(14) 
C(9)-H(9) 1.00(3) C(5)-C(4)-H(4) 107.5(12) C(13)-C(12)-H(12) 117.9(14) 
C(10)-C(11) 1.359(4) N-C(5)-C(8) 109.85(19) C(8)-C(13)-C(12) 121.4(3) 
C(10)-H(10) 0.98(3) N-C(5)-C(4) 110.13(18) C(8)-C(13)-H(13) 119.8(15) 
C(11)-C(12) 1.368(4) C(8)-C(5)-C(4) 112.99(19) C(12)-C(13)-H(13) 118.9(15) 
C(11)-H(11) 0.95(3)     
C(12)-C(13) 1.386(3)     
C(12)-H(12) 1.01(3)     
C(13)-H(13) 0.97(3)     
147 
 Appendix D, Table 4. Anisotropic displacement parameters (Å2 x 103) for chris601. The aniso-
tropic displacement factor exponent takes the form: -2π2[h2(a*)2U11 + ... + 2hk(a*)(b*)U12]. 
 
 U11 U22 U33 U23 U13 U12
O 73(1) 78(1) 45(1) 7(1) -6(1) 33(1) 
N 42(1) 58(1) 36(1) 2(1) 0(1) 10(1) 
C(1) 43(1) 57(2) 40(1) 4(1) -2(1) 2(1) 
C(2) 65(2) 68(2) 39(2) 3(1) -2(1) 12(2) 
C(3) 63(2) 61(2) 41(2) -4(1) -2(1) 8(2) 
C(4) 47(1) 47(2) 40(1) -3(1) 3(1) 1(1) 
C(5) 41(1) 41(1) 40(1) 5(1) -1(1) 1(1) 
C(6) 69(2) 66(2) 46(2) -5(1) -7(1) 17(2) 
C(7) 91(3) 113(3) 68(2) -14(2) -10(2) 46(3) 
C(8) 40(1) 45(1) 35(1) 3(1) 5(1) 4(1) 
C(9) 65(2) 56(2) 43(2) 6(1) 4(1) 6(2) 
C(10) 81(2) 84(2) 43(2) 10(2) -4(2) 20(2) 
C(11) 57(2) 100(3) 50(2) -14(2) -13(1) 22(2) 
C(12) 58(2) 71(2) 72(2) -12(2) -14(2) -2(2) 
C(13) 53(2) 54(2) 56(2) 7(1) -8(1) 0(1) 
 
Appendix D, Table 5. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2 
x 103) for chris601. 
 
 x y z U(eq) 
H(1N) 9320(20) 1570(40) 9814(17) 70(9) 
H(2A) 8680(20) 1890(40) 12063(18) 80(10) 
H(2B) 9810(20) 3030(40) 12251(18) 91(9) 
H(3A) 9070(19) 6150(40) 11537(15) 57(8) 
H(3B) 8182(19) 5420(40) 12115(17) 66(8) 
H(4) 7178(17) 3660(30) 10859(13) 40(6) 
H(5) 8870(17) 5580(30) 9938(13) 45(6) 
H(6) 7600(20) 8190(50) 10597(18) 93(11) 
H(7A) 5660(30) 8600(50) 10490(20) 109(12) 
H(7B) 5600(30) 5810(60) 10660(20) 113(14) 
H(9) 7830(20) 6990(40) 8699(16) 74(9) 
H(10) 6660(20) 6430(50) 7403(19) 95(10) 
H(11) 5750(20) 3030(50) 7150(19) 91(9) 
H(12) 6040(20) 170(40) 8157(15) 74(8) 
H(13) 7222(19) 780(40) 9431(16) 69(8) 
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